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1. Introduction
The Danish Integrated Antimicrobial Resistance 
Monitoring and Research Programme, DANMAP, was 
established in 1995 on the initiative of the Danish Ministry 
of Health and the Danish Ministry of Food, Agriculture 
and Fisheries, as a coordinated national surveillance and 
research programme for antimicrobial consumption and 
antimicrobial resistance in bacteria from animals, food and 
humans. The programme is coordinated by Statens Serum 
Institut and the National Food Institute at the Technical 
University of Denmark (DTU). The Danish Health and 
Medicines Authority, the Danish Food Administration and 
the National Veterinary Institute at the DTU also provide 
data. The DANMAP programme is funded jointly by the 
Ministry of Science, Innovation and Higher Education; 
the Ministry of Food, Agriculture and Fisheries; and the 
Ministry of Health.
The objectives of DANMAP are:
•	 to monitor the consumption of antimicrobial agents 
for food animals and humans;
•	 to monitor the occurrence of antimicrobial resistance 
in bacteria isolated from food animals, food of animal 
origin and humans;
•	 to study associations between antimicrobial 
consumption and antimicrobial resistance;
•	 to identify routes of transmission and areas for further 
research studies. 
The monitoring of antimicrobial resistance is based on 
three categories of bacteria: Human and animal pathogens, 
zoonotic bacteria, and indicator bacteria. 
Human and animal pathogens are included because these 
cause infections and they reflect primarily resistance 
caused by use of antimicrobial agents in the respective 
reservoirs.
Zoonotic bacteria are included because they can develop 
resistance in the animal reservoir, which may subsequently 
compromise treatment effect when causing infection in 
humans.
Indicator bacteria are included due to their ubiquitous 
nature in animals, food and humans and their ability to 
readily develop antimicrobial resistance in response to 
selective pressure in both reservoirs.
This report, DANMAP 2011, describes the annual 
consumption of antimicrobial agents and the occurrence 
of resistance in different reservoirs in Denmark in 2011. 
Results from the monitoring programme as well as from 
selected research projects are presented in overview tables 
and figures. The report also include a list of abbreviations, 
explanations of terminology and description of materials 
and methods. 
1.1   About DANMAP
The National Food Institute at DTU would like to thank:
•	 the meat inspection staff and the company personnel 
at the slaughter houses for collecting samples from 
animals at slaughter. Without their careful recording 
of the animals’ farm of origin the results would be less 
useful;
•	 the Laboratory of Swine Diseases, the Danish 
Agriculture and Food Council, Kjellerup and the 
National Veterinary Institute at DTU for making 
isolates of animal pathogens available to the 
programme;
•	 the Department of Medication Statistics and Research 
Support at SSI (formerly the Danish Medicines Agency) 
for collecting and transmitting data on veterinary 
consumption of antimicrobial agents from the 
pharmacies;
•	 the staff of the Regional Veterinary and Food Control 
Authorities for collection of food samples and isolation 
of bacteria;
•	 the staff of the Zoonosislab at the National Food 
Institute at DTU; 
•	 the staff of the research group of Antimicrobial 
resistance and molecular typing at the National Food 
Institute at DTU. 
 
•	 the Departments of Clinical Microbiology in 
the DANRES group - Danish Study Group for 
Antimicrobial Resistance Surveillance - for providing 
data on resistance in bacteria from human clinical 
samples;
•	 the Danish National Antimicrobial Council for partially 
funding the prevalence study of ESBL-producing 
bacteria performed in October 2011;
•	 the staff of the Neisseria and Streptococcus Typing Unit 
at SSI;
•	 the staff of the Foodborne Pathogens Unit at SSI;
•	 the staff of the Staphylococcus Laboratory at SSI;
•	 the staff of the Antimicrobial Resistance Reference 
Laboratory and Surveillance Unit at SSI;
•	 Søren Uldum and Christina Wiid Svarrer from the 
Atypical Pneumonia Unit at SSI for data on Mycoplasma 
pneumoniae; 
•	 all Danish Hospital Pharmacies for providing additional 
data on consumption of certain antimicrobial agents;
•	 Erik Villadsen from the Department of Health 
Documentation at SSI for providing data on hospital 
activity.
1.2   Acknowledgements
Please note that in this year’s report, the specific 
MIC distributions as well as some detailed tables of 
antimicrobial consumption in animals and humans are 
presented in a web annex located at www.danmap.org. Pdf 
versions of this and previous DANMAP reports are also 
available at the DANMAP website. 
Statens Serum Institut would like to thank: 
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The Danish Study Group for Antimicrobial Resistance 
Surveillance provides data from the Departments of 
Clinical Microbiology (DCM) in Denmark.
DCM, Hvidovre Hospital:
Alice Friis-Møller
Jenny Dahl Knudsen
Elly Kristensen
Pia Littauer
Kristian Schønning
Henrik Westh
DCM, Rigshospitalet:
Maria Kristin Bjõrnsdottir
Michael Tvede
DCM, Herlev Hospital:
Magnus Arpi
Hanne Wiese Hallberg
Tina Larsen
DCM, Hillerød Hospital:
Dennis Schrøder Hansen
Ellen Larsen
Lisbeth Nielsen
DCM, Slagelse Hospital:
Ram Dessau
Ole Heltberg
Bent Røder
1.3   DANRES
DCM, Odense University Hospital:
Bente Gahrn-Hansen
Thøger Gorm Jensen
Ulrik Stenz Justesen
DCM, Esbjerg Hospital: 
Susanne Hartvig Hartzen
DCM, Vejle Hospital:
Anette Holm
Jens Kjølseth Møller
DCM Midt-Vest, Herning Hospital:
Helga Schumacher
Marianne Hedegaard Søndergaard
Ingrid Astrup
DCM Midt-Vest, Viborg Hospital: 
Birgitte Tønning
DCM, Skejby Hospital:
Svend Ellermann-Eriksen
Lars Erik Lemming 
Marianne Bøgild Pedersen
Marianne Kragh Thomsen 
DCM, Aalborg Hospital: 
Lena Mortensen
Henrik C. Schønheyder
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2. Summary
Det totale antibiotikaforbrug til svin er faldet 
væsentligt efter indførelsen af ”Gult kort” ordningen, 
ligesom svinebranchens frivillige stop har reduceret 
forbruget af cefalosporiner til svin til nær nul. 
Antibiotikaforbruget til kæledyr er steget siden 2005, 
hvilket hovedsageligt skyldes en stigning i forbruget 
af amoxicillin kombineret med clavulansyre.
2.1 Sammendrag 
DANMAP har siden 1995 beskrevet det årlige forbrug af 
antibiotika og forekomsten af antibiotikaresistens hos dyr 
og mennesker i Danmark. 
Antibiotikaforbrug til dyr 
Siden 2001 er al anvendelse af receptordineret medicin 
til dyr registreret i det offentlige register VetStat. I VetStat 
databasen indgår oplysninger om dyreart, aldersgruppe og 
besætningsniveau samt i et vist omfang oplysninger om 
den sygdom, der behandles. 
I 2011 blev der brugt 107,9 ton antibiotika til dyr i Danmark, 
hvor størstedelen blev anvendt i svineproduktionen (77 %), 
og en mindre andel i kvæg (14 %), pelsdyr (4 %), fisk (2 %) 
og fjerkræproduktionen (1 %). Det totale forbrug i tons til 
dyr i 2011 var 15 % lavere end i 2010.
Svin: I 2011 faldt det totale antibiotikaforbrug til svin med 
i alt 19 ton. Opgjort i antal standard doser pr produceret 
svin, svarer dette til et fald på 30 % i forhold til året før. 
Antibiotika forbruget til svin har været faldende siden 
”Gult kort-ordningen” blev bekendtgjort den 1. juli 2010. 
Ordningen er rettet mod svinebesætninger med højest 
antibiotikaforbrug per svin med henblik på at reducere 
forbruget.
I 2011 var faldet i antal standard doser pr svin især tydeligt 
for pleuromutiliner (60 %), tetracykliner (27 %) og 
makrolider (26 %), som primært ordineres i forbindelse 
med mave-tarm lidelser. Desuden nærmede forbruget af 
3. og 4. generations cefalosporiner sig nul som følge af, at 
svinebranchen frivilligt indførte stop for brugen af disse 
stoffer, som er kritisk vigtige til behandling af mennesker, i 
juli 2010. 
Kvæg: Det totale antibiotikaforbrug til kvæg har ligget 
relativt stabilt på ca. 14–15 ton om året siden 2005, og i 
2011 var forbruget 14,7 ton. Beta-lactamase følsomme 
penicilliner, som hovedsageligt bruges til behandling af 
yverbetændelse hos malkekøer, målt i standard doser 
udgjorde mere end halvdelen (59 %) af forbruget til kvæg. 
I forhold til kvægholdets størrelse, opgjort som biomasse 
(ton levende dyr), er forbruget generelt lavt. Det højeste 
forbrug er til kalve; som er på niveau med forbruget i 
kalkuner, men kun halvt så højt som forbruget til svin. 
Forbruget til kalve udgøres hovedsageligt af tetracykliner 
og makrolider. Forbruget af amfenikoler til behandling af 
luftvejsinfektioner hos kalve er steget væsentligt over de 
sidste 10 år. Forbruget af 3. og 4. generations cefalosporiner, 
både til systemisk og intramammær behandling af 
malkekvæg, er faldet med henholdsvis 34 % og 68 % siden 
2008 målt i kg aktivt stof. Forbruget af fluorkinoloner har 
ligget tæt på nul siden 2003. 
Fjerkræ: Antibiotikaforbruget til fjerkræ faldt med 
8 %, fra 879 kg i 2010 til 810 kg i 2011, men niveauet lå 
stadig højere end i perioden 2001–2008. Dette generelle 
fald i forbrug til fjerkræ skyldes især et nedsat forbrug 
til kalkuner, æglæggende høner og forældredyr i 
slagtekyllingeproduktionen. Ser man på slagtekyllinger 
alene, steg forbruget af antibiotika - særlig forbruget af 
amoxicillin - i 2011. Forbruget af fluorkinoloner har været 
lavt siden 2006. I 2011 blev fluorkinoloner slet ikke brugt 
til fjerkræ, ligesom cefalosporiner ikke har været anvendt 
til fjerkræ i mindst 10 år. 
Fisk: Fra 2010 til 2011 faldt total forbruget af antibiotika i 
fiskeproduktionen til 2.700 kg, svarende til et overordnet 
fald på 11 %. Målt i standard doser, udgjorde sulfonamid/
trimethoprim størstedelen af forbruget (60 %). Kinoloner 
(oxolinsyre) og florfenicol udgjorde henholdsvis 30 % og 
10 %. Under forudsætning af at produktionen af fisk i 2011 
var den samme som året før, faldt forbruget af antibiotika 
til saltvandsfisk med 50 % (til 4,5 ADDkg pr kg fisk 
produceret), mens forbruget til ferskvandsfisk steg med 
12 % (til 2,6 ADDkg pr kg fisk produceret). 
Kæledyr og heste: Informationerne i VetStat vedrørende 
antibiotikaforbruget i kæledyr er mangelfulde 
sammenlignet med informationerne vedrørende 
produktionsdyr, men der blev brugt ca. 2 ton antibiotika til 
kæledyr og ca. 1 ton til heste i 2011. Målt i standard doser 
er brugen af antibiotika til oral behandling af kæledyr 
steg med 8 % fra 2010 til 2011, og stigningen siden 2005 
er nu på i alt 36 %. Stigningen kan i særlig grad tilskrives 
et øget forbrug af ‘kombinationspenicillinet’ amoxicillin 
i kombination med clavulansyre. Brug af amoxicillin/
clavulansyre, som er et af de mest brugte antibiotika 
til kæledyr, udgjorde 91 % målt i kg aktivt stof af det 
veterinære forbrug af ‘kombinationspeniciliner’ i 2011. 
For fluorkinoloner blev omkring halvdelen (51 %) af 
fluorkinoloner, som blev benyttet veterinært, anvendt 
til behandling af kæledyr. I 2011 var forbruget af 3. og 4. 
generations cefalosporiner til kæledyr stabilt og udgjorde 
cirka 3 kg. Brugen af 3. og 4. generations cefalosporiner 
i udvalgte hestepraksis varierede mellem 0 % og 30 % af 
det totale antibiotikaforbrug opgjort i standard doser i 
den enkelte praksis (Textbox 1). Det høje forbrug af især 
kritisk vigtige stoffer for human behandling og forbrug af 
bredspektrede antibiotika til kæledyr og heste samt den 
store variation af forbrug imellem hestepraksis kan afspejle 
mangelfuld behandlingsvejledning i brug af antibiotika til 
kæledyr og heste.
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2.SUMMARY
I 2011 lå det totale forbrug af antibiotika til 
systemisk brug til mennesker (primærsektoren og 
hospitalssektoren sammenlagt) på samme høje 
niveau som i 2010. Forbruget i primærsektoren 
udgjorde 90 %, mens forbruget på hospitalerne 
udgjorde de resterende 10 %. Fra 2002 til 2011 steg 
det totale forbrug af antibiotika til mennesker i 
Danmark med 28 %. Forbruget af bredspektrede 
antibiotika udgjorde 39 % af det totale forbrug i 
primærsektoren i 2011, hvilket er en stigning på 78 % 
sammenlignet med 2002.
Antibiotikaforbrug til mennesker  
Lægemiddelstyrelsen har, siden begyndelsen af 1990erne, 
overvåget forbruget af receptordineret medicin på 
patientniveau. 
Totalforbrug: I 2011 lå det totale forbrug af antibiotika 
til systemisk brug til mennesker (primærsektoren og 
hospitalssektoren sammenlagt) på samme niveau som i 
2010 (18,84 DDD pr. 1000 indbyggere pr. dag (DID) i 2010 
sammenlignet med 18,90 DID i 2011). Forbrugsniveauet i 
2011 fulgte dog stadig den generelt stigende tendens fra de 
seneste år. Primærsektoren udgjorde 90 % af forbruget, og 
forbruget i denne sektor var i 2011 det højeste siden 1995. Fra 
2002 til 2011 steg det totale forbrug af antibiotika i Danmark 
med 28 % (4,13 DID).
Primærsektor: Antibiotikaforbruget i primærsektoren i 2011 
var relativt konstant sammenlignet med 2010 (17.06 DID i 
2011 og 16,93 DID i 2010). Som i de tidligere år udgjorde 
beta-laktamase følsomme penicilliner den største gruppe 
af antibiotika (31 %), og penicilliner udgjorde 63 % af det 
totale forbrug i 2011. I 2011 var forbruget af bredspektrede 
antibiotika 6,58 DID (39 %), en stigning på 0,1 DID 
(2 %) i forhold til 2010. Fra 2010 til 2011 steg forbruget 
af ’kombinationspenicilliner’ med 31 %, mens mindre 
stigninger blev observeret for beta-laktamase følsomme 
penicilliner (1,1 %) og makrolider (1,2 %). 
Der kan være forskellige forklaringer på det stadigt høje 
forbrug i 2011: (1) Et øget antal patienter i behandling, 
(2) et udbrud af Mycoplasma pneumoniae (atypisk 
pneumoni) i oktober–december 2011, som medførte et 
øget forbrug af dels beta-laktamase følsomme penicilliner 
(til behandling af nedre luftvejsinfektioner) og dels 
makrolider (til behandling af bekræftede og mistænkte M. 
pneumoniae infektioner) og (3) en kontinuerlig respons på 
ændringer i de nationale behandlingsvejledninger (især for 
’kombinationspenicilliner’).
Sygdomsspecifikke ændringer, som kan medføre et øget 
antal behandlede patienter, kan ikke vurderes på grund af 
manglende indikationskoder. 
I det seneste årti er forbruget af antibiotika i primærsektoren 
steget med 29 %, fra 13,26 DID i 2002 til 17,06 DID i 2011. 
I 2011 udgjorde bredspektrede antibiotika 6,58 DID (39 %) 
af det samlede antibiotikaforbrug i primærsektoren, hvilket 
er en stigning på 78 % sammenlignet med 2002 (3,85 DID, 
29 %). Denne stigning skyldes sandsynligvis til dels et øget 
antal DDD per behandlet patient (definerede dagsdoser) 
og et øget antal DDD per udskrevet medicinpakning. 
Sidstnævnte kan afspejle ændrede retningslinjer for 
behandling, med kortere behandlingstider men med højere 
doser. Andre forklaringer for det stigende antibiotikaforbrug 
er på nuværende tidspunkt svære at vurdere på grund af 
manglende indikationskoder. Dette forventes dog at blive 
bedre fremover, da det i 2012 blev vedtaget at fjerne de brede 
indikationskoder (’mod betændelse’ og ’mod infektion’) og 
erstatte dem med mere specifikke indikationskoder på alle 
danske antibiotikarecepter. 
Analyser af sammenhængen mellem demografiske faktorer 
og det stigende forbrug af antibiotika fra 2001 til 2010, 
påviste stigninger i specifikke antibiotika-typer og substanser, 
især blandt personer over 65 år og blandt yngre voksne. 
Alders-relaterede stigninger i tetracykliner og pivmecillinam 
skyldes højst sandsynligt ændringer i behandlingsmønstret 
for hhv. akne og urinvejsinfektioner. Stigninger i forbruget af 
roxithromycin, uanset aldersgruppe, hænger sandsynligvis 
sammen med flere store udbrud af M. pneumoniae. Generelt 
tyder det på, at forbrugsstigningerne mellem 2001 og 2010 
skyldes en kombination af sygdomsspecifikke faktorer og 
ikke mindst en tendens til, at de danske praktiserende læger 
udskriver mere antibiotika per besøg og i højere doser 
(Textbox 3).
Hospitalssektor: Det samlede forbrug af antibiotika i hele 
hospitalssektoren (rehabiliteringscentre, hospices, private-, 
psykiatriske-, special- og somatiske hospitaler) i 2011 faldt 
fra 1,91 DID i 2010 til 1,84 DID i 2011 (et fald på 3,7 %). 
Siden 2002 er forbruget steget med 0,38 DID (26 %). I 2011 
udgjorde bredspektrede antibiotika 1,22 DID af totalforbruget 
sammenlignet med 0,75 DID i 2002 (en stigning på 67 %). 
Somatiske hospitaler: I 2011 steg det totale 
antibiotikaforbrug på somatiske hospitaler opgjort i DDD 
per 100 sengedage (DBD) med 3,6 % (3,12 DBD), fra 87,72 
DBD i 2010 til 90,84 DBD i 2011. Ved opgørelse i DDD per 
100 indlæggelser (DAD) blev der ikke observeret en ændring 
fra 2010 til 2011 (282,53 DAD i 2011 og 284,89 DAD i 2010 
(0,8 %). Disse tal er baseret på et fald på 0,08 DDD (4,2 %) 
fra 2010 til 2011, kombineret med færre sengedage og flere 
indlæggelser i 2011 sammenlignet med 2010. 
Fire antibiotikagrupper dominerede forbrugsstigningen 
fra 2010 til 2011, opgjort som DBD: kombination 
af sulfonamider/trimethoprim (1,07 DBD, 35 %), 
‘kombinationspenicilliner (1,38 DBD, 19 %), fluorkinoloner 
(0,26 DBD, 6,7 %) og makrolider (0,17 DBD, 4,7 %). Fra 
2010 til 2011 faldt forbruget af beta-laktamase resistente 
penicilliner (0,41 DBD, 5,3 %) mens der var mindre nedgang 
for penicilliner med udvidet spektrum (0,20 DBD, 1,4 %) og 
beta-laktamase følsomme penicilliner (0,17 DBD, 1,8 %). 
I 2011 udgjorde cefalosporiner 19 % af det totale 
antibiotikaforbrug på somatiske hospitaler, efterfulgt af 
penicilliner med udvidet spektrum (15 %), fluorkinoloner 
(12 %) og beta-laktamase følsomme penicilliner (10 %). 
I løbet af de seneste ti år er forbruget af antibiotika på 
somatiske hospitaler steget fra 51,73 DBD i 2002 til 90,84 
DBD i 2011 (76 %) eller fra 258,46 DAD i 2002 til 282,53 
DAD i 2011 (9,3 %), afhængigt af nævneren. Udover 
at fremhæve stigninger i det totale antibiotikaforbrug 
understreger disse tal også den ændrede hospitalisering i 
Danmark med et stigende antal indlæggelser og faldende 
antal sengedage siden 2002.
12                     
                   
DANMAP 2011  
SUMMARY2.
Resistensforekomsten i Salmonella Typhimurium 
isolater fra dansk svinekød steg voldsomt i 2011, 
mens niveauet i isolater fra svin blot fortsatte 
den stigning der er set gennem de seneste år. 
Forekomsten af tetracyklinresistens blandt S. 
Typhimurium isolater fra svin og svinekød steg 
signifikant til trods for, at tetracyklin forbruget til 
svin er faldet de to foregående år. Dette understøtter 
teorien om at stigningen, i hvert fald delvist, skyldes 
spredningen af resistente kloner.
Resistensforekomsten blandt Campylobacter jejuni 
isolater fra dansk kyllingekød var signifikant lavere 
end i isolater fra udenlandsk kyllingekød. Det 
samme gjorde sig gældende for isolater fra humane 
tilfælde, hvor der blandt de tilfælde der var opstået 
i Danmark blev fundet signifikant lavere resistens 
end blandt de rejserelaterede tilfælde.
Resistens i zoonotiske bakterier 
Zoonotiske bakterier som Salmonella og Campylobacter 
er sygdomsfremkaldende bakterier, som kan overføres 
fra dyr til mennesker, enten via direkte kontakt eller via 
kontaminerede fødevarer. 
I DANMAP 2011 præsenteres antibiotika 
resistensforekomsten for Salmonella Typhimurium 
udelukkende fra danske svin og fra dansk svinekød, da der 
var for få isolater fra andre kilder – fjerkræ og kvæg. 
Blandt S. Typhimurium isolater fra danske svin 
blev der i 2011 observeret signifikante stigninger i 
resistensforekomsten af ampicillin, neomycin, sulfonamid 
og tetracyklin i forhold til 2010. I modsætning til tidligere 
blev der i 2011 fundet generelt højere resistensforekomst 
i dansk svinekød end i danske svin. Ingen af de fundne S. 
Typhimurium isolater var resistente over for cefalosporiner 
(ceftiofur og cefotaxim), fluorkinoloner (ciprofloxacin) 
eller kinoloner (nalidixansyre).
Blandt S. Typhimurium fra mennesker var forekomsten 
af fluorkinolon og cefalosporin resistens hyppigere hos de 
rejserelaterede tilfælde (hhv. 16 % og 12 %) i forhold til 
de patienter, som havde erhvervet infektionen i Danmark 
(hhv. 2 % og 1 %). 
Forekomsten af resistens i S. Typhimurium isolater fra 
svin, dansk svinekød og humane tilfælde var i 2011 stærkt 
påvirket af den klonale spredning af de monofasiske 
varianter af S. Typhimurium, som er resistente overfor 
ampicillin (A), streptomycin (S), sulfonamide (Su) og 
tetracyklin (T), også kaldt ASSuT resistensprofilen. Denne 
tendens ses gennem hele ”jord til bord” kæden, hvor 
andelen af multiresistente isolater steg markant, samtidig 
med at andelen af fuldt følsomme isolater faldt.
Blandt S. Enteritidis isolaterne fra humane infektioner 
i 2011, blev kinolon (ciprofloxacin og nalidixansyre) 
resistens fundet i 18 % at de sporadiske humane tilfælde 
erhvervet i Danmark. Dette svarer til en stigning på 10 % i 
forhold til året før. Resistensforekomsten blandt de hjemligt 
erhvervede infektioner nærmer sig derved niveauet blandt 
de rejserelaterede tilfælde (24 %) og blandt tilfælde med 
ukendt oprindelse (27 %). 
Resistensforekomsten i Campylobacter jejuni isolater fra 
danske kyllinger og kvæg og i Campylobacter coli isolater 
fra danske svin var på samme niveau som i 2010. Generelt 
er tetracyklinresistens forekomsten steget siden 2005, 
hvilket især er tydelig for C. coli isolater fra svin i perioden 
2008 til 2011. I denne periode var tetracyklin et af de 
hyppigst anvendte antibiotika til svin.
Som i foregående år var fluorkinolon (ciprofloxacin) 
resistensforekomsten i C. jejuni signifikant højere blandt 
isolater fra importeret kyllingekød (57 %) end fra dansk 
produceret kyllingekød (11 %). Denne forskel er øget over 
de seneste år. 
Forekomsten af tetracyklin- og fluorkinolonresistens 
steg i C. jejuni isolater fra human tilfælde i forhold 
til 2010 - både bland de hjemlig erhvervede og rejse 
relaterede tilfælde. Som i de foregående år var fluorkinolon 
resistensforekomsten i C. jejuni isolater fra rejse relaterede 
humane tilfælde (84 %) signifikant højere end i isolater fra 
personer, hvor infektionen var erhvervet i Danmark 
(33 %).
Resistens i indikatorbakterier 
Indikator bakterier er inkluderet i DANMAP 
overvågningen for at kunne give et indblik i de generelle 
resistens forekomster i raske husdyr og kød. 
Blandt Enterococcus faecium isolater fra svin, steg 
antibiotika resistensforekomsten for beta-lactamer 
(penicillin og ampicillin) signifikant fra 2010 til 2011. 
Derudover er streptomycinresistensen gradvist steget, 
uden at dette har kunnet knyttes til en tilsvarende stigning 
i forbrug. Stigningen kan dog hænge sammen med 
forekomsten af tetracyklinresistens, som kan medføre 
co-selektion for streptomycinresistens. Forekomsten af 
erythromycinresistens faldt både blandt isolater fra svin og 
blandt isolater fra slagtekyllinger. På trods af, at det er mere 
end ti år siden, at brugen af vækstfremmerne avoparcin og 
virginiamycin (quinupristin/dalfopristin) ophørte, blev der 
i 2011 stadig fundet lav forekomst af resistens mod disse 
stoffer.
Forekomsten af resistens i Enterococcus faecalis isolater 
fra svin steg signifikant for en række antibiotika: 
chloramphenicol, erythromycin, kanamycin og 
gentamicin. Blandt disse isolater forekom ofte co-resistens, 
hvor kombinationen af chloramphenicol-, kanamycin- og 
gentamicinresistens sammen med tetracyklin og/eller 
erythromycinresistens var dominerende. 
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Vancomycin og quinupristin/dalfopristin resistens 
forekommer stadig på lavt niveau i E. faecium fra 
svin, til trods for at brugen af disse vækstfremmere 
ophørte for mere end ti år siden.
Blandt både E. faecium and E. faecalis isolater var 
forekomsten af resistens mod erythromycin, kanamycin 
and streptomycin signifikant højere i isolater fra importeret 
kyllingekød end fra dansk produceret kyllingekød. 
Tilsvarende var tetracyklinresistensen i E. faecalis isolater 
fra importeret svinekød højere end i isolater fra dansk 
svinekød.
Resistensforekomsten i indikator E. coli isolater fra 
danske kyllinger og kvæg var på samme niveau som i 2010. 
Forekomsten af streptomycinresistens faldt signifikant i 
isolater fra svin, og idet streptomycin resistens ofte (99 % 
i 2010 og 75 % i 2011) forekommer i kombination med 
tetracyklin- og/eller sulfonamidresistens. 
I dyr sås de højeste resistensforekomster blandt indikator 
E. coli fra svin, bortset fra fluorkinolon (ciprofloxacin) 
hvor resistensforekomsten var højere i isolater fra kyllinger. 
De seneste ti år har forekomsten af fluorkinolonresistens i 
isolater fra svin og kvæg været meget lav, mens niveauet i 
isolater fra kyllinger har varieret mellem 7 % og 13 %. I de 
seneste ti år er fluorkinolon kun anvendt i meget begrænset 
omfang i den danske husdyrproduktion, med undtagelse 
af i kyllingeproduktionen, hvor det var almindeligt brugt 
indtil 2007. 
Resistensforekomsten var signifikant højere i indikator 
E. coli isolater fra importeret kyllingekød end fra 
dansk produceret kyllingekød (for 11 ud af 16 testede 
antibiotika), herunder både for cefalosporiner (ceftiofur) 
og fluorkinolon. Tilsvarende var chloramphenicol- 
og kinolonresistensen i E. coli isolater fra importeret 
svinekød højere end i isolater fra dansk svinekød. Som 
de foregående år var resistensforekomsten i E. coli fra 
importeret og dansk oksekød lavt. 
ESBL-producerende bakterier er resistente overfor bred-
spekterede cefalosporiner, der ofte bruges til behandling 
af livstruende infektioner humant. Derfor er forekomsten 
af disse, selv i et lavt niveau, et potentielt alvorligt 
problem. Ved brug af selektive op formeringsmetoder 
blev forekomsten af disse bakterier undersøgt i 
svinebesætninger, hos kvæg og svin på slagterierne samt i 
kød fra detailforretninger og engros lagre.
Det frivillige forbud mod brug af cefalosporiner i den 
danske svineproduktion har medført en reduceret 
forekomst af ESBL-producerende E. coli i svin. Hos 
kvæg forblev forekomsten på samme niveau som i 2010, 
sandsynligvis fordi 3. og 4. generations cefalosporiner 
stadig benyttes til intramammær og systemisk behandling. 
Forekomsten af ESBL-producerende E. coli i dansk 
kyllingekød steg (fra 8,6 % i 2010 til 44 % i 2011) og er 
nu på samme niveau som i importeret kyllingekød (48%), 
på trods af at cefalosporiner ikke har været brugt i den 
danske kyllingeproduktion i mindst ti år. Forekomsten 
skyldes sandsynligvis at ESBL producerende E. coli 
introduceres via importerede forældredyr. Derudover 
er forbruget af bred-spektrede penicilliner i den danske 
kyllingeproduktion øget, hvilket kan resulterer i co-
selektion af ESBL producerende E. coli.  
Tilstedeværelsen af de forskellige ESBL-gener afhang 
af dyrearten. Hos svin og kvæg var det hyppigst 
forekommende ESBL-gen CTX-M-1, men også CTX-M-14 
og CTX-M-15 blev påvist. CMY-2 blev ofte påvist i både 
dansk og importeret kyllingekød. Alle er ESBL-gener der 
forekommer i ESBL-producerende E. coli, som forårsager 
human sygdom.  Dansk såvel som importeret kyllingekød 
synes at være et vigtigt reservoir for ESBL-producerende E. 
coli.
Det frivillige stop for brugen af cefalosporiner i 
den danske svineproduktion afspejler sig i et fald 
i forekomsten af ESBL-producerende E. coli i både 
svinebesætninger og i svin ved slagtning. Selv i 
lande som Danmark, hvor cefalosporiner ikke 
anvendes i slagtekyllingeproduktionen er kyllingekød 
tilsyneladende også en vigtig kilde til ESBL-
producerende E. coli.
Resistens i bakterier fra diagnostiske indsendelser 
fra mennesker  
Rapporteringen af antibiotikaresistens i bakterier fra 
diagnostiske indsendelser fra mennesker er baseret på 
frivillig indsendelse af data fra DANRES gruppen, som 
dækker de Klinisk Mikrobiologiske Afdelinger (KMA) 
i Danmark. Undtagelser omfatter methicillin resistente 
Staphylococcus aureus (MRSA) og invasive Streptococcus 
pneumoniae, som er anmeldepligtige. Data vedr. disse 
bakterier kommer fra referencelaboratorierne på SSI. 
Blandt Escherichia coli isolater fra blod var 3. generations 
cefalosporin resistensforekomsten 8 % i 2011, hvilket er 
det samme niveau som i 2010, men højere end i de andre 
nordiske lande i 2010. Ciprofloxacin resistens var 14 % i 
2011 (min. 12 %, max. 31 % for de individuelle KMAer), 
dette var det samme niveau som i 2010. I løbet af de 
seneste 10 år er resistens overfor cefuroxim, ciprofloxacin 
og gentamicin steget signifikant. Resistens overfor 3. 
generations cefalosporiner er rapporteret siden 2008; i 
denne periode er resistensforekomsten steget. Carbapenem 
(meropenem) resistens blev ikke observeret i E. coli isolater 
fra blod i 2011. 
Blandt E. coli isolater fra urin fra hospitaler var 3. 
generations cefalosporin resistensforekomsten 5 % i 2011, 
hvilket er det samme niveau som i 2010. Fluorkinolon 
resistensforekomsten steg signifikant fra 2010 til 2011 (i 
2011: ciprofloxacin 13 %, nalidixansyre 17 %). I løbet af 
de seneste 10 år er resistens overfor fluorkinoloner steget 
signifikant (i 2002: ciprofloxacin 2 %, nalidixansyre 6 %). 
Aminoglykosid (gentamicin) resistensforekomsten steg 
signifikant fra 3,7 % i 2010 til 4,4 % i 2011. 
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Blandt E. coli isolater fra urin fra praksis var 3. 
generations cefalosporin resistensforekomsten 3 % i 2011, 
hvilket er det samme niveau som i 2010. Sulfonamid 
resistensforekomsten faldt signifikant fra 37 % i 2010 til 
35 % i 2011. 
Carbapenem (meropenem) resistens blev observeret 
i E. coli isolater fra urin fra både hospitaler og 
praksis. Forekomsten af carbapenem resistens er ikke 
anmeldepligtig; derfor kunne frekvensen af carbapenem 
resistens i E. coli ikke beregnes. 
Blandt Klebsiella pneumoniae isolater fra blod var 
resistensforekomsten for 3. generations cefalosporiner 
(10 %), fluorkinoloner (ciprofloxacin 12 %, nalidixansyre 
18 %) og aminoglykosid (gentamicin 6 %) på samme 
niveau som i 2010. Niveauet var højere end hvad der 
blev rapporteret for de andre nordiske lande i 2010 og 
på samme niveau som i flere andre europæiske lande. 
Carbapenem (meropenem) resistens blev observeret i ét K. 
pneumoniae isolat fra blod i 2011. 
Blandt K. pneumoniae isolater fra urin faldt 
resistensforekomsten for 3. generations cefalosporiner 
signifikant i isolater fra hospitaler (fra 12 % i 2010 til 
10 % i 2011) og fra praksis (fra 7 % i 2010 til 5 % i 2011). 
Cefuroxim resistensforekomsten faldt signifikant fra 13 % 
i 2010 til 11 % i 2011 i isolater fra hospitaler. Fluorkinolon 
resistensforekomsten faldt signifikant fra 2010 til 2011 
blandt urin-isolater fra hospitaler (ciprofloxacin fra 14 % 
i 2010 til 11 % i 2011) og praksis (ciprofloxacin fra 12 % i 
2010 til 9 % i 2011, nalidixansyre fra 20 % i 2010 til 
14 % i 2011). Der sås også et signifikant fald i forekomsten 
af mecillinamresistens fra 2010 til 2011 i isolater fra 
hospitaler (i 2011: 12 %) og praksis (i 2011: 12 %). Blandt 
K. pneumoniae isolater fra hospitaler steg sulfonamid 
resistensforekomsten signifikant fra 29 % i 2010 til 33 % i 
2011. 
Carbapenem (meropenem) resistens blev observeret i 
K. pneumoniae isolater fra urin fra både hospitaler og 
praksis. En af de carbapenemresistente isolater var KPC-2 
positiv (Textbox 11). Forekomsten af carbapenemresistens 
er ikke anmeldepligtig; derfor kunne frekvensen af 
carbapenemresistens i K. pneumoniae ikke beregnes. 
I E. coli isolater fra blod (2008–2010) blev der observeret 
en stigende resistensforekomst af gentamicin, ciprofloxacin 
og 3. generations cefalosporin og multi-resistens 
(gentamicin, ciprofloxacin og 3. generations cefalosporin) 
parallelt med et stigende forbrug af bredspektrede 
antibiotika (2007–2010) (Textbox 8). 
I oktober 2011 screenede 12 af 13 KMAer alle E. coli og K. 
pneumoniae urin- og blod-isolater for ESBL-produktion. 
ESBL-prævalensen fra 2011 blev sammenlignet med 
data fra tilsvarende studier udført i 2007 og 2009. Fra 
oktober 2009 til oktober 2011 steg prævalensen af ESBL-
producerende E. coli signifikant i urinprøver fra både 
praksis (fra 2,3 % i 2009 til 3,2 % i 2011) og hospitaler (fra 
3,8 % i 2009 til 4,7 % i 2011). Som i tidligere år dominerede 
CTX-M-15 blandt ESBL-producerende E. coli og K. 
pneumoniae isolater fra urinvejs- og blod-infektioner fra 
patienter, mens CTX-M-1, CTX-M-14 og CMY-2 kun var 
til stede i et begrænset antal isolater (Textbox 9). 
Resistensforekomsten for 3. generations cefalosporiner, 
ciprofloxacin og gentamicin i K. pneumoniae fra urinvejs-
og blod-infektioner fra patienter på hospital var signifikant 
højere i den østlige del af Danmark (Sjælland) end i den 
vestlige del (Fyn og Jylland). Den samme tendens sås 
blandt K. pneumoniae urin-isolater fra patienter i praksis, 
hvor resistensforekomsten for 3. generations cefalosporiner 
og fluorkinoloner (ciprofloxacin og nalidixansyre) var 
signifikant højere i isolater fra den østlige del af Danmark 
(Sjælland) end i isolater fra den vestlige del (Fyn og 
Jylland) (Textbox 10). 
I perioden 2008–2011 blev der påvist 15 carbapenemase-
producerende enterobakterier (CPE) i Danmark. Disse 
omfattede 2 VIM-, 3 KPC-, 3 NDM-1- og 7 OXA-48-
producerende isolater. Af de 15 observerede tilfælde blev 
10 påvist i 2011 og de fleste af disse var importeret fra 
Libyen fra patienter sendt til Danmark for at modtage 
medicinsk assistance for skader pådraget under konflikten 
i Libyen (Textbox 11). Der er ikke anmeldepligt af CPE i 
Danmark, og der kan muligvis have været flere cases i 2011 
end dem, der er beskrevet i Textbox 11.
Resistensforekomsten i Pseudomonas aeruginosa isolater 
fra blod var lav for alle de testede antibiotika. 
I 2011 var resistensforekomsten  for penicillin og 
erythromycin stadig lav blandt Streptococcus pneumoniae 
og gruppe A, B, C og G streptokokker. 
Forekomsten af ampicillinresistens i Enterococcus faecium 
isolater fra blod var 93 % i 2011, dette var det samme 
niveau som i 2010. Resistensforekomsten for vancomycin 
var 1,3 % i E. faecium mens ingen Enterococcus faecalis 
blod-isolater var vancomycinresistente. Kun én KMA 
testede enterokokker fra blod-infektioner for høj-niveau 
gentamicinresistens (HLGR). Her var 31 % af de testede 
E. faecalis isolater og 74 % af de testede E. faecium isolater 
HLGR. 
I 2011 blev der indrapporteret 1.525 tilfælde af 
Staphylococcus aureus bakteriæmi svarende til en 
incidens på 24,6 tilfælde per 100.000 indbyggere. Antallet 
af methicillinresistente S. aureus (MRSA) var 21 (1,4 %), 
hvilket er på samme niveau som tidligere år og blandt 
de laveste incidenser observeret i Europa. Den højeste 
resistensforekomst udover penicillinresistens var resistens 
for fusidinsyre (13,3 %), erythromycin (6,6 %), clindamycin 
(5,8 %) og norfloxacin (3,6 %). Niveauet af resistens overfor 
de testede antibiotika var det samme som i 2010. 
Antallet af nye MRSA tilfælde (både koloniserede og 
inficerede personer) steg i 2011 til 1292 sammenlignet 
med 1097 i 2010. Den stigning, der blev observeret i 
2010, fortsatte således i 2011. Stigningen blev primært 
set i tilfælde kategoriseret som samfundserhvervede, 578 
i 2010 vs. 751 i 2011. Andelen af patienter med infektion 
var lavere i 2011 end i 2010 (53 % vs. 59 %). Antallet af 
hospitalserhvervede tilfælde var fortsat lavt og udgjorde 
kun 5 % af det totale antal MRSA tilfælde i 2011. 
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I 2011 steg antallet af nye MRSA tilfælde til 1292. 
Stigningen sås primært i tilfælde kategoriseret som 
samfundserhvervede. Antallet af hospitalserhvervede 
tilfælde var fortsat lavt og udgjorde kun 5 % af det 
totale antal MRSA tilfælde i 2011. Antallet af MRSA 
af typen CC398, som er associeret med svin, steg 
til 164 i 2011. Svin er stadig det vigtigste reservoir 
for MRSA CC398 og forekomsten i de positive 
besætninger er muligvis steget.
Fra oktober 2009 til oktober 2011 steg prævalensen 
af ESBL-producerende E. coli signifikant i urinprøver 
fra både praksis og hospital. 
Resistensforekomsten for 3. generations 
cefalosporiner og ciprofloxacin i K. pneumoniae fra 
urinvejs- og blodinfektioner fra hospitalspatienter 
var signifikant højere i den østlige del af Danmark 
(Sjælland) end i den vestlige del (Fyn og Jylland). 
I perioden 2008–2011 blev der påvist 15 tilfælde 
med carbapenemase producerende enterobakterier 
i Danmark, hvoraf de fleste var importerede. Ti af 
disse tilfælde blev påvist i 2011.
Antallet af MRSA tilhørende det klonale kompleks 
CC398, som er associeret med svin, steg fra 111 i 2010 til 
164 i 2011. I 24 af disse tilfælde var der ikke rapporteret 
nogen kendt kontakt til svin eller personer med kontakt 
til svin. Tolv af disse tilfælde var kategoriseret som 
samfundserhvervede uden kendt eksponering, men 
størstedelen af tilfældene boede i områder med rapporteret 
CC398 i mennesker og/eller svin. Den mest almindelige 
spa type relateret til CC398 var type t034 (n = 130), hvoraf 
49 af t034-tilfældene havde en egentlig MRSA infektion. 
MRSA isolater med den nye mecA homolog mecC blev 
fundet i 37 tilfælde (9 i 2009, 21 i 2010). 
Hel-genom sekventering af 90 CC398 isolater viste en 
fylogenetisk adskillelse mellem isolater fra svin, kalkuner 
og mennesker. Fylogenien understøtter, at CC398 i svin er 
efterkommere af et menneske-til-dyr værts-skifte. Efter at 
være blevet introduceret i svin undergik CC398 en række 
ændringer, der bl.a. indebar tab af flere gener af betydning 
for den medfødte immunitet i mennesker (f.eks. scn) og 
erhvervelse af tetracyklin og methicillinresistens (MRSA)- 
gener. Tabet af flere funktioner associeret med human 
adaptation kan forklare, hvorfor MRSA CC398 har en 
nedsat evne til at kolonisere og smitte mennesker. På den 
anden side viser resultaterne, at MRSA CC398 er i stand 
til at generhverve de samme gener, hvilket kan styrke dens 
evne til at kolonisere og inficere mennesker (Textbox 12).
Forekomsten af MRSA i danske svinebesætninger (16 
%) var på samme niveau som i 2010, mens forekomsten i 
svin ved slagtning var steget markant (44 %) i forhold til 
2009 (13 %). Dette kunne indikere en højere forekomst i 
de positive besætninger end tidligere, hvilket kan føre til 
øget transmission mellem svinene under transport og før 
slagtning. Dette er yderligere understøttet af en øget trend 
i forekomsten i dansk svinekød, så muligvis er slagtekæden 
mere forurenet end tidligere år. I kød var MRSA 
forekomsten signifikant højere i importeret kyllingekød 
sammenlignet med 2010, men indtil videre regnes kød 
ikke for en kilde til human infektion. MRSA blev ikke 
fundet i kvæg ved slagtning. Svin anses derfor stadig for 
det vigtigste reservoir for MRSA CC398.
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2.2  Summary
 
Resistance Monitoring and Research Programme, 
DANMAP, has monitored antimicrobial resistance and 
consumption of antimicrobial agents in food animals and 
in humans. 
Antimicrobial consumption in animals 
Data on all medicines prescribed by veterinarians have 
been registered at farm and species level by the official 
VetStat programme since 2001. 
In 2011, the total veterinary consumption of antimicrobial 
agents amounted to 107.9 tonnes. This represents a 
15% decrease compared to 2010, mainly attributed to 
a decreased consumption in pigs. The antimicrobial 
consumption in pigs, cattle, fur animals, aquaculture, and 
poultry accounted for 77%, 14%, 4%, 2% and 0.7% of the 
total veterinary consumption, respectively. 
Pigs: The total consumption of veterinary antimicrobial 
agents in Danish pig production decreased by 19 
tonnes from 2010 to 2011, corresponding to a 30% 
decrease in number of defined doses per pig produced. 
This continued the trend observed since measures to 
reduce consumption were announced by the veterinary 
authorities on July 1st 2010 (the ‘yellow card’ initiative). 
The ‘yellow card’ control of imposes preventive measures 
in the pig herds with highest consumption per pig. In 
2011, the decrease in number of defined doses consumed 
could mainly be attributed to a reduction in the use of the 
main classes of pleuromutilins (60%), tetracyclines (27%) 
and macrolides (26%) prescribed for gastrointestinal 
disease. The use of 3rd and 4th generation cephalosporins 
was almost zero in the pig production, due to a voluntary 
ban on cephalosporins enforced by the Danish pig 
industry from July 2010. 
Cattle: Overall, the antimicrobial consumption in 
cattle was similar to 2010. In 2011, approximately 14.7 
tonnes of antimicrobial agents were prescribed for cattle. 
Estimated in number of defined doses per animal, the 
use of beta-lactamase sensitive penicillins accounted for 
more than half (59%) of the consumption in dairy cattle 
and was mainly prescribed to treat mastitis. In general, 
the consumption measured by biomass is low in cattle, 
with calves accounting for the highest consumption per 
biomass (at the level of turkeys and half the level of pigs). 
In calves, the main antimicrobials used were tetracyclines, 
followed by macrolides. The use of amfenicols for 
treatment af respiratory disease in calves has increased 
significantly over the last decade. In contrast, use of 
3rd and 4th generation cephalosporins has decreased 
since 2008 both for systemic (34%) and intramammary 
treatments (68%) when measured in kg active compound, 
and the use of fluoroquinolones has been close to zero 
since 2003. 
Poultry: The consumption of antimicrobial agents in 
poultry decreased by 8% to approximately 810 kg in 2011 
compared to 2010, but was higher than the levels observed 
during 2001–2008. The decrease in the total consumption 
in poultry can be explained by reduced consumption in 
turkeys, layers and parent flocks in the broiler production. 
In contrast, the consumption in broilers continued to 
increase in 2011. The use of fluoroquinolones has been 
low since 2006 and they were not used for poultry in 2011. 
Cephalosporins have not been used in Danish poultry 
production for at least a decade. 
Aquaculture: from 2010 to 2011 the antimicrobial con-
sumption in aquaculture decreased by 11% to 2,700 kg. 
Measured in defined doses, the major class of antimicrobial 
was sulfonamide/trimethoprim, constituting 60% of 
the con sumption in aquaculture. The consumption of 
quinolones (oxolinic acid) and florfenicol comprised 30% 
and 10%, respectively. Assuming an unchanged production 
volume, the consumption in salt water fish decreased 
by 50% (to 4.5 ADDkg/kg fish produced), while the 
consumption in fresh water fish increased by 12% in 2011 
(to 2.6 AD Dkg/kg fish produced). 
Companion animals: The available information on 
antimicrobial consumption in companion animals is not as 
detailed as for production animals. The total consumption 
in companion animals was estimated to 3 tonnes with pet 
animals accounting for approximately 2 tonnes. For oral 
treatment, the consumption in daily doses increased by 
8% from 2010 to 2011, continuing the trend since 2005. 
This trend is mainly caused by an increase in the use of 
combination penicillins (amoxycillin with clavulanic acid), 
which is combination is the drug of choice in pet animals. 
Measured in kg active compound, most (91%) of the 
combination penicillins and approximately half (51%) of 
the fluoroquinolones used for animals in Denmark during 
2011 was used for pets. The consumption of 3rd and 
4th generation cephalosporins in pet animals was stable 
and accounted for 5% (approximately 3 kg) of the total 
veterinary consumption.
 
Use of 3rd and 4th generation cephalosporins in 
horse practice was highly variable between veterinary 
practitioners, ranging from 0% to 30% of the total practice 
prescription of antimicrobials (Textbox 1). 
The extended use of antimicrobial agents critical for 
treatment of human infections and the use of broad-
spectrum antibiotics for pets and horse, as well as the 
large variation in antimicrobial use in different horse 
practices can reflect inadequate guidelines for the use of 
antimicrobial agents in pets and horses.
The total consumption in pigs has decreased 
significantly due to the yellow card initiative and the 
voluntary ban of use of cephalosporins for pigs. Use 
of antimicrobial agents in pet animals has increased 
since 2005, mainly due to use of amoxicillin with 
clavulanic acid.
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Antimicrobial consumption in humans  
In humans, the Danish Medicines Agency has monitored 
the use of prescription medicines at the level of the 
individual patient since the early 1990s. 
Total consumption: The overall consumption of 
antimicrobial agents for systemic use (primary health 
care and hospital care) remained at the same level as in 
2010 (18.84 DIDs in 2010 compared to 18.90 DIDs in 
2011), although still following the trend towards a general 
increase. Primary health care contributed with 90% of the 
overall consumption. The level of consumption in primary 
health care in 2011 was the highest observed since 1995. 
Since 2002, the total consumption of antimicrobial agents 
in Denmark has increased by 4.13 DID (28%). 
Primary health care: In primary health care, the 
consumption of antimicrobial agents for systemic use 
was 17.06 DID, compared to 16.93 DID in 2010. Beta-
lactamase sensitive penicillins still represented the largest 
therapeutic group of antimicrobial agents consumed 
(31%), and penicillins overall accounted for 63% of all 
antimicrobial agents consumed. Broad-spectrum agents 
represented 6.58 DID (39%); 0.1 DID (2%) higher than 
2010. From 2010 to 2011, the consumption of combination 
penicillins increased by 31%. Additionally, smaller upward 
changes were observed for beta-lactamase sensitive 
penicillins (1.1%) and macrolides (1.2%). 
There were several possible explanations for the high 
level of consumption in 2011: (1) an increased number of 
patients treated, (2) a Mycoplasma pneumoniae outbreak 
in October–December 2011 correlating with increased 
consumption of beta-lactamase sensitive penicillins 
(treatment for lower respiratory tract infection) and 
macrolides (for confirmed or suspected M. pneumoniae 
infection), and (3) a continuous response to changes 
in treatment guidelines (particularly for ‘combination 
penicillins’). Disease-specific changes (causing an 
increased number of treated patients) are difficult to assess 
due to lack of specific codes of indication. 
During the past decade, antimicrobial consumption in 
primary health care has increased by 29%, from 13.26 
DID in 2002 to 17.06 DID in 2011. In 2011, broad-
spectrum agents accounted for 39% (6.58 DID) of the 
total antimicrobial consumption in primary health care 
which, compared to 2002 (3.85 DID, 29%), represented 
an increase of 78%. This increase is most likely partially 
driven by rises in DDDs per treated patient and number 
of DDDs per prescribed package. The latter may reflect 
changed guidelines advising shorter treatment regimens 
at higher dosages. Possible other underlying reasons for 
the increased consumption are not possible to assess with 
certainty because of the lack of indication codes. However, 
following the decision to implement mandatory codes 
of indication for all prescribed antimicrobial agents in 
primary care in Denmark from 2012, improved data will 
become available. 
An analysis of the demographic factors associated with 
the increased antimicrobial consumption from 2001 
to 2010 showed that antimicrobial-type and substance 
specific increases were driven primarily by people older 
than 65 and adolescents. Observed age-related increases in 
tetracyclines and pivmecillinam most likely reflect changes 
in the treatment of acne and urinary tract infections, 
respectively. Population-wide increases in the consumption 
of roxithromycin, irrespective of age, may partly be 
explained by the occurrence of several large outbreaks of 
M. pneumoniae. Generally, evidence suggests that increases 
observed from 2001 to 2010 are a combination of disease-
specific factors and not least an inclination of general 
practitioners to prescribe more antimicrobial agents per 
visit and in larger doses (Textbox 3). 
Hospital care: For all hospital types (i.e. rehabilitation 
centres, hospices, private-, psychiatric-, specialised- and 
somatic hospitals), the total consumption of antimicrobial 
agents decreased from 1.91 DID in 2010 to 1.84 DID in 
2011 (a decrease of 3.7%). Since 2002, the total hospital 
consumption has increased by 0.38 DID (26%). In 2011, 
broad-spectrum agents comprised 1.22 DID of the total 
consumption, compared to 0.75 DID in 2002 (an increase 
of 67%). 
Somatic hospitals: In somatic hospitals, the consumption 
of antimicrobial agents (J01) expressed in DDDs per 100 
occupied bed-days (DBD) increased by 3.12 DBD (3.6%) 
from 87.72 DBD in 2010 to 90.84 DBD in 2011. When 
expressed as the number of DDDs per 100 admissions 
(DAD), it remained relatively constant (284.89 DAD in 
2010 compared to 282.53 DAD in 2011, a change of 0.8%). 
These figures reflect a 0.08 DDD decrease (4.2%) from 
2010 to 2011, combined with less occupied bed-days and 
more hospitals admissions in 2011 than 2010. 
When expressed as DBDs, four therapeutic groups 
accounted for most of the increase: combinations 
of sulfonamides and trimethoprim (1.07 DBD, 
35%), ‘combination penicillins’ (1.38 DBD, 19%), 
fluoroquinolones (0.26 DBD, 6.7%) and macrolides (0.17 
DBD, 4.7%). From 2010 to 2011, consumption decreased 
for beta-lactamase resistant penicillins (0.41 DBD, 5.3%), 
while smaller decreases were observed for penicillins with 
extended spectrum (0.20 DBD, 1.4%) and beta-lactamase 
sensitive penicillins (0.17 DBD, 1.8%). 
In 2011, cephalosporins accounted for 19% of the total 
consumption of antimicrobial agents in somatic hospitals, 
followed by penicillins with extended spectrum (15%), 
fluoroquinolones (12%) and beta-lactamase sensitive 
penicillins (10%). 
Over the past decade, the consumption of antimicrobial 
agents in somatic hospitals has increased from 51.73 
DBD in 2002 to 90.84 DBD in 2011 (76%) or from 258.46 
DAD in 2002 to 282.53 DAD in 2011 (9.3%), the increase 
depending on the choice of denominator. In addition to 
highlighting increases in antimicrobial consumption, these 
numbers also reflect changing hospitalization patterns by 
showing increased numbers of hospital admissions and a 
decreasing number of bed-days since 2002.
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In 2011, the overall consumption of antimicrobial 
agents for systemic use (primary health care and 
hospital care) remained at the same high level as in 
2010. Antimicrobial consumption in the primary 
sector represented 90% of the total consumption 
and the hospital sector accounted for the remaining 
10%. From 2002 to 2011, the total consumption of 
antimicrobial agents in Denmark increased by 28%. 
In the primary sector, the consumption of broad 
spectrum antimicrobial agents accounted for 39% 
of the total antimicrobial consumption in 2011, 
representing a 78% increase since 2002.
Resistance in zoonotic bacteria 
In 2011, data on antimicrobial resistance in zoonotic 
bacteria were available for Salmonella Typhimurium and 
Campylobacter. Due to insufficient number of isolates from 
other sources, only S. Typhimurium isolates from Danish 
pigs and Danish pork and humans were included in the 
report. 
Among Salmonella Typhimurium isolates from Danish 
pigs, a significant increase in resistance to ampicillin, 
neomycin, sulfonamide and tetracycline was observed 
from 2010 to 2011. In contrast to previous years, the 
levels of resistance were generally higher in isolates from 
Danish pork than from Danish pigs. In 2011, no isolates 
of S. Typhimurium from pigs were found resistant to 
cephalosporins (ceftiofur and cefotaxime) or quinolones 
(ciprofloxacin or nalidixic acid). 
Among isolates from human cases, the level of resistance 
to fluoroquinolones (ciprofloxacin) and cephalosporins 
was higher in cases associated with travel (16% and 
12%, respectively) compared to resistance levels in cases 
acquired domestically (2% and 1%, respectively). 
In 2011, the occurrence of resistance the Salmonella 
isolates from pigs, Danish pork and humans were 
markedly influenced by the clonal spread of the 
monophasic variants of S. Typhimurium which are 
resistant to ampicillin (A), streptomycin (S), sulfonamide 
(Su) and tetracycline (T), often referred to as the ASSuT-
profile. This tendency is observed throughout the farm to 
fork pathway, where the proportion of multi-resistance 
increased dramatically, while the number of fully sensitive 
isolates decreased. 
Among the S. Enteritidis isolates from human infections 
in 2011, 18% of isolates from domestic sporadic human 
cases were resistant to quinolones, a 10% increase 
compared with 2010. The level of resistance among the 
domestic sporadic isolates thereby approaches the level of 
resistance in isolates from cases with a known history of 
travel (24%) or unknown origin (27%). 
Use of tetracycline in Danish pig production 
has decreased over the last two years, while the 
occurrence of tetracycline resistance continues to 
increase significantly. This indicates that the increase 
is, at least in part, explained by the spread of resistant 
Salmonella clones, especially the monophasic S. 
Typhimurium like clones, which are the predominant 
clones in isolates from Danish pork.
 
While the level of resistance in S. Typhimurium 
isolated from Danish pigs continued the gradual 
increase observed over the last years, the resistance 
level in S. Typhimurium from Danish pork increased 
much more dramatically from 2010 to 2011.
No significant changes in resistance were observed for 
Campylobacter jejuni isolates from Danish broilers and 
cattle or for Campylobacter coli from Danish pigs from 
2010 to 2011. However, the levels of tetracycline resistance 
have increased since 2005, and this trend has been 
particularly clear in C. coli isolates in pigs from 2008 to 
2011. During this period, tetracyclines have been the most, 
or second most frequently used antimicrobial agents in 
pigs. 
As in previous years, the level of fluoroquinolones 
(ciprofloxacin) resistance in C. jejuni was significantly 
higher among isolates from imported broiler meat (57%) 
compared with isolates from Danish broiler meat (11%), 
and the difference between domestic and imported broiler 
meat is increasing. 
From 2010 to 2011, the level of tetracycline and 
fluoroquinolone resistance increased in C. jejuni isolates 
from cases of human campylobacteriosis, from both 
domestically acquired cases and from cases associated with 
travel. This is an indication of the impact of resistance in 
imported food stuffs on human disease. Furthermore, as 
has been observed in previous years, C. jejuni isolates from 
cases associated with a history of travel continue to have 
a significantly higher level of fluoroquinolone resistance 
(84%) compared to domestically acquired cases (33%).
The level of resistance in Campylobacter jejuni from 
Danish broiler meat was significantly lower than 
in isolates from imported meat. A similar pattern 
was observed among the human C. jejuni cases, 
where cases associated with a history of travel had 
significantly higher levels of resistance compared to 
domestically acquired cases.
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Resistance in indicator bacteria 
Indicator bacteria, Enterococci and Escherichia coli, 
are included in the DANMAP programme to provide 
information about the general levels of resistance in 
healthy production animals and meat. 
For Enterococcus faecium isolates from pigs there was a 
significant increase in antimicrobial resistance to beta-
lactams (penicillin and ampicillin) from 2010 to 2011. 
Furthermore, resistance to streptomycin has gradually 
increased, even though there have been no indications 
of increased use. This increase could be linked to the 
occurrence of tetracycline resistance, which may lead to 
co-selection for streptomycin resistance. In E. faecium 
from broilers resistance to avoparcin and quinupristin/ 
dalfopristin remains at low levels, more than a decade after 
the use of these growth promoters was discontinued.
Among Enterococcus faecalis isolates from pigs, a 
significant increase in resistance in antimicrobial 
resistance to the aminoglycosides kanamycin and 
gentamicin was observed, together with an increase 
in resistance to chloramphenicol, erythromycin, 
kanamycin and gentamicin. In these isolates, co-
resistance to tetracycline and erythromycin was seen 
for chloramphenicol, kanamycin and gentamicin was 
frequent.
 
For both E. faecium and E. faecalis isolates, resistance 
to erythromycin, kanamycin and streptomycin was 
significantly higher in imported broiler meat compared to 
Danish broiler meat. Similarly, significantly higher levels 
of tetracycline resistance were found in E. faecalis isolates 
from imported pork, compared to isolates from Danish 
pork.
Resistance to vancomycin and quinupristin/
dalfopristin persists at low levels among E. faecium 
isolated from pigs even though avoparcin and 
virginiamycin have not been used for more than ten 
years.
No significant changes in resistance were observed for 
indicator E. coli isolates from Danish broilers and cattle 
from 2010 to 2011, where as the level of streptomycin 
resistance decreased significantly in isolates from pigs. In 
isolates from pigs, resistance to streptomycin very often 
occur in combination with tetracycline and/or sulfonamide 
(99% in 2010 and 75% in 2011).
In general, the highest resistance levels were found 
in indicator E. coli isolates from pigs, except for 
fluoroquinolone (ciprofloxacin) resistance which was 
higher in isolates from broilers. The fluoroquinolone 
resistance in isolates from pigs and cattle has remained at 
a low level over the past decade, while the level in isolates 
from broilers varied between 7% and 13%. In this context, 
it is noted that fluoroquinolones have not been used in 
production animals in Denmark to any significant extent 
for a decade, except for the production of broilers where it 
was widely used until 2007.  
In 2011, E. coli isolates from imported broiler meat, the 
resistance levels were significantly higher compared to 
isolates from Danish broiler meat (for 11 of the 16 tested 
antimicrobial agents), including cephalosporin (ceftiofur) 
and fluoroquinolone resistance. Correspondingly, 
resistance to chloramphenicol and quinolones ( 
ciprofloxacin and nalidixic acid) was significantly higher 
in isolates from imported pork compared with those 
from Danish pork. As previous years, the occurrence of 
resistance in indicator E. coli from imported and Danish 
beef was low.
ESBL-producing bacteria are resistant to extended-
spectrum cephalosporins, which are often essential for 
treatment of infections in humans. Consequently, even 
a low occurrence of these bacteria can potentially be 
hazardous. Therefore, the occurrence of ESBL-producing 
E. coli in pig at the farms, cattle and pigs at slaughter and in 
meat at retail was investigated using selective enrichment. 
The voluntary ban of cephalosporin usage in the Danish 
pig production has reduced the level of ESBL-producing E. 
coli in pigs. In contrast, the prevalence of ESBL-producing 
E. coli in cattle remained unchanged compared to 2010. 
Probably because 3rd and 4th generation cephalosporins 
are still used for intramammary and systemic treatment in 
cattle, even though the usage is decreasing. 
The occurrence of ESBL-producing E. coli in Danish 
Broiler meat increased from 8.6% in 2010 to 44% in 2011; 
a level similar to what is observed in the imported broiler 
meat (48%), even though cephalosporins have not been 
used in the Danish broiler production for a decade. A 
possible explanation is the increased use of extended 
spectrum penicillins in the Danish broiler production, 
which may co-select for ceftriaxone resistant E. coli being 
introduced via imported breeding animals.
The presence of ESBL-genes differed depending on animal 
reservoir. CTX-M-1 was the most common ESBL-gene 
in pigs and cattle, but also CTX-M-14 and CTX-M-15 
was found. All are ESBL-genes that are often found in 
ESBL-producing E. coli causing human infections. Broiler 
meat, both Danish and imported, seemed to be the most 
important meat sources and CMY-2 was the most common 
type in broiler meat. CMY-2 was also found in ESBL-
producing E. coli causing human infections.
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Resistance in human clinical bacteria 
Data on antimicrobial resistance in bacteria from 
diagnostic submissions from human patients were 
gathered by voluntary reporting from the DANRES group 
which covers the Departments of Clinical Microbiology 
(DCM) in Denmark. Exceptions were methicillin resistant 
Staphylococcus aureus (MRSA) and invasive Streptococcus 
pneumoniae that are notifiable. Data on these bacteria 
were obtained from the reference laboratories at SSI. 
Among Escherichia coli blood isolates, resistance to 
3rd generation cephalosporins was 8% in 2011, the 
same level as reported in 2010, but above the 2010 level 
in the other Nordic countries. In 2011, ciprofloxacin 
resistance was 14% (min. 12%, max. 31% at the individual 
DCM), the same level as in 2010. Over the last decade, 
resistance to cefuroxime, ciprofloxacin and gentamicin 
has increased significantly. Resistance to 3rd generation 
cephalosporins has only been reported since 2008; in this 
period the resistance has increased. In 2011, carbapenem 
(meropenem) resistance was not observed in E. coli blood 
isolates. 
In E. coli urine isolates obtained from hospitals, 
resistance to 3rd generation cephalosporins was 5% in 
2011, the same level as in 2010. A significant increase in 
fluoroquinolone resistance (in 2011: ciprofloxacin 13%, 
nalidixic acid 17%) was observed from 2010 to 2011. Over 
the last decade, an increase in fluoroquinolone resistance 
has been observed (in 2002: ciprofloxacin 2%, nalidixic 
acid 6%). Aminoglycoside (gentamicin) resistance 
increased significantly from 3.7% in 2010 to 4.4% in 2011. 
In E. coli urine isolates obtained from primary health 
care, resistance to 3rd generation cephalosporins was 3% 
in 2011, the same level as in 2010. Sulfonamide resistance 
decreased significantly from 37% in 2010 to 35% in 2011. 
Carbapenem (meropenem) resistance was observed in E. 
coli urine isolates from both hospitals (n = 5) and primary 
health care (n = 3). The occurrence of carbapenem 
resistance is not mandatory reportable and no calculation 
of the frequency of carbapenem resistance could be made 
for E. coli. 
In Klebsiella pneumoniae blood isolates, resistance to 
3rd generation cephalosporin (10%), fluoroquinolones 
(ciprofloxacin 12%, nalidixic acid 18%) and 
aminoglycoside (gentamicin 6%) was the same level as 
reported in 2010. The level was above the level reported 
by the other Nordic countries and corresponded to the 
occurrence reported by several other European countries 
in 2010. In 2011, carbapenem (meropenem) resistance 
was observed in one K. pneumoniae blood isolate. 
In K. pneumoniae urine isolates, 3rd generation 
cephalosporin resistance decreased significantly in 
isolates obtained from hospitals (from 12% in 2010 to 
10% in 2011) and from primary health care (from 7% in 
2010 to 5% in 2011). Cefuroxime resistance decreased 
significantly from 13% in 2010 to 11% in 2011 in 
isolates obtained from hospitals. A significant decrease 
in fluoroquinolone resistance was observed from 2010 to 
2011 among urine isolates from hospitals (ciprofloxacin 
from 14% in 2010 to 11% in 2011) and primary health care 
(ciprofloxacin from 12% in 2010 to 9% in 2011, nalidixic 
acid from 20% in 2010 to 14% in 2011). Also, mecillinam 
resistance decreased significantly from 2010 to 2011 
in isolates from hospitals (in 2011: 12%) and primary 
health care (in 2011: 12%). In K. pneumoniae isolates 
obtained from hospitals, sulfonamide resistance increased 
significantly from 29% in 2010 to 33% in 2011. 
Carbapenem (meropenem) resistance was observed in 
K. pneumoniae urine isolates from both hospitals (n = 5) 
and primary health care (n = 1). One of the carbapenem 
resistant isolates was KPC-2 positive (Textbox 11). It is 
not mandatory to report the occurrence of carbapenem 
resistance and calculation of the frequency of carbapenem 
resistance could not be made for K. pneumoniae. 
An increased frequency of gentamicin, ciprofloxacin, 3rd 
generation cephalosporin resistance and multi-resistance 
(gentamicin, ciprofloxacin, 3rd generation cephalosporins) 
in E. coli blood isolates (2008–2010) has been found to 
parallel an increased consumption of broad spectrum 
antimicrobial agents (2007–2010) (Textbox 8). 
In October 2011, 12 of the 13 DCM screened all E. coli 
and K. pneumoniae urine and blood isolates for ESBL-
production. The ESBL-prevalence obtained in 2011 was 
compared to data from similar studies performed in 
2007 and 2009. From October 2009 to October 2011, 
the prevalence of ESBL-producing E. coli increased 
significantly in urine samples from both community 
(from 2.3% in 2009 to 3.2% in 2011) and hospitals (from 
3.8% in 2009 to 4.7% in 2011). As in previous years, 
CTX-M-15 dominated among ESBL-producing E. coli and 
K. pneumoniae isolates from urinary tract and bloodstream 
infections from patients, while CTX-M-1, CTX-M-14 and 
CMY-2 were present in a limited number of the isolates 
only (Textbox 9). 
In the Eastern part of Denmark (Zealand), the occurrence 
of resistance to 3rd generation cephalosporin, ciprofloxacin 
and gentamicin in K. pneumoniae from urinary tract and 
bloodstream infections from hospitalised patients was 
significantly higher than in the western part of the country 
(Funen and Jutland). The same tendency was observed 
in K. pneumoniae urine isolates from primary health care 
patients, where resistance to 3rd generation cephalosporins 
and fluoroquinolones (ciprofloxacin and nalidixic acid) 
was significantly higher in isolates from the eastern part 
of Denmark (Zealand) than the western part (Funen and 
Jutland) (Textbox 10). 
In the period 2008–2011, 15 carbapenemase producing 
enterobacteria (CPE) were detected in Denmark. These 
included 2 VIM-, 3 KPC-, 3 NDM-1- and 7 OXA-48- 
producing isolates. Of the 15 CPE cases observed, 10 
were detected in 2011 and most of these were recovered 
from Libyan patients sent to Denmark to receive medical 
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assistance for injuries during the Libyan conflict (Textbox 
11). CPE are not mandatory reportable in Denmark, and 
it is possible that more cases could have been present than 
those described in Textbox 11. 
Antimicrobial resistance in Pseudomonas aeruginosa 
blood isolates was low for all the tested antimicrobial 
agents. 
Resistance to penicillins and erythromycin in 
Streptococcus pneumoniae and in Group A, B, C and G 
streptococci remained low in 2011. 
In 2011, resistance to ampicillin was 93% in Enterococcus 
faecium isolates from blood, the same level as in 
2010. Vancomycin resistance was 1.3% in E. faecium, 
whereas none of Enterococcus faecalis blood isolates 
were vancomycin resistant. Only one DCM tested all 
enterococci from bloodstream infections for High-level 
gentamicin resistance (HLGR). Here, 31% of the E. faecalis 
isolates tested and 74% of E. faecium isolates were HLGR. 
In 2011, 1,525 cases of Staphylococcus aureus bacteraemia 
were reported, corresponding to 24.6 cases per 100,000 
citizens. The number of methicillin resistant S. aureus 
(MRSA) was 21 (1.4%), a level similar to previous years 
and among the lowest incidences recorded in Europe. The 
highest frequency of resistance in addition to penicillin 
was observed for fusidic acid (13.3%), erythromycin 
(6.6%), clindamycin (5.8%) and norfloxacin (3.6%). 
Susceptibility to the tested antimicrobial agents was at the 
same level as in 2010. 
The number of new cases of MRSA (both infected and 
colonized persons) increased in 2011 to 1,292 compared 
to 1,097 in 2010. Thus the increase observed in 2010 
continued in 2011. The increase was primarily seen in 
cases categorised as community-acquired (CA), 578 in 
2010 vs. 751 in 2011. The proportion of cases presenting 
with infection was lower in 2011 than in 2010 (53% 
vs. 59%). The number of hospital-acquired (HA) cases 
continued to be low and constituted only 5% of the total 
number of MRSA cases in 2011. 
The number of MRSA belonging to clonal complex CC398, 
which is associated with pigs, increased from 111 in 2010 
to 164 in 2011. In 24 of these cases, no known contact to 
pigs or people with contact to pigs was reported. Twelve 
of these cases were categorised as CA with no known 
exposure but the majority of the cases lived in areas 
with reported CC398 in humans and/or pigs. The most 
frequent spa type related to CC398 was type t034 (n = 
130). Forty-nine t034 cases represented infections. MRSA 
isolates carrying the new mecA homologue mecC were 
demonstrated in 37 cases (9 in 2009, 21 in 2010). 
Whole genome sequencing of 90 S. aureus isolates 
belonging to the pig related CC398 clone revealed a 
phylogenetic distinction between isolates obtained from 
pigs, turkeys and humans. The phylogeny indicates that 
CC398 in pigs are descendants of a human-to-animal host 
jump. After being introduced in pigs, CC398 underwent 
rapid diversification, accompanied by loss of several 
genes that encode modulators of human innate immunity 
(e.g., scn) and acquired the tetracycline and methicillin 
resistance (MRSA) genes. The loss of several functions 
associated with human adaptation may explain why MRSA 
CC398 has lost part of its colonization and transmission 
ability in humans. On the other hand, the findings show 
that MRSA CC398 is able to reacquire the same genes, 
which may enhance its ability to colonize and infect 
human (Textbox 12).
The prevalence of MRSA in Danish pig farms (16%) were 
at the same level as in 2010, while the level in pigs at 
slaughter increased dramatically from 2010 to 2011. This 
may reflect higher within-herd prevalence, increasing the 
transmission between pigs during transport and before 
slaughter. Also, the prevalence in Danish pork increased, 
suggesting that the pork production chain is more highly 
contaminated compared to previous years. In meat, MRSA 
was found in a significantly higher prevalence compared 
to 2010 in imported broiler meat, but so far meat is not 
considered a source for human infection. The relatively 
frequent occurrence of MRSA in meat combined with very 
few cases in humans in urban areas indicates that there is 
very little risk of MRSA being food borne hazard.
In 2011, the total number of new MRSA cases 
increased to 1292. This increase was primarily 
apparent in cases defined as having community-
acquired infection. The number of hospital-
acquired cases remained low and accounted for only 
5% of the total number of MRSA cases in 2011. The 
number of MRSA type CC398, which is associated 
with pigs, increased to 164 in 2011. Pigs are still 
the most important reservoir for MRSA CC398 
and the occurrence in positive herds have possibly 
increased.
 
From October 2009 to October 2011, the prevalence 
of ESBL-producing E. coli increased significantly in 
urine samples, from both primary health care and 
the hospital sector. 
The prevalence of resistance to 3rd generation 
cephalosporins and ciprofloxacin in K. pneumoniae 
from urinary tract and bloodstream infections in 
hospital patients was significantly higher in the 
eastern part of Denmark (Zealand) compared to the 
western part (Funen and Jutland). 
During 2008–2010, a total of 15 cases of 
carbapenemase-producing enterobacteriaceae were 
detected of which the majority was imported. Ten of 
these cases were detected in 2011.
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3. General information
Source: Statistics Denmark [www.dst.dk] and the Danish Medical Association [www.laeger.dk]. GP=general practitioner
Figure 3.1 The five health care regions and 14 Departments of Clinical Microbiology (DCM) of Denmark
DANMAP 2011
The distribution of the Danish population in which 
antimicrobial agents were used in 2011 is displayed in 
Figure 3.1, together with the five health care regions and 
the 14 Departments of Clinical Microbiology (DCMs). 
In 2011, the number of slaughtered cattle increased by 
6% compared to 2010 (Table 3.1). The number of pigs 
produced (slaughtered or exported) increased by 3%, 
mainly due to an 8% increase in production of weaning pigs 
(around 30 kg). Hence, the production in kg pork produced 
(including export) only increased, by 2% (Table 4.1). The 
export of fattening pigs (15–50 kg) has increased almost 
fivefold since 2004 and at export; these pigs have received 
a large amount of antimicrobial agents relative to their 
bodyweight. 
From 2010 to 2011, the production of turkeys and turkey 
meat decreased by 19% and 33%, respectively. The annual 
production of turkeys has fluctuated considerably over 
the last decade. Since 2006, more than 99% of the turkeys 
produced have been exported for slaughter, thus all turkey 
meat availeble in Denmark are listed as imported.
The amount of meat available for consumption in 
Denmark during 2007–2011 is presented in Table 3.2. 
The amount of domestically produced meat available for 
consumption in Denmark is estimated as production 
minus export, and includes chilled and frozen fresh meat 
as well as natural-marinated broiler meat. Overall,
2.7 mill tonnes pork, 2.0 mill tonnes beef and 1.3 mill 
tonnes broiler meat was available for consumption in 
Denmark during 2011. Approximately 64% of the pork and 
broiler meat, and 50% of the beef was of Danish origin. 
Compared to 2010, the volume of imported pork and 
broiler meat increased by 7% and 4%, respectively, where 
as the volume of imported beef and turkey meat decreased 
by 2% and 16% respectively. 
North Denmark 
Region
Central Denmark Region
 Region of 
Southern 
Denmark
The Sealand
Region
The Capital Region of 
Denmark
DCM Aalborg
DCM Midt-Vest
(Viborg)
DCM Herlev
DCM Esbjerg
DCM Vejle
DCM Region Sealand
(Nykøbing F)
DCM Odense
DCM 
Sønderborg
DCM Midt-Vest
(Herning)
DCM Region Sealand
(Slagelse)
DCM Århus
DCM 
Rigshospitalet
DCM Hvidovre
DCM Hillerød
North Denmark Region
No. of inhabitants 580,293 
No. of inhabitants/km2 73        
No. of inhabitants/GP 1692
The Sealand Region
No. of inhabitants 818,321 
No. of inhabitants/km2 113        
No. of inhabitants/GP 1583
The Capital Region of Denmark
No. of inhabitants 1,713,624 
No. of inhabitants/km2 669         
No. of inhabitants/GP 1568
Region of Southern Denmark
No. of inhabitants 1,201,365 
No. of inhabitants/km2 98        
No. of inhabitants/GP 1485
Central Denmark Region
No. of inhabitants 1,265,601 
No. of inhabitants/km2 96        
No. of inhabitants/GP 1519
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3. General information Table 3.1. Production of food animals, meat and milk, Denmark
DANMAP 2011
Source: Statistics Denmark (2012), the Danish Directorate for Fisheries and Danish Agriculture and Food Council. All data include export of 
live animals for slaughter.
a) The production of farmed fish includes fish transferred from one production facility to another. In 2010, this included 4 tonnes transferred 
between freshwater facilities (9.4% of the freshwater production), and 2.7 tonnes transferred from freshwater to salt water facilities (18% of the 
saltwater production)
b) Including export of all age groups (not only for slaughter)
c) Export of 15-50 kg pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as it 
takes place outside Denmark
d) Increase from 2010 to 2011
Year
Broilers Turkeys Cattle(slaughtered) Dairy cows Pigs
 Farmed fish(a) 
Fresh 
water
Salt 
water
1,000 
heads mill. kg
1,000 
heads mill. kg
1,000 
heads
mill. 
kg
1,000 
heads
mill. Kg
milk
1,000 
heads(b)
Export
1,000
heads(c)
mill. kg mill. kg mill. kg
2002 136350 190 1073 12.8 668 169 611 4455 24203 - 1892 32 8
2003 129861 181 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 181 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 180 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 163 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 178 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 186 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 181 1175 11.1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 199 1184 14.0 519 142 574 4830 28505 7074 1974 28 10
2011 115454 201 960 9.4 551 145 575 4801 29399 7632 2008 - -
Increase 
(%)(d) -2 1 -19 -33 6 2 0 -1 3 8 2 - -
DANMAP 2011
Table 3.2. Danish and imported chilled and frozen fresh meat available for consumption (in 100 tonnes)(a), Denmark
Source: Statistics Denmark (2012)
a) The volumes of Danish meat is estimated as production minus export
b) Natural-marinated broiler meat included
c) Increase from 2010 to 2011
Year Pork Beef Broiler meat
(b) Turkey meat
Danish Import Danish Import Danish Import Import
2007 1847 402 730 803 626 304 84
2008 2158 831 831 814 478 325 83
2009 1868 833 845 888 513 303 70
2010 1851 896 968 1005 555 437 87
2011 1759 961 1004 984 829 453 74
Increase 
(%)(c) -5 7 4 -2 49 4 -16
Table 3.3 shows the antimicrobial agents that are 
registered for treatment of bacterial infections in animals 
and humans. Some of these antimicrobial agents are 
considered critically important for humans by WHO. An 
antimicrobial agent is considered critically important if it 
is the only compound, or one of limited available therapy, 
to treat serious human disease. Critically important 
antimicrobial agents are also agents used in non-human 
sources to treat diseases that may be transmitted to 
humans, or human diseases caused by bacteria that 
may acquire resistance genes from non-human sources. 
Fluoroquinolones, 3rd and 4th generation cephalosporins, 
macrolides and glycopeptides are among the antimicrobial 
agents considered critically important for humans 
[AGISAR, WHO 2009].
Growth promoters, which are no longer used for animals 
in Denmark, are shown in parentheses in Table 3.3. Most 
of the antimicrobial agents used for growth promotion 
in Denmark had effects on Gram-positive bacteria. Since 
1995, the indicator enterococci from animals and meat 
(and in some years from healthy humans) have been used 
as a measure of resistance to the growth promoters.
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Table 3.3.  Antimicrobial agents marketed (a) for systemic and veterinary intramammary therapeutic use in animals and 
humans, Denmark 2011
ATC / ATCvet codes (b) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
J01BA / QJ01BA Amphenicols Florfenicol
J01CA / QJ01CA Penicillins with extended spectrum Ampicillin, amoxicillin
Ampicillin, pivampicillin, 
amoxicillin, pivmecillinam, 
mecillinam
J01CE / QJ01CE Beta-lactamase sensitive penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, procaine 
penicillin, penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant penicillins Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-lactamase inhibitors Amoxicillin/clavulanate
Amoxicillin/clavulanate, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin
J01DC Second-generation cephalosporins Cefuroxime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins Cefoperazone, ceftiofur, cefovecin Cefotaxime, ceftazidime, ceftriaxone
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem, imipenem/cilastatin
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides
Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin
Erythromycin, roxithromycin, 
clarithromycin, azithromycin
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01G / QJ01RA,QA07AA Aminoglycosides Streptomycin, dihydrostreptomycin, gentamicin, neomycin, apramycin Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones
Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ofloxacin, ciprofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / Not in 
ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, (bacitracin) Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) Animal growth promoters used before 1999 are listed in parentheses, but not marketed in 2011
b) ATCvet codes starts with a Q
c) Although intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) are used to treat human patients, they 
are not reported by DANMAP
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4. Antimicrobial consumption in animals
4.1  Introduction
The antimicrobial consumption in humans has gradually 
increased since the end of the 1990’ies. In contrast, 
changes in the antimicrobial use for animals, during the 
same period, have been more notable. Figure 4.1 shows the 
total antimicrobial consumption in animals and humans 
since 1990 and 1997, respectively.
Figure 4.1. Consumption of antimicrobial agents and growth promoters in animal production, number of pigs produced  
and prescribed antibacterials in humans, Denmark
DANMAP 2011
Since the early 1990’ies there has been both political and 
public focus on the use of antimicrobial agents in the 
Danish animal production. This resulted in the ban of 
avoparcin for growth promotion in 1994 and voluntary 
phasing out of the remaining antimicrobial agents for 
growth promotion from 1996 to1999. The antimicrobial 
growth promoters comprised mainly tylosin (macrolide) 
and other antimicrobial agents acting on mainly the 
Gram-positive flora. 
Use of coccidiostatic agents as feed additives for poultry is 
legal without prescription. These data are not presented in 
this report, but are published on the DANMAP web page 
(web annex, Table A4.5).
Regarding veterinary prescription medicines, a number of 
interventions affect the present antimicrobial consumption 
pattern in Denmark [DANMAP 2010]. 
Some of the implemented legislation has clearly influenced 
the prescription pattern. For example, a steep decrease 
in antimicrobial consumption from 1994 to 1995 was 
likely the result of 1) Limitation of veterinarians profit 
from sales of medicine [Directive (DK) 60/1995], and 
2) Enforcement of the so called “cascade rule” [Order 
(DK) 142/1993], which dramatically limits the use of 
(cheaper) extemporaneously produced medicines; this 
particularly affected the use of tetracyclines from 1994. 
Another important intervention was the restriction on the 
use of fluoroquinolones in production animals, through 
legislation implemented in 2002 and 2003. Effects of 
other parts of the legislation may be less obvious, but 
are important to keep in mind, when interpreting the 
veterinary prescription patterns.
During the period 2001–2009, the antimicrobial 
consumption in production animals increased gradually 
by 36% (Figure 4.1), where the number of pig produced 
increased by 19% during the same period (Table 3.1). 
However, from 2010 to 2011 consumption decreased 
by 17%, following the introduction of the “yellow card” 
Sources: Human therapeutics: The Danish Medicines Agency. Veterinary consumption: 1990–2000 data based on reports from the 
pharmaceutical industry of total annual sales; 1990–1994 data from ‘Use of antibiotics in the pig production’ [Federation of Danish 
pig producers and slaughterhouses. N. E. Rønn (Ed.)]; 1996–2000 data from Danish Medicines Agency and Danish Plant Directorate;  
2001–2011 data from VetStat 
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legislation, which enforces legal actions on pig farmers 
with high antimicrobial use per pig [DANMAP 2010]. 
Furthermore, in July 2010, the pig industry imposed a 
voluntary ban on use of cephalosporins, due to concerns 
regarding extended beta-lactamase resistance (ESBL). 
Despite an increase of 17% in the total meat production 
since 1994 (Table 3.1), the overall consumption was 51% 
lower in 2011 than in 1994, before the aforementioned 
interventions were implemented.
Official guidelines for the choice of antimicrobial agents in 
pigs and cattle have been available for veterinarians since 
1996. The guidelines provide specific recommendations 
for the selection of the appropriate antimicrobial agents for 
treatment of all common indications in major production 
animal species. Initially, guidelines were developed by 
the National Veterinary Serum Laboratory (presently, the 
National Veterinary Institute). Since 2005, the guidelines 
have been updated by the Danish Veterinary and Food 
Administration (DVFA) in collaboration with the National 
Veterinary Institute, the National Food Institute, the 
Practicing Veterinarians Organization, University experts, 
and the Danish Agriculture and Food Council. The latest 
update was in 2010, when new dynamic evidence based 
treatment guidelines for pigs were launched [DANMAP 
2010].
4.1.1  Data sources
Data on antimicrobial use have been collected in Denmark 
since 1996, including historical data back to 1990. Until 
2001, data were available on product level, based on reports 
from the pharmaceutical industry of the total annual 
sales. In addition, sales of antimicrobial growth promoters 
and coccidiostatic agents approved as feed additives were 
reported by the feed mills to the Plant Directorate before 
2001. Since 2001, the consumption data presented in the 
DANMAP report have been obtained from the national 
monitoring programme, VetStat (web annex, Table A4.1). 
In Denmark, all therapeutic medicine is prescription-only, 
and VetStat collects data on all medicines prescribed by 
veterinarians for use in animals. Data on consumption of 
antimicrobial feed additives, including coccidiostatic agents 
(non-prescription) and antimicrobial growth promoters 
(no longer in use), are also collected by VetStat. The 
VetStat database contains detailed data on all prescription 
medicines for animals, including item ID (Nordic Item 
Number) and amount, date of sale, recipient (farm-ID or 
practice ID), prescribing veterinarian (ID), species, age 
group, and disease group (see Section 10.2 for further 
description).
4.1.2  Methods
The measures of antimicrobial consumption are numerous, 
each of which has advantages and limitations. Therefore, 
the chosen measure must depend on the purpose and the 
available information. 
Numerators
The consumption may be measured in grams of active 
compound or in number of doses. Doses are species 
specific and defined as “Defined Animal Daily Doses” 
(ADD), and these can vary importantly, particularly 
between mammals and poultry. Consequently, grams of 
active compound are only used as the measure for the 
overall consumption in DANMAP.
ADDkg is defined as the assumed average maintenance 
dose per day, for treatment of one kg animal for the 
main indication in a specified species. Since this value is 
independent of the weight of the animals treated, ADDkg 
is used for measuring consumption across age groups. 
Correspondingly, the ADDx, is the species and/or age-
group specific assumed average maintenance dose for a 
standard body weight of ‘x’ kg. The standard body weight 
is the assumed average body weight at treatment; e.g. for 
weaning pigs (7–30 kg) it is 15 kg. Thus, the antimicrobial 
consumption for weaning pigs can be measured in ADD15 
(for more details, see DANMAP 2009). 
Denominators
In DANMAP, the animal production is used as the 
preferred denominator the description of trends in 
consumption within species. Animal production is 
measured either in kg-meat-produced (including export of 
live animals) or in number of animals produced, including 
slaughtered and exported animals.
For comparison of selection pressure between species, the 
population at risk (biomass-year-at risk) is a more suitable 
denominator. The biomass-year-at risk takes into account 
both species differences in body-mass and life-span (Figure 
4.2). Measuring the population at risk as animal-year-at-
risk (or biomass-year-at risk) is similar to the denominator 
used in human pharmaco epidemiology (inhabitant days, 
as in DID, see Chapter 5), except for timespan (year vs. 
1000 days).
For the evaluation of trends over time, data should 
be adjusted for changes in production structure, as 
discussed in DANMAP 2009. For example, important 
changes have occurred in the pig production, with the 
5-fold increase in number of pigs exported around 30 
kg bodyweight, involving 26% of pigs produced in 2011. 
Pigs produced only to 30 kg contribute relatively little 
to the total production (by weight), while the amount of 
antimicrobials used for this part of the production (birth 
to 30 kg, i.e. including sows, piglets and weaning pigs) 
comprise two thirds of the total antimicrobial consumption 
for pigs. Thus, the consumption would be underestimated 
if it was merely divided by number of pigs produced(see 
also Figure 4.3). Conversely, the consumption would be 
overestimated if the pigs exported at 30 kg were included 
in the production by bodyweight produced. 
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Pigs, 77%
Cattle, 14%
Poultry, 1%
Fur Animals, 4%
Pet animals, 2%
Aquaculture, 2%
Kg active compound
Pigs, 47%
Cattle, 47% Poultry, 2%
Fur Animals, 2%
Pet animals, 1%
Aquaculture, 1%
Live biomass, mill kg
In this report, trends in antimicrobial consumption in 
pigs are measured using number of pigs produced as 
the denominator, adjusted for changes in production. 
The adjustment is based on the assumption that pigs 
exported at 30 kg, compared to those not exported, on 
average received the same amount of antimicrobial agents 
before export, as other pigs from farrowing to 30 kg. This 
calculation provides a more robust measure of production 
(see formulas in Section 10.2.).
4.2  Total antimicrobial consumption
In 2011, the total veterinary consumption of antimicrobial 
agents, including agents used for companion animals 
amounted to 107.9 tonnes (Table 4.1), representing a 15% 
decrease compared to 2010. The decrease was mainly 
attributed to a 19% decrease in consumption in pigs. 
The distribution of total consumption of antimicrobial 
agents between the three major animal species has not 
changed importantly from previous years. In 2011, the 
antimicrobial consumption in pigs, cattle and poultry 
comprised 77%, 14%, and 0.7% of the total veterinary 
consumption, respectively (Figure 4.2).
The two major species, cattle and pigs, comprise equal 
proportions of the standing live biomass. However, the 
vast majority of cattle biomass is comprised by dairy cows, 
which have a very low consumption of antimicrobial 
agents compared to growing animals. Antimicrobial 
consumption in cattle comprises only a minor part of the 
total veterinary consumption.
Figure 4.2. Live biomass (mill kg) and antimicrobial consumption (kg) in main animal species, Denmark
Note: The live biomass is estimated from census data (pigs, cattle and pet animals), production (poultry, fur animals, aquaculture). The 
estimation procedures are described in Section 10.2. For poultry: the figures comprise only the biomass and antimicrobial consumption for 
the main production types (turkey and broiler production)
DANMAP 2011
                                                                           
       31DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN ANIMALS 4.
Table 4.1. Antimicrobial agents sold (kg active compound)(a) by animal species and age group, Denmark 
DANMAP 2011
Therapeutic group(a) Amcol Amglc Ceph FQ Quinol Linco Macro Pleuro Pen-β-sens
Pen-
other
Sulfa-
TMP Tet Others Total
ATCvet groups(c) QJ01B
QJ01
G
QJ01
DA
QJ01
MA
QJ01
MB
QJ01
FF
QJ01
FA
QJ01
XX
QJ01
CE
QJ01
CA
QJ01
E
QJ01
AA
QJ01
X
Pigs, total 226 4409 1 5 0 2257 9894 7531 16158 7316 7135 26129 382 81443
- Sows and piglets 181 1942 <1 5 0 495 502 683 8396 3815 5895 1887 56 23859
- Weaners 23 2195 <1 <1 0 686 6010 2805 1565 2440 1061 14603 324 31713
- Finishers 22 270 <1 <1 0 1076 3378 4040 6196 1058 174 9635 3 25853
- Age not given <1 <1 <1 <1 0 <1 3 3 <1 2 5 3 <1 18
Cattle, total (c) 504 755 117 1 0 24 227 4 7933 1197 2092 1813 10 14678
- Intramammaries 0 19 69 0 0 3 0 0 193 150 6 <1 2 442
- Cows and bulls 24 330 42 <1 0 7 138 <1 6902 689 1042 1300 <1 10475
- Calves<12
  months 459 280 2 <1 0 2 52 0 353 185 419 422 7 2181
- Heifers, Steers 20 24 <1 0 0 <1 9 0 158 23 58 53 <1 345
- Age group unknown 
(d) 1 102 3 1 0 12 27 4 328 150 567 38 <1 1235
Poultry, total(e) 1 1 0 <1 0 <1 148 5 50 292 43 227 <1 769
- Broilers 0 0 0 0 0 0 27 0 26 254 0 86 0 394
- Breeding and 
rearing, broilers 0 0 0 0 0 0 0 0 8 10 0 3 0 21
- Layers               
incl. rearing 0 0 0 0 0 0 4 4 <1 6 3 <1 <1 18
- Turkeys <1 0 0 0 0 0 108 0 11 5 4 122 0 251
- Geese and ducks 0 <1 0 0 0 0 <1 0 <1 0 4 3 <1 7
- Gamebirds <1 1 0 0 0 <1 6 1 4 13 25 10 <1 61
- Species unknown <1 <1 0 <1 0 <1 3 <1 0 3 8 3 0 17
Other production 
animal species 188 377 <1 1 357 185 707 0 7 1886 2857 1017 <1 7582
- Small ruminants <1 2 <1 0 0 <1 4 0 3 4 3 11 <1 29
- Fur animals <1 373 <1 1 0 185 703 0 1 1877 684 994 <1 4820
- Aquaculture 188 <1 0 0 357 0 0 0 0 <1 2160 6 0 2711
- Other production 
animals <1 <1 <1 <1 0 <1 0 0 2 2 11 <1 <1 17
species unknown(f) 0 <1 <1 <1 0 0 -1 0 <1 2 <1 4 <1 6
Companion animals, 
total <1 33 317 14 0 68 16 2 390 677 1097 90 42 2748
- Pet animals <1 22 313 12 0 68 15 <1 106 670 349 64 41 1663
- Horses or pets <1 2 <1 <1 0 <1 <1 0 25 4 50 3 <1 84
- Horses <1 10 3 2 0 <1 <1 2 259 4 698 23 <1 1002
Species unknown(g) 
- Systemic use 2 88 2 1 0 6 -10 7 241 71 128 145 0 680
- Topical drugs <1 2 0 <1 0 0 0 0 0 0 <1 25 3 30
- Intramammaries 0 1 1 0 0 <1 0 0 4 <1 3 0 <1 9
Total 922 5665 438 24 357 2541 10981 7549 24783 11440 13356 29445 438 107940
a) Amcol = amphenicols; Amglc = aminoglycosides; Ceph = cephalosporins; FQ = fluoroquinolones; Quinol = other quinolones; Linco = 
lincosamides; Macro = macrolides; Pleuro = Pleuromutilins; Pen-β-sens = beta-lactamase sensitive penicillins; Pen-other = penicillins with 
extended spectrum, cloxacillin and amoxicillin/clavulanic acid; Sulfa-TMP = sulfonamides+trimethoprim; Tet = tetracyclines. Sulfaclozin (a 
prescription coccidiostat) is included in the sulfonamide/trimethoprim group
b) Only the ATCvet group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds
c) In 2011, half of the prescribed antimicrobials for cattle was purchased at pharmacies; half was either administered or handed out by 
veterinary practitioners. Reporting from large animal practice on medicines for cattle is validated against data on medicines sold from 
pharmacies to cattle practice (not mixed practice), and the proportion in accordance is included under the respective age groups. Medicines 
sold to cattle practice, but usage not reported by a veterinarian are included under "age group unknown"
d) About 10% of the pharmacy sales for use in cattle practice is not reported (possibly due to factor errors at reporting), when used or sold in 
practice, amounting to 1.2 tonnes in 2011. In addition, part of pharmacy sales to farms are lacking age group ID, amounting to 33 kg in 2011
e) In 2011, sulfamethoxazole was used in poultry on special permission, due to problems with resistance in E.coli infections. A total of 
approximately 40-50 kg was used, species/age group not known, and the data are not part of the VetStat database, presumably mostly in the 
broiler production. These data are not included in this table, as the precise target species/age group not known, and the data are not part of the 
VetStat database
f) Sales to farmers (valid farm ID codes) given, but animal species not identifiable. Negative numbers are due to redrawel of sales to specific 
species (not picked up by the farm owner)
g) Negative numbers are due to over-reporting by veterinarians of antimicrobial medicines used in practice to specific species
32                          
                   
DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN ANIMALS4. Textbox 1
Patterns of antimicrobial consumption in Danish horse practices
Background: In general, national monitoring programs have focused on surveillance of antimicrobial consumption 
rates as well as antimicrobial resistance in food animals, food and humans, while antimicrobial consumption in 
companion animals has received little attention. The aim of this study was to investigate the prescription patterns and 
trends in antimicrobial consumption in 11 Danish horse practices.
Materials and methods: Data on prescription of antimicrobial agents in 11 horse practices during 2007 through 2010 
were extracted from the pharmacy data at Statens Serum Institute (SSI; formerly the Danish Medicine Agency). These 
data only included antimicrobial agents prescribed by veterinarians currently employed in those practices, excluding 
prescription for use in other practices. Thus historical data were increasingly incomplete further back in time, when 
other veterinarians were employed in these practices. Only antimicrobial agents prescribed for horses or for use in 
practice were included. The consumption was measured in kg active compound by antimicrobial class as well as 
in ADDs, defined as the highest approved dose for 400 kg horse according to the registered summary of product 
characteristics (SPC). 
For validation purposes, data for the 11 practices were also extracted from VetStat, including additional prescriptions 
by formerly employed veterinarians for use in the 11 practices. Differences in proportions of antimicrobial classes and 
differences in prescription patterns between different practice types were tested using an analysis of variance (Tukey-
Kramer) and multiple comparison test (LS-means and Tukey).
Results: In the 11 practices, the consumption of beta-lactamase sensitive penicillin (Penicillin-G) and sulfonamide-
trimethoprim (S-TMP) was significantly higher than consumption of the other antimicrobial classes, increasing from 
62% to 81% of the total use in 2007 and 2010, respectively (Table 1). 
Yearly consumption of S-TMP was relatively constant, accounting for approximately one third of all antimicrobial 
agents consumed. The majority of S-TMP given was as oral paste, as the only approved oral antimicrobial preparation 
for horses. This might explain the high consumption due to high owner compliance. Penicillin-G consumption 
increased from 32% in 2007 to 48% in 2010 (Table 1). Also, the proportional use of cephalosporins and tetracyclines 
increased during the four year, coinciding with decreasing use of aminoglycosides, macrolides and lincosamides. In 
2007, aminoglycosides (mainly gentamicin) was the third most used class, accounting for 28%; however the usage 
was reduced to only 2% in 2010. From 2008-2010, cephalosporins were the third most used class after penicillins and 
S-TMP. 
Comparison with the more complete VetStat data (Figure 1), indicated that the pharmacy data from SSI for the 
11 practices underestimated the usage; particularly of cephalosporins by 21% across the study period 2007-2010. 
Especially 2007 data were underestimated, while 2010 data were most complete. In 2010, the consumption of 
cephalosporin accounted 0.32% of the total consumption (in kg active compound) in the 11 practices. At the 
National level (Table 4.1), 0.34% of the antimicrobial agents prescribed for horses (or horse practice) in 2011 were 
cephalosporins, suggesting that the 2010 data for the 11 practices were relatively representative.
Between practice variation
Over the four year period, the proportion of penicillin-G used varied significantly between practice type, with the 
highest use in horse hospitals and mobile practices (Figure 1). The use of other antimicrobial classes did not differ 
significantly between practice types, but large variations were seen in the use of S-TMP (between 13% and 74%) and 
3rd generation cephalosporins (between 2% and 31%) between individual practices. 
Fluoroquinolones only accounted for 1% of the overall usage (Figure 1), and as for the cephalosporins, there were 
large variations in usage. In 2010, one of the hospitals (HSP1) used 80% of the total amount of fluoroquinolones and 
one practice (CL2) used 61% of all cephalosporins used in the 11 practices that year.
The proportion of 3rd and 4th generation cephalosporins used in horse hospitals was lower (2% and 6%) than in the 
other practice types (clinics and mobile practices; between 18% and 22%) (Figure 1). This was somewhat surprising 
because the hospitals were expected to treat more severe and complicated cases. As expected, the proportion of 
fluoroquinolones was higher in the hospitals (2%) as compared to the other practice types (between 0.1% and 2%) 
(Figure 1).
The decreasing use of aminoglycosides (gentamicin) was probably related to the fact that it is not approved for horses, 
combined with increasing attention from the authorities towards non-complience with the cascade rule [Order (DK) 
142/1993]. However, a questionnaire study conducted in the 11 practices shows that cephalosporins are now used 
for indications that were treated previously with gentamicin. Thus, the increasing use of cephalosporin might be 
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Table 1. Proportional consumption(a) (ADD400)(b) of antimicrobial agents in 11 Danish horse practices, 
Denmark 2007–2010
Source: C. Hensgen, Master Thesis, LIFE Faculty, Copenhagen University, 2012
a) National consumption in Danish horse practices estimated from data from the Statens Serum Institute (formerly Danish medicine 
Agency). Note that the historical data become increasingly incomplete (see text)
b) ADD400 is defined as the maximum approved dose for a 400 kg horse according to the SPC
c) Includes amoxicillin combined with clavulanic acid 
Antimicrobial agent
Year
2007 2008 2009 2010
Beta-lactamase sensitive penicillin 32 51 47 48
Aminoglycosides 28 6 3 2
Broad spectrum penicillin(c) 1 2 2 2
Sulfonamide-Trimethoprim 32 27 28 34
Tetracyclines <1 2 3 3
Cephalosporins 6 10 15 11
Macrolides <1 <1 <1 <1
Lincosamides <1 <1 <1 <1
Fluoroquinolones <1 1 1 1
DANMAP 2011
related to the decreasing use of gentamicin. However, this does not explain the large differences in cephalosporin 
use between practices. The large variation in prescription practices, and in particular variation in use of critically 
important antimicrobial agents, stresses the need for guidelines for antimicrobial use in horse practice, and 
probably also more frequent use of resistance testing in some practices, particular before using critically important 
agents.
Camilla Hensgen, Vibeke Frøkjær Jensen and Keith Baptiste
For further information: Vibeke Frøkjær Jensen (vfje@food.dtu.dk)
Figure 1. Antimicrobial consumption (ADD400) pattern in 11 Danish horse practices, Denmark 2007–2010
DANMAP 2011
Note: MP = mobile Practice; CL = Clinic; HSP = Hospital; Total = sales from pharmacies to the 11 practices or to horse owners, by 
request of vets, presently employed in the practices; Vetstat = sales from pharmacies to the 11 practices (disregarding identity of the 
prescribing vet), or prescribed for horses by a veterinarian presently employed in the practice
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4.3  Antimicrobial consumption by animal 
species
A comparison of trends in consumption of antimicrobial 
agent, by species, is shown in Figure 4.3. Note that 
different units are used in the three diagrams within the 
figure, and that the trend lines differ depending on the 
unit used. For example, for turkeys, the highest peak 
was in 2009 when measured by mg but in 2002, when 
measured by ADD. This difference is explained by a shift 
in consumption from amoxicillin towards tetracyclines. 
Correspondingly, the consumption in aquaculture is 
extremely high when measured in mg, but more similar to 
the consumption in other species (pigs) when measured in 
ADDkg. This is becaue the dominant drug (sulfonamide-
trimethoprim) in aquaculture is used in a very high dosage 
(in all species). Finally, trends may also be affected by 
shifts in the production, as described for pigs in section 
4.2. 
For comparison between species, kg meat produced 
has been used in Figure 4.3 A and B; this measure 
overestimates the selection pressure in species with long 
lives (e.g. cattle) relative to species slaughtered at an early 
age (e.g. poultry). Alternatively, live biomass should be 
used for comparison of selection pressure between species. 
Using this method, the difference between pig and poultry 
production becomes less pronounced (Figure 4.3, C). 
The consumption in dairy cattle is very low, measured 
in ADDkg per kg live biomass, while the antimicrobial 
consumption in young growing cattle (half of which is for 
slaughter) is at the level seen in the turkey production. 
Because cattle in Denmark are almost entirely dairy cattle, 
living many years after reaching the slaughter weight, the 
consumption cannot be directly compared with other 
species using ‘kg meat produced’ as the denominator.
In 2011, antimicrobial sales for use in pet animals 
amounted to more than 5.6 ADDkg/ kg-live- biomass 
(app. 10-15% underestimation, see section 4.3.4). Thus, the 
consumption in pet animals was higher than for cattle and 
poultry, but lower than for pigs.
Figure 4.3. Antimicrobial consumption per kg meat produced from pigs, broilers, turkey and aquaculture measured 
against different denominators, Denmark
Figure A: Export of animals for rearing or slaughter is included. However, the data for pig production are not adjusted for the increasing 
export of pigs at 30 kg body weight, although the body mass at export is included in the production (see text). Thus, the figures overestimate 
the increasing consumption in the pig production, particularly during the last three years
In 2006, the consumption reached 262 mg/kg fish produced in salt water, related to unusually warm summer months. The doses for fish are 
defined as 30 mg/kg for sulfonmide-trimethoprim, 10 mg/kg for oxolinic acid and 15 mg for florphenicol (source: Danish Aquaculture)
Figure B: The doses for fish are defined as 30 mg/kg for sulfonamide-trimethoprim, 10 mg/kg for oxolinic acid and 15 mg for florphenicol 
(source: Danish Aquaculture)
Figure C: The biomass is estimated from census data (pig and cattle) og from production data (poultry). See Section 10.2
DANMAP 2011
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4.3.1  Antimicrobial consumption in pigs 
In 2011, the total antimicrobial consumption in pigs was 
81.4 tonnes active substance (Table 4.1), representing 
a decrease of 19 tonnes compared to 2010, while the 
production of pigs continued to increase. The decrease 
in 2011 was mainly attributed to decreasing use of agents 
with high potency; therefore, the decrease was larger when 
measured in ADDs.
Relative to the meat production, including live export, 
the consumption decreased by 29% from 4.6 ADDkg per 
kg to 3.3 ADDkg per kg pork produced (Figures 4.3 and 
4.4). Due to evolving demographics in the pig production, 
the trends should be measured with adjustment for the 
increasing export of pigs at 30 kg; the consumption 
decreased by 30% ADDkg per pig produced (adjusted) 
from 2010 to 2011. 
The consumption of antimicrobial agents for systemic use 
in pigs (2002–2011), given as Animal Daily Doses (ADDs) 
to the different age groups, is presented in web annex A4.2.
Since 2002, the antimicrobial consumption in pigs 
increased gradually, reaching a maximum in 2009, with 
a total increase of 47% in ADDkg per pig produced 
(adjusted for increase in live export, Figure 4.4). The 
increase continued into first half of 2010. However, in 
July 2010, the consumption decreased abruptly following 
the announcement of the yellow card initiative July 1st, 
and the decreasing trend continued into first half of 2011. 
In 2011, the antimicrobial consumption per pig had 
returned to 2001-2002 levels, i.e. just after the full growth 
promoter ban was enforced. The decrease in antimicrobial 
consumption involved all age groups (Figure 4.4). Looking 
at the entire decrease since 2009, the antimicrobial 
consumption decreased by 34% in sow herds, 35% in 
weaning pigs, and 31% in finishers. 
Figure 4.4. Consumption of antimicrobial agents in sows, weaners(a), finishers(b) and total pig production(c), given as 
Animal Daily Doses (ADDs), Denmark
DANMAP 2011
a) Consumption in sows and weaners is given as ADD25 divided by number of weaning pigs producedb) Consumption in finishers is given as ADD25 divided by number of finisher pigs producedc) The" adjusted total" is given with the same units as the total, but adjusted for the increasing export of pigs at 30 kg (see text). Consumption 
per kg meat produced is given as ADDkg divided by meat production including live export
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Tetracyclines, macrolides and pleuromutilins have been the 
most commonly used antimicrobial agents in the Danish 
pig production for a decade (Figure 4.5). They are almost 
entirely administered orally, and particularly used for 
gastrointestinal disease in weaning pigs and finishers. The 
overall decrease seen in 2011 was mainly related to a 60% 
decrease in consumption of pleuromutilins, a 27% decrease 
in use of tetracyclines and a 26% decrease in macrolides, 
as compared to 2010. Furthermore, the use of broad 
spectrum penicillins was reduced by 21%, while minor 
decreases was seen in other antimicrobial classes. A large 
relative reduction (98%) was also observed for 3rd and 4th 
generation cephalosporins in 2011, approximating zero 
following a voluntary ban on cephalosporins, enforced by 
the by the pig industry in July 2010 (Figure 4.7).
Over the past decade, the consumption of macrolides 
has fluctuated between 2.2–2.6 ADD25 per pig produced, 
with an overall slightly increasing clear trends, reaching 
2.8 ADD25 per pig in 2009. However, from 2010 to 2011, 
the consumption decreased importantly from 2.7 ADD25 
per pig produced to 2 ADD25 per pig produced. The 
consumption of pleuromutilins was high during 2008-
2010, following a 53% increase since 2007, where the prices 
for tiamulin were reduced making it price competitive 
with macrolides and tetracyclines. It is not clear if 
economic incentives have assisted the large decrease in 
pleuromutilins in 2011.
 
According to the Danish Agriculture and Meat Council, 
the reductions in the antimicrobial consumption have 
not affected the position of the Danish pork industry on 
the world trade market, and only very limited effects on 
productivity and economy have been reported [Danish 
veterinary Bulletin no.6, 2012]. While the yellow card has 
led to increasing use of vaccines, and a slight decrease in 
productivity in some herds, disease outbreaks have not 
increased. 
Whereas the decrease in consumption in 2010 was 
confined to gastrointestinal disease, other indications were 
also involved in the 2011 decrease (Figure 4.6). In weaning 
pigs, gastrointestinal infections are the major indications 
for prescription (70% in 2010), and decreased by 31% from 
2010 to 4.1 ADD15 per pig produced in 2011, which is 
below the level of 2002. Respiratory disease is the target 
disease for 21% of the antimicrobial use in weaning pigs, 
and decreased by 24% in 2011 compared with 2010. The 
prescription for respiratory disease is still at the same level 
as in 2008, and 140% higher than in 2002, suggesting that 
the level of respiratory disease has increase significantly 
from 2002 to 2011. 
The decrease in prescription for gastrointestinal disease 
could be due to better disease prevention (changes in 
management incl. vaccination) and to some degree also 
abolishment of metaphylactic treatments. Sales of vaccines 
for GI diseases in pigs increased dramatically in 2010. 
In particular, vaccines against E.coli diarrhoea increased 
by 350%, from 0.35 million doses in 2009 to 1.56 million 
doses in 2011. Use of PCV2 vaccines (porcine corona virus, 
associated with the PMWS syndrome, see DANMAP 2005) 
has increased gradually since 2006, and tripled from 3.5 
million in 2009 to 9.5 million in 2011. Previously, increase 
in systematic metaphylactic antimicrobial treatment, 
mainly against gastrointestinal disease, has been suggested 
as the cause of increasing antimicrobial use in weaning 
pigs during the past decade [Focus Area 2, DANMAP 
2009]. 
In sow herds, the prescription for gastrointestinal 
disease decreased by 41% from 2010 to 2011, while 
the prescription for other diseases (except mastitis) 
decreased between 18-26%. In finishers, the prescription 
for gastrointestinal disease decreased by 34% in 2011 
compared to 2010, while the prescription for respiratory 
disease decreased by 32%. For respiratory disease 
the prescription was above the 2002 level, while for 
gastrointestinal disease it was similar to the 2002 level. 
In all age groups, the prescription for respiratory disease 
has been increasing throughout the last decade until 2010 
(Figure 4.6). 
Regarding target disease, it should be noted that these 
statistics are derived from the information on indication 
(disease group) in the VetStat database. The indication 
is entered by the veterinarian and refers to current or 
expected disease within a 30 day period (based on his/ 
her knowledge of the herd). However, in some cases, the 
prescribed antimicrobial agents may be used for other 
diseases than originally indicated on the prescription, in 
which case the antimicrobial agent is re-prescribed by the 
veterinarian at the farm. Such re-prescriptions are not 
registered in VetStat.
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Figure 4.5. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, 
Denmark
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data from 
veterinary practice are not included (<1% of the consumption in pigs)   
a) ADD25: doses for treatment of 25 kg pigs, to compare treatment across age groups. ADD15: Doses for treatment of 15 kg pigs, the assumed 
average dose for treatment of weaners (7.5–30 kg).  ADD50: Doses for treatment of 50 kg pigs, the assumed average dose for treatment 
of finishers (30–110 kg), estimate based on the number of pigs produced excluding those pigs exported at 15–50 kg. ADD200: Doses for 
treatment of 200 kg pigs: the medicines are used either in sows (bodyweight>200 kg) or in piglets (<2 kg–7.5 kg)   
b) Total pigs produced includes pigs exported at 30 kg, which has increased in numbers from 1.7 million in 2004 to 7.6 million in 2011, 
comprising an 26%, although consumption in these pigs is included only from birth to 30 kg body weight. See discussion in the text 
c) Lincosamide/spectinomycin combinations comprise 65% of this group
d) Beta-lactamase sensitive penicillins  
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Figure 4.6. Antimicrobial consumption by indication(a) for sows/piglets, weaner and finisher pigs, Denmark
a)  The indication given on the prescription. At prescription, VetStat codes are used, representing the target organ system. In this figure, 
indications representing <0.1ADD (per sow year or pig produced) is not shown
DANMAP 2011
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Figure 4.7. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
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4.3.2  Antimicrobial consumption in cattle
In 2011, an estimated 14.7 tonnes of antimicrobial 
substance were prescribed for cattle, similar to 2010 (Table 
4.1). Data on antimicrobial consumption in cattle are not 
as accurate as data in the other major species, because a 
large proportion is sold via veterinary practice.
However, pharmacy data have a very high quality, and 
an increasing proportion of the medicine for cattle has 
being purchased through the pharmacies, although 53% 
of the antimicrobial agents for cattle are still sold via the 
veterinary practices. Pharmacy data, including sales to 
cattle practice, indicate that the overall consumption 
in cattle has been stable over time, around 14 tonnes, 
during 2005–2011. During this period, the veal and beef 
production has fluctuated around the same level (145,000 
tonnes in 2005 and 2011) and the milk production has 
increased by 8% (Table 3.1). 
Consumption of antimicrobial agents for systemic use in 
cattle (2005–2011), given as Animal Daily Doses (ADDs) 
to different age groups, are presented in the web annex 
(Table A4.3). For cattle, data are only shown for the period 
2005–2011, because data quality was not acceptable 
prior to 2005 due to reporting errors from the veterinary 
practices. In 2011, underreporting from veterinary 
practice corresponded to an overall 8% underreporting of 
total use in cattle. 
Based on the type of technical errors, it is assumed that the 
missing data are random, and thus that the data from the 
veterinarians are representative for the relative choice of 
drugs over time. Data validation against pharmacy data on 
sales to cattle practice supports this assumption (Figures 
4.8 and 4.9).
In 2011, the choice of antimicrobial agents for systemic 
treatment of cows was almost identical to the distribution 
in 2010. Beta-lactam sensitive penicillins for systemic 
use in cows accounted for 59%, followed by tetracyclines 
(20%). In cows and bulls, the proportional use of beta-
lactamase sensitive penicillins has increased from 48% 
in 2005 to 59% of the overall consumption in 2011, 
while the use of macrolides decreased from 11% to 3% 
of the consumption for systemic use in cows. This trend 
is in accordance with the official guidelines. The major 
indication for treatment of cows was mastitis (66% of the 
systemic treatment in grown cattle).
Also for intramammary treatment (including drying off), 
penicillins, mainly narrow spectrum (beta-lactamase 
sensitive or beta-lactmase resistant), was the major 
classes used, comprising 46% of the treatments (Table 
4.2b). Combinations of benzylpenicillins (mainly with 
dihydrostreptomycin) comprised an additional 27%. 
A decrease of 8% in use of intramammary treatment 
per cow-year was observed from 2010 to 2011. Some 
intramammary formulas are entirely used for drying off 
treatment, and the use of these has increased by 6%, while 
the use of intramammary application for therapeutic 
purposes has decreased by 16%. 
The use of antimicrobial agnets for mastitis in cattle has 
been regulated since 2006 [Order (DK) 1045/2006 and 
785/2010], however these trends are probably also a result 
of a “milk quality campaign” run by the cattle association 
(Dansk Kvæg) since 2010. The goals of the campaign are 
to reduce treatment of clinical mastitis by 50%, mainly 
through a reduction of treatment of subclinical mastitis, 
but also by increasing the frequency of microbiological 
testing (cell counts) for discriminating the necessity to 
treat. Some increase in drying-off treatment is accepted, 
due to refraining from treating during lactation. Also 
the use of narrow spectrum penicillins in case of Gram-
positive infections, unless sensitivity testing shows 
resistance, has been emphasized [Dansk Kvæg, 2012]. 
From 2005 to 2011, the overall use of intramammary 
treatments per cow-year decreased by 12%, while the 
proportion of narrow spectrum penicillins increased from 
23% to 46% of the intramammary treatments (Table 4.4).
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The major indication in calves was respiratory disease, 
accounting for 67% of systemic use in calves in 2011, 
followed by gastrointestinal disease (17%). In calves, 
tetracyclines (mainly oxytetracyclines) remained the 
major drug of choice in 2011, although the proportion 
decreased from 30% of total systemic use in 2010 to 27% 
in 2011 (Figure 4.9). From 2006 to 2009, macrolides were 
the most frequently used class, but the use was reduced 
from 35% in 2009 to 24% in 2010-2011. In 2011, the use of 
amfenicols increased from 9% to 12% of the medicines for 
systemic use, and was almost entirely (96%) prescribed for 
respiratory disease. The use of amfenicols (florfenicol) has 
increased gradually since 2005. 
The use of fluoroquinolones in cattle was only 1 kg active 
compound, and has remained at a low level since 2003. 
Systemic use of 3rd and 4th generation cephalosporins 
in cattle decreased by 7% and intramammary use 
decreased by 34% measured in kg active compound in 
2011 compared to 2010. This was part of a continuously 
decreasing trend, and since 2008 the consumption of 
3rd and 4th generation cephalosporins for systemic 
and intramammary use has decreased by 34% and 68%, 
respectively (Figure 4.7). These trends probably reflect a 
response to debate, guidelines and information in recent 
years about the consequences regarding development of 
ESBL. The more recent trend may be a result of regulations 
implemented in 2010, requiring testing for antimicrobial 
resistance, in cases where antimicrobial agents, other than 
simple penicillins, are prescribed for mastitis. The trend 
has also been supported by the above mentioned campaign 
by the Danish cattle Association.
DANMAP 2011
Table  4.2a. Total treatments with antimicrobial agents for intramammary application in cattle, Denmark 
Total treatments per indication (a) 
2005 2006 2007 2008 2009 2010 2011
ADDs (1000's)
Drying off treatment  (4 teats) 73 75 78 86 96 104 110
Therapeutic treatment (2 teats) 420 408 388 377 378 350 293
Table  4.2b. Total treatments with antimicrobial agents for intramammary application in cattle, Denmark DANMAP 2011
Use per antimicrobial class(a)
2005 2006 2007 2008 2009 2010 2011
ADDs (1000's)
Penicillins(b) 127 132 156 185 230 246 235
Aminoglycoside-benzylpenicillin 
combinations(c) 204 184 155 152 162 161 140
Cephalosporins,
1st generation 103 98 89 85 89 89 96
Cephalosporins,
3rd and 4th generation 110 124 127 112 76 51 34
Others(d) 21 20 16 15 14 12 9
Total 566 558 544 549 570 559 514
Total ADD/cow-year 1.01 1.00 1.00 0.98 1.00 0.97 0.89
a) For intramammary therapeutic treatment, 1 ADD is defined as the dose to treat two teats for 24 hours. For drying off treatment, 1 ADD 
is defined as the dose to treat 4 teats
b) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC)
c) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or 
nafcillin (QJ51RC)
d) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
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Figure 4.9. Proportional consumption (in ADD) of antimicrobial agents(a) for systemic treatment in calves, Denmark
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a) The antimicrobial classes not shown (fluoroquionolones, lincosamides, and pleuromutilins), each account for less than one percent of 
the consumption
a) The antimicrobials not shown (amphenicols, fluoroquionolones, lincosamides, aminoglycosides, colistin and pleuromutilins ), each account 
for less than one percent of the consumption
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Figure 4.8. Proportional consumption (in ADD) of antimicrobial agents(a) for systemic treatment in cows and bulls, Denmark
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4.3.3  Antimicrobial consumption in poultry
In Denmark, the poultry production comprises mainly the 
broiler production (Gallus gallus), followed by egg layers 
(Gallus gallus) and turkey production. In addition, there is 
a minor production of ducks, geese, and game birds, while 
pigeons are kept for sports. Consumption of antimicrobial 
agents for systemic use in poultry (2002–2011), given as 
Animal Daily Doses (ADDs) to the different species, are 
presented in the web annex (Table A4.4).
In 2011, the total antimicrobial consumption in poultry 
was 769 kg active substance plus an additional 40-50 
kg sulfamethoxazole used on special license (Table 
4.1), representing an 8% decrease compared to 2010. 
In general, increasing disease problems caused a steep 
increase in antimicrobial consumption for poultry in 2009 
(see DANMAP 2009); these disease problems seems to 
be under control in 2010 and 2011, as indicated by the 
decrease in antimicrobial consumption, both for the layers, 
broiler rearing, and the turkey production. However, 
regarding the broilers the consumption has continued to 
increase in 2011. Consequently, the overall consumption in 
poultry in 2011 (769 kg) was still higher than the levels in 
previous years (2002–2008), when the annual consumption 
fluctuated between 400-600 kg.
Note: the use of sulfamethoxazole is not included in 
the data mentioned below, because the target species is 
unknown and an ADD has not been defined. However, 
according to poultry practitioners it has been used for 
multi-resistant E. coli infections in the broiler production.
 
In Denmark, the antimicrobial consumption in domestic 
fowl (Gallus gallus) is generally low (Figure 4.3. and Figure 
4.10). Therefore, a few disease outbreaks in some farms 
will affect the national consumption, causing considerable 
fluctuations in annual consumption.
The total consumption in broilers in 2011 was 414 kg 
including breeding and rearing (Table 4.1). For broilers, 
the additional increase in consumption was mainly in 
the prescription of amoxicillin, which has been the major 
drug of choice for at least a decade (Figure 4.8). Among 
202 professional broiler producing farms, antimicrobial 
consumption was prescribed for 60 farms, corresponding 
to 29.7% of the farms. However, these farms received a total 
of only 182 prescription; as only the broilers present at time 
of prescription were likely to be treated, this means that 
only a small fraction (estimated 3%) of the flocks have been 
treated. Due to the decrease in consumption in the parent 
and grandparent flocks (breeding and rearing), the overall 
consumption (0.013 ADDkg per kg meat produced) in the 
broiler production was at the same level as in 2009–2010, 
but twice to five times higher than in previous years 
(Figure 4.10). In 2011, only 5% of the antimicrobial agents 
used in the broiler production were used in the parents 
and grandparent flocks.
The antimicrobial consumption in the layer production 
(Gallus gallus) is also quite low, and the total consumption 
in 2011 was only 18 kg (Table 4.1), corresponding to a 
decrease of 62% compared with 2010 (Figure 4.11).
In turkeys, the annual consumption is highly variable. 
In 2011, the consumption was 251 kg which was similar 
to 2010 level. However, relative to the production, the 
consumption increased to 1 ADDkg per kg meat produced, 
representing a 34% increase from 2010. This was still 10% 
lower than the median for the past decade (web annex 
A4.4 and Figure 4.11). The peak in 2009 was mainly due 
to Pasteurella multocida infections (according to the 
poultry practitioners), and a vaccination campaign was 
conducted to control the disease in April–October 2009. 
Also, vaccination against haemorrhagic enteritis (viral) in 
turkeys was initiated in April 2010. 
In 2011, the use of tetracyclines increased slightly to 73% 
of the antimicrobial consumption in turkeys. Tetracyclines 
have been the drug of choice in the turkey production 
since 2008. Prior to 2007, amoxicillin constituted 70–99% 
of the antimicrobial consumption in turkeys, while the 
use had decreased to 3–4% in 2010–2011. The changes 
in prescription practice occurred after the marketing 
of tetracyclines and other agents for use in poultry 
during 2007–2008. Before 2007, only amoxicillin and 
fluoroquinolones were approved for use in poultry. 
In 2010–2011, fluoroquinolones were used neither in 
turkeys nor in Gallus gallus, and the consumption has 
decreased importantly since 2006 where fluoroquinolones 
comprised 7% of the antimicrobial consumption in these 
species.
Annual production data are not available for game birds. In 
2004, the population was estimated at 1 million pheasants, 
0.5 million ducks and 0.1 million other birds (mainly 
guinea fowl). Assuming a constant population and carcass 
weights of 650 g for pheasants, 750 g for (wild) ducks and 
300 g for guinea fowl, the consumption has fluctuated 
between 1.3–2.9 ADDkg per kg carcass, during 2002–2011 
(Figure 4.11 and web annex, Table A4.4).
                                                                           
       43DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN ANIMALS 4.
DANMAP 2011
Figure 4.10. Consumption of antimicrobial agents in the poultry production, Denmark
Note: ADDkg is the dose necessary for treating 1 kg live-body-weight
a) For layers and layer rearing, only the production of eggs for consumption is included (not the slaughter/export of hens)
b) Includes sulfaclozin (a coccidiostat/antibacterial) and sulfonamide/trimethoprim combinations
c) Includes primarily fluoroquinolones, but also aminoglycosides, pleuromutilins, QA07AA10 (colistin), QJ01FF (lincosamides, including 
combinations with spectinomycin), QJ01B (amphenicols) and QJ01R (penicillin/streptomycin combinations)
0.00
0.05
0.10
02 03 04 05 06 07 08 09 10 11
AD
D
kg
/ k
g 
m
ea
t  
pr
od
uc
ed
Broiler production 
(incl. rearing and production)
0.0
0.5
1.0
1.5
2.0
2.5
02 03 04 05 06 07 08 09 10 11
AD
D
kg
 / k
g 
m
ea
t  
pr
od
uc
ed
Tetracyclines Amoxicillin Penicillins, β-lactamase sensitive
Sulfonamides(b) Macrolides Fluoroquinolones
Others (c)
Turkey production
0.00
0.01
0.02
0.03
0.04
0.05
02 03 04 05 06 07 08 09 10 11
AD
D
kg
 / 
 k
g 
 e
gg
  p
ro
du
ce
d
Layer production 
(incl. rearing and production)(a)
0.00
0.05
0.10
02 03 04 05 06 07 08 09 10 11
AD
D
kg
 / k
g 
m
ea
t  
pr
od
uc
ed
Broiler production 
(broilers only)
44                          
                   
DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN ANIMALS4.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
02 03 04 05 06 07 08 09 10 11
AD
D
kg
 / 
kg
 m
ea
t  
pr
od
uc
ed
 
Broilers Layers (a)
Turkeys Game birds (b)
Figure 4.11. Total consumption of antimicrobial agents in 
various poultry production species, Denmark
Note: ADDkg is the dose necessary for treating 1 kg body-weight
a) For layers and layer rearing, only the production of eggs for 
consumption is included (not the slaughter/export of hens)
b) Carcass weight of pheasants estimated at 550 g for hens and 750 g 
for cocks. Carcass weight for game ducks is estimated at 750 g, and 
300 g for guinea fowl. The production was assumed constant at the 
2004 level
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4.3.4  Antimicrobial consumption in fur animals, 
aquaculture and pet animals
In 2011, the production of mink increased by 7% to 
15 million mink, while the production of chinchillas 
was unchanged at 34,000 chinchillas. Antimicrobial 
consumption in fur animals increased to 4.8 tonnes, 
representing a 30% increase compared with 2010 (Table 
4.1). Aminopenicillins remained the most commonly used 
antimicrobial class in fur animals, comprising 40%, similar 
to 2010. Macrolides, tetracyclines and sulfonamide-
trimethoprim combinations comprised another 39%. The 
use of fluoroquinolones increased from 0.4 kg in 2010 to 1 
kg in 2011. 
The antimicrobial consumption in aquaculture decreased 
by 11% to 2,700 kg in 2011 compared to 2010 (Figure 4.3). 
Measured in ADDkg, the major class of antimicrobial 
was sulfonamide/trimethoprim, increasing to 60% 
the consumption in aquaculture. The consumption of 
quinolones (oxolinic acid) comprised 30% and florfenicol 
10%.
Assuming an unchanged production volume, the 
consumption in salt water fish was decreased by 50% to 
4.5ADDkg in 2011, as compared to 9 ADDkg per kg fish 
produced in 2009 – 2010 (Figure 4.3). Fish production 
The consumption of antimicrobial agents in companion 
animals (pet animals and horses) was an estimated 3 
tonnes. The estimation was based on pharmacy data on the 
prescription for these species, prescription of medicines 
approved only for oral use in these species, combined with 
data on sales for companion animal and horse practices, 
respectively (Table 4.1). This estimate does not include 
the parenteral and topical use for these species in mixed 
practice. For pet animals alone, the total use was estimated 
at 2 tonnes.
In 2011, antimicrobial sales for use in pet animals 
amounted to more than 5.6 ADDkg per kg live biomass; 
this estimate does not include parenteral and topical 
antimicrobial use in mixed practice, causing an 
underestimation of approximately 10-15%. Consumption 
of antimicrobial medicines for oral use in dogs and cats 
amounted to 4.3 ADDkg per kg biomass.
In pet animals (mainly cats and dogs), the prescription 
for oral treatment measured in ADDkg per kg biomass 
increased by 8%, as part of a continuous increase of 36% 
since 2005. This was almost entirely related to an 88% 
increase in use of amoxicillin with clavulanic acid (Figure 
4.12). The use of 1st generation cephalosporins for oral 
use was almost unchanged in 2011, at a similar level as in 
2005.
 
In pet animals, the consumption of 3rd and 4th generation 
cephalosporins amounted to 0.32 ADDkg per kg live 
biomass in 2011. The use of fluoroquinolones amounted to 
0.22 ADDkg per kg live biomass. For comparison, the use 
of cephalsoporins for systemic use was 0.06 ADDkg per 
kg live biomass in cattle, while the use in pigs is now close 
to none, and it has not been used in poultry for at least 10 
years. The use of fluoroquinolones has been close to none 
in pigs and cattle since 2003, and close to none in poultry 
since 2007, due to legal restrictions.
is very sensitive to water temperatures and the decrease 
in consumption was partly due to a very cold summer 
in 2011, but also increasing vaccination intensity has 
contributed to a gradual 51% decrease in antimicrobial use 
in salt water aquaculture through 2006–2010 [personal 
communication: N.H. Henriksen, Danish Aquaculture].
 In fresh water fish, the antimicrobial consumption 
fluctuates less than in salt water, but increased by 12% in 
2011 to 2.6 ADDkg per kg fish produced, when assuming 
the same production volume as in 2010. The increase may 
partly be explained by a very cold winter followed by a 
very warm spring in 2011, having a negative impact on 
the immune competence of the fish. Another explanation 
may have been a delay in deliverance of vaccines against 
red mouth disease in late 2010, causing inadequate 
immune competence against this particular disease in 
2011 [personal communication: N.H. Henriksen, Danish 
Aquaculture].
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Considering the close contact between pet animals and 
humans, and the increasing evidence for transfer of 
resistance between the pet reservoir and humans, the high 
consumption of broad spectrum antimicrobial agents 
in pets should be a matter of concern. In particular, the 
consumption of critically important antimicrobial agents 
in pet animals could potentially pose an important risk to 
owners of diseased dogs. Presently, there is no information 
available about the antimicrobial resistance in pet animals. 
In horse practice, sulfonamide-trimethoprim and beta-
lactamase sensitive penicillins are used for the vast majority 
of treatments. However, a recent study has shown a very 
large variation in prescription habits between practices, 
with some practices using 3rd generation cephalosporins in 
a third of the treatments (Textbox 1). 
These observations urgently call for treatment guidelines 
or other means to control the use of critically important 
antimicrobials in companion animals.
Vibeke Frøkjær Jensen and 
Birgitte Borck Høg
In 2011, the consumption of 3rd and 4th generation 
cephalosporin (parenteral use only) in pet animals was an 
estimated 3 kg in 2011, corresponding to 5% of the total 
veterinary consumption of these antimicrobial agents. In 
addition, 1.3 kg 2nd generation cephalosporins (medicinal 
products for human use) was used in a few practicies. The 
use of fluoroquinolones in pet animals was an estimated 
12 kg in 2011, corresponding to 51% of the total veterinary 
use of fluoroquinolones in Denmark. 
Regarding amoxicillin-clavulanic acid, 91% of the 
veterinary consumption was used in pet animals; this 
combination has a very broad spectrum and should be 
reserved to infections caused by bacteria that are resistant 
to more narrow spectrum agents, or as a potential 
empirical choice for severe infections where instant effect 
is essential.
In conclusion, the treatment frequency using critically 
important antimicrobial agents is much higher for pet 
animals compared with food animals. Further more, 
broad-spectrum antimicrobial agents comprise a much 
lower proportion of the use in humans compared to the 
proportion of broad-spectrum antimicrobial agents in pet 
animals. 
Figure 4.12.  Antimicrobial consumption (oral treatments) in cats and dogs, Denmark
DANMAP 2011
The live biomass was estimated based on the assumption of average weight of dogs (20 kg), and cats (4 kg). Census data are available only for 
2000 [Statistics Denmark], and the population size was assumed to be constant
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5. Antimicrobial consumptions in humans
5.1  Introduction
In Denmark, systemic antimicrobial agents for humans 
are available only on prescription. National and local 
guidelines, primarily based on resistance patterns, 
advocate the prudent use of antimicrobial agents, however, 
there are no restrictions for medical doctors to prescribe 
antimicrobial agents.
Throughout this section, the antimicrobial consumption 
in 2011 is compared to that of 2010 and of the last 
decade (2002). Combinations of penicillins, including 
beta-lactamase inhibitors (J01CR) are referred to as 
‘combination penicillins’. 
In this section, the term ‘antimicrobial agents’ covers only 
antibacterial agents for systemic use in humans. Currently 
available antimicrobial agents for systemic treatment in 
humans (and in animals) are listed in Table 3.2.
Narrow- and broad-spectrum agents. Antimicrobial agents 
have been classified as either narrow-spectrum or broad-
spectrum agents according to the spectrum of the activity 
against Gram-positive and Gram-negative bacteria (Table 
5.1).
Defined Daily Dose (DDD). The DDD is defined as the 
assumed average maintenance dose per day for a drug used 
for its main indication in adults. It should be emphasised 
that DDD is a unit of measurement and does not 
necessarily reflect the recommended or prescribed daily 
dose [http://www.whoc.no]. 
DDD per 1,000 inhabitants per day (DID). 
Consumption in both primary health care, hospital 
care and the overall total consumption is presented 
in DID, allowing for comparison between sectors and 
ATC group(a) Therapeutic group
Narrow-spectrum
J01CE                        Beta-lactamase sensitive penicillins     
J01CF                        Beta-lactamase resistant penicillins     
J01DB First-generation cephalosporins (included in data from primary health care as a broad-spectrum agent in the group J01D)
J01DF Monobactams
J01EA                        Trimethoprim and derivatives   
J01EB                        Short-acting sulfonamides       
J01FA                        Macrolides                  
J01FF                        Lincosamides                
J01XA Glycopeptides
J01XC                        Steroid antibacterials (fusidic acid)     
J01XD                        Imidazol derivatives
J01XE Nitrofuran derivatives (nitrofurantoin)
J01XX Other antibacterials
Broad-spectrum
J01AA                        Tetracyclines               
J01CA                        Penicillins with extended spectrum
J01CR                        Combinations of penicillins, incl. beta-lactamase inhibitors   
J01D                        Cephalosporins and related substances (primary health care only)         
J01DC Second-generation cephalosporins
J01DD Third-generation cephalosporins
J01DH Carbapenems
J01EE                        Combinations of sulfonamides and trimethoprim, incl. derivatives 
J01GB Aminoglycosides
J01MA                        Fluoroquinolones            
J01XB                        Polymyxins                 
DANMAP 2011
Table 5.1. Classification of antimicrobial agents for systemic use in humans into narrow-spectrum and broad-spectrum 
agents, Denmark
a) From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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for illustration of the consumption in hospital care 
without taking account of hospital activity (discharges). 
Data presented in DID provide a rough estimate of the 
proportion of the population within a defined area treated 
daily with certain drugs. For example, 10 DIDs indicates 
that 1% of the population on average gets a certain 
treatment daily.
Packages per 1,000 inhabitants per year. Assuming that 
one prescription contains one package, this measurement 
is used as a surrogate for the number of prescriptions or 
treatments given to the primary health care population.
Treated patients per 1,000 inhabitants per year. llustrates 
the number of patients treated in primary health care.
Kilogram. To allow comparison with consumption of 
antimicrobial agents in animals, total human consumption 
is also presented in kilograms.
DDD per 100 occupied bed-days (DBD) and DDD per 100 
admissions (DAD). Consumption in somatic hospitals is 
presented in both DBD and DAD to account for hospital 
activity. 
Figure 5.1. Total consumption of antimicrobial agents (J01) in humans by sector, Denmark
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5.2  Total consumption in both primary 
health care and hospital care
In 2011, the total consumption of antimicrobial agents 
for systemic use (primary health care and hospital care) 
remained at the same level as in 2010 (18.84 DID in 2010 
compared to 18.90 DID in 2011, Figure 5.1). In primary 
health care, the reported consumption still remained on an 
increasing level, in line with that observed during previous 
years. The consumption in hospital care, as measured 
by DID, decreased by 3.7% from 2010 to 2011. The total 
consumption of broad-spectrum agents also remained 
constant in 2011 (7.76 DID in 2010 compared to 7.80 
DID in 2011, Figure 5.2). Primary health care represented 
90% of all prescribed DDDs in Denmark in 2011. The 
consumption observed in primary health care in 2011 was 
the highest on record since 1995.
The distribution of DIDs between primary health care and 
hospital care differed between antimicrobial agents (Figure 
5.3). For example, penicillins with extended spectrum 
(J01CA) had a ratio of consumption in primary health care 
vs. hospital care of around 12/1 while the same ratio for 
fluoroquinolones (J01MA) and macrolides (J01FA) was 3/1 
and 28/1, respectively. 
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Figure 5.2. Total consumption of antimicrobial agents (J01) in humans by narrow-spectrum and broad-spectrum 
agents, Denmark
DANMAP 2011
Note: "Narrow-spectrum" includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, 
sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and 'other antibiotics'.
"Broad-spectrum" includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase 
inhibitors, cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, 
fluoroquinolones, and polymyxins
Since 2002, the overall consumption of antimicrobial 
agents has increased by 28%, or 4.13 DID (Figure 5.1). 
During the same period, broad-spectrum agents alone 
have increased by 3.2 DID (70%), comprising 31% of 
the overall consumption in 2002 and 41% in 2011. The 
proportion of DDDs prescribed in primary health care 
remained relatively constant during the last decade, 
between 89–90%. 
The detailed distribution of DIDs among antimicrobial 
groups in primary health care and hospital care is 
presented in Table 5.3 and Table A5.6 in web annex, 
respectively. 
In 2011, 51 tonnes of antimicrobial agents for systemic 
use (J01) were used in humans in Denmark. This level is 
similar to that reported in 2010 but represents an increase 
of 7.6 tonnes (18%) compared to 2002 (Table A5.6 in web 
annex).
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Figure 5.3. Distribution of DIDs between primary health care and hospital care, Denmark
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5.3  Primary health care
5.3.1  Total consumption in primary health care
In 2011, the total consumption of antimicrobial agents 
for systemic use (J01) in primary health care remained at 
the same level as in 2010 (17.06 DID in 2011, compared 
to 16.93 DID in 2010) but not deviating from the general 
upwards tendency observed since 1995. Increases were 
observed for three out of the 19 therapeutic groups (Table 
5.2). The most pronounced increases were observed for 
‘combination penicillins’ (0.22 DID) while relatively small 
upward changes were seen for beta-lactamase sensitive 
penicillins (0.06 DID) and macrolides (0.03 DID). 
Consumption decreased within four groups: penicillins 
with extended spectrum (0.06 DID), tetracyclines (0.05 
DID), beta-lactamase resistant penicillins (0.03 DID) and 
short-acting sulfonamides (0.02 DID).
The consumption of antimicrobial agents in primary health 
care in 2011 was the highest observed since the initiation of 
DANMAP in 1995. 
Compared to 2010, each treated patient in primary health 
care used an equal number of DDDs in 2011 (19.4 DDD vs. 
19.6 DDD), as discussed in section 5.3.2. However, in 2011 
more patients were treated and more packages prescribed 
than in 2010 (Tables A5.2 and A5.3 in web annex) which 
explains why the consumption in 2011 is slightly higher 
even though the number of DDDs used per patient 
remained constant. 
The observed consumption of antimicrobial agents 
was markedly larger in the second half of 2011 for all 
antimicrobial agents (J01) in particular macrolides (J01FA) 
and beta-lactamase sensitive penicillins (J01CE). This 
pattern is most likely caused by the generally increased 
burden of lower respiratory tract infections (LRTIs) 
in late 2011, confirmed by an outbreak of Mycoplasma 
pneumoniae in October – December 2011 (Figure 5.11). 
According to national guidelines, LRTIs of suspected 
bacterial origin are treated with beta-lactamase sensitive 
penicillins and suspected or confirmed M. pneumoniae 
infections with macrolides. 
Another driving factor behind the high overall 
consumption was a 0.89 DID (32%) increase in 
consumption of ‘combination penicillins’. Indeed more 
patients were treated and more packages prescribed in this 
therapeutic group in 2011 (web annex, Tables A5.2 and 
Table 5.2. Consumption of antimicrobial agents for systemic use in primary health care (DDD/1000 inhabitant-days), 
Denmark
a) From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group
Year
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
J01AA            Tetracyclines               1.04 1.07 1.17 1.28 1.38 1.48 1.54 1.61 1.69 1.64
J01CA            Penicillins with extended spectrum 2.51 2.52 2.63 2.79 2.95 3.25 3.26 3.29 3.47 3.41
J01CE            Beta-lactamase sensitive penicillins     5.00 5.07 5.20 5.28 5.40 5.67 5.30 5.12 5.25 5.31
J01CF            Beta-lactamase resistant penicillins     0.77 0.85 0.92 0.97 1.05 1.09 1.12 1.13 1.17 1.14
J01CR            Combinations of penicillins, including beta-lactamase inhibitors   0.04 0.05 0.06 0.08 0.12 0.19 0.27 0.45 0.68 0.89
J01D            Cephalosporins and related substances          0.03 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA            Trimethoprim and derivatives   0.36 0.38 0.41 0.44 0.47 0.49 0.49 0.48 0.51 0.50
J01EB            Short-acting sulfonamides       0.36 0.36 0.36 0.35 0.35 0.31 0.28 0.27 0.26 0.24
J01EE            Combinations of sulfonamides and trimethoprim, including derivatives 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01FA            Macrolides                  2.15 2.13 2.23 2.41 2.31 2.42 2.28 2.21 2.44 2.47
J01FF            Lincosamides                0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.03 0.04 0.04
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01MA        Fluoroquinolones            0.18 0.25 0.28 0.33 0.37 0.44 0.51 0.52 0.57 0.57
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB            Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03
J01XC            Steroid antibacterials (fusidic acid)     0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01
J01XD            Imidazole derivatives                  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XE Nitrofuran derivatives (nitrofurantoin) 0.41 0.42 0.43 0.45 0.46 0.47 0.47 0.49 0.51 0.50
J01XX            Other antibacterials (methenamine >99%)        0.34 0.32 0.30 0.28 0.27 0.26 0.27 0.26 0.27 0.26
J01 Antibacterial agents for systemic use (total) 13.26 13.53 14.06 14.75 15.23 16.17 15.91 15.95 16.93 17.06
DANMAP 2011
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A5.3) and an increased number of DDDs were supplied to 
each treated patient (Table 5.3). The possible reasons for 
this increase are discussed in section 5.3.2. 
As observed in 2010, beta-lactamase sensitive penicillins 
still represented the largest therapeutic group of 
antimicrobial agents consumed in 2011 (31%), followed by 
penicillins with extended spectrum (20%) and macrolides 
(15%) (Figure 5.4). Penicillins accounted for 63% of 
the total consumption in 2011. Consumption of broad-
spectrum agents showed a small upwards change of 0.10 
DID (1.5%) compared to 2010 (Figure 5.5). 
From 2002 to 2011, antimicrobial consumption (J01) 
increased by 28.7% from 13.26 DID in 2002 to 17.06 DID 
in 2011 (Table 5.2). Broad-spectrum agents represented 
6.58 DID (38.6%) of the total consumption in 2011 
compared to 3.85 DID (29%) in 2002; representing an 
increase of 78% (Figure 5.5). The consumption of all 
leading groups of antimicrobial agents was higher in 
2011 than a decade earlier, and a steady increase from 
year to year has been observed for most of these groups 
(Figure 5.6). Only short-acting sulfonamides (J01EB), 
combinations of sulfonamides and trimethoprim (J01EE) 
and ‘other antibacterials’ (J01XX) were at a lower level in 
2011 compared to 2002.  
The total number (J01) of DDDs per treated patient was 
19.4 compared to 19.6 in 2010. For substances with the 
highest consumption (DID), each treated patient received 
from 11.5 – 21.9 DDDs in 1.5 – 1.6 packages with the 
exception of tetracyclines (44 DDDs in 1.9 packages) 
(Table 5.3 and Table A5.4 in web annex).
Three different indicators of antimicrobial consumption 
at treated patient level in primary health care are available 
(Figure 5.7). From 2002 to 2011, the largest increases 
were observed in DDDs per treated patient (24%) and 
DDDs per prescribed package (20%) (Table 5.3). Steroid 
5.3.2  Measures at treated patient level
5.3.2  Tetracyclines (J01AA)
In 2011, the overall consumption of tetracyclines 
decreased by 0.05 DID (2.9%) compared to 2010 (Table 
5.2). The most commonly used substance was tetracycline 
(0.78 DID, 48%) followed by doxycycline (0.47 DID, 
29%), lymecycline (0.38 DID, 23%) and oxytetracycline 
(0.01 DID, 0.03%) (Figure 5.8). Compared to 2010, 
consumption of tetracycline and lymecycline increased 
while consumption of doxycycline and oxytetracycline 
decreased.
Since 2002, a considerable increase in the consumption 
of tetracyclines has been observed (Table 5.2). As shown 
in the DANMAP 2007 and 2008 reports, tetracyclines 
are often prescribed for teenagers and young adults, 
primarily against acne (tetracycline, J01AA07) and as 
malaria prophylaxis (doxycycline, J01AA02). Acne usually 
requires long treatment regimens and hence more DDDs 
per treated patient, and the continuous increase in DDDs 
per treated patient may therefore partly be related to 
increases in the number of acne prescriptions. A total 
understanding of the observed increase in the past decade, 
however, is not possible due to incomplete codes of 
indication.
Figure 5.4. Distribution of the total consumption of antimicrobial agents in primary health care, Denmark
DANMAP 2011
antimicrobials (fusidic acid), tetracyclines, ‘combination 
penicillins’ and fluoroquinolones showed the largest 
increases. 
The reasons for these changing patterns are unclear, 
primarily because codes of indication for  prescriptions are 
incomplete. A list of changes in packages and prescription 
guidelines is presented in DANMAP 2010. In early 2012, 
an agreement was reached between the Danish Ministry of 
Health and The Organisation for General Practitioners to 
remove broad codes of indication (‘against infection’ and 
‘against inflammation’) from all electronic prescriptions, 
thereby increasing the likelihood of a practitioner 
providing more disease- or pathogen-specific information 
on a prescription.
Note: Bold highlights indicate broad-spectrum antibacterial agents
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DANMAP 2011
Figure 5.5. Consumption of antimicrobial agents (J01) in primary health care by narrow-spectrum and broad-
spectrum agents, Denmark
Note: "Narrow-spectrum" includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, 
sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and 'other antibiotics'.
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase 
inhibitors, cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, 
fluoroquinolones, and polymyxins
9.
41
9.
55
9.
86
10
.2
2
10
.3
5
10
.7
6
10
.2
6
10
.0
1
10
.4
6
10
.4
8
3.
85 3.
98 4.
20 4.
53 4.
88 5
.4
1
5.
65
5.
94 6
.4
8
6.
58
0
5
10
15
20
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
D
D
D
/1
00
0 
in
ha
bi
ta
nt
-d
ay
s
Narrow-spectrum Broad-spectrum
Figure 5.6. Consumption of leading antimicrobial groups for systemic use in primary health care, Denmark
DANMAP 2011
0
1
2
3
4
5
6
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
D
D
D
/1
00
0 
in
ha
bi
ta
nt
-d
ay
s
Beta-lactam. sens. penicillins
(J01CE)
Penicillins with extend.
spectrum (J01CA)
Macrolides (J01FA)
Tetracyclines (J01AA)
Beta-lactam. resis. penicillins
(J01CF)
Fluoroquinolones (J01MA)
Combinations of penicillins,
including beta-lactamase
inhibitors (J01CR)
                                                                           
       55DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN HUMANS 5.
90%
100%
110%
120%
130%
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
In
de
x:
 2
00
1 
= 
10
0%
DDD/1000 inh./day Packages/1000 inh./year Treated pat./1000 inh./year (a)
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Table 5.3. Number of DDDs and packages per treated patient among leading groups of antimicrobial agents in 
primary health care, Denmark
ATC 
group(a) Therapeutic group Indicator
Year
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
J01AA Tetracyclines               
DDDs / patient 33.0 34.4 36.9 39.0 40.9 43.0 44.4 45.2 45.9 44.0
Packages / patient 1.9 1.9 1.9 2.0 1.9 2.0 2.0 2.0 2.0 1.9
DDDs / package 17.5 18.1 19.0 19.6 21.0 22.0 22.7 22.7 22.7 22.6
J01CA Penicillins with extended spectrum
DDDs / patient 13.2 13.4 13.6 13.9 14.2 14.4 14.7 14.8 14.9 14.8
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
DDDs / package 8.2 8.2 8.4 8.5 8.9 9.0 9.2 9.2 9.0 9.2
J01CE Beta-lactamase sensitive penicillins     
DDDs / patient 10.5 10.7 11.1 11.3 11.5 11.7 11.8 11.8 11.8 11.8
Packages / patient 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4 1.4
DDDs / package 7.2 7.3 7.5 7.7 8.0 8.2 8.2 8.4 8.4 8.4
J01CF Beta-lactamase resistant penicillins     
DDDs / patient 11.8 11.8 12.4 12.7 13.0 13.4 13.7 13.9 14.2 13.8
Packages / patient 1.6 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.4
DDDs / package 7.5 7.4 7.8 8.0 8.6 8.7 9.0 9.1 9.3 9.6
J01CR
Combinations of 
penicillins, incl. beta-
lactamase inhibitors   
DDDs / patient 14.7 16.6 17.2 16.8 19.3 19.1 19.9 20.4 21.1 21.9
Packages / patient 1.7 1.8 2.0 2.0 1.8 1.6 1.6 1.5 1.5 1.6
DDDs / package 8.6 9.1 9.1 9.3 10.7 11.7 12.4 13.3 13.7 14.1
J01FA Macrolides                  
DDDs / patient 11.7 12.1 12.4 12.4 12.6 12.4 12.5 12.5 12.2 11.5
Packages / patient 1.5 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 7.6 7.8 7.9 8.0 8.3 8.1 8.1 8.1 8.1 7.9
J01MA Fluoroquinolones            
DDDs / patient 8.6 10.3 9.5 9.6 10.3 10.6 11.0 11.2 11.2 11.5
Packages / patient 1.4 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 6.0 6.6 6.4 6.5 6.9 7.0 7.5 7.6 7.6 7.7
J01
Antibacterial agents 
for systemic use 
(total)
DDDs / patient 16.0 16.4 17.0 17.5 17.9 17.3 18.9 19.2 19.6 19.4
Packages / patient 2.0 2.1 2.1 2.1 2.0 1.9 2.1 2.1 2.1 2.1
DDDs / package 7.8 7.9 8.1 8.3 8.7 8.9 9.1 9.3 9.3 9.3
a) From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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5.3.4  Penicillins (J01C)
The overall consumption of penicillins in 2011 showed 
a small upward change of 0.19 DID (1.8%) compared to 
2010 (Table 5.2). In the four main groups, increases in 
consumption were observed for ‘combination penicillins’ 
(30.9%). For the individual substances, the consumption 
of amoxicillin and enzyme inhibitor (J01CR02) increased 
by 32% while smaller upward changes were observed for 
all other substances apart from pivampicillin (J01CA02), 
amoxicillin (J01CA04) and dicloxacillin (J01CF01) 
(Figure 5.9). The current guidelines advocate the use of 
‘combination penicillins’ (primarily amoxicillin/clavulanic 
acid) for broad treatment of respiratory infections, and 
particularly for patients with exacerbation of chronic 
obstructive pulmonary disease. 
During the past decade (2002 – 2011), the consumption 
of penicillins (J01C) increased by 2.45 DID (29.5%). This 
increase was apparent for all four groups of penicillins; 
penicillins with extended spectrum (0.91 DID, 36.2%), 
‘combination penicillins’ (0.85 DID, 2200%), beta-
lactamase resistant penicillins (0.37 DID, 48.1%) and 
beta-lactamase sensitive penicillins (0.31 DID, 6.2%).  
Phenoxymethylpenicillin continues to be the most 
commonly consumed penicillins; however the order 
has changed among the other substances during the last 
decade (Figure 5.9). 
5.3.5  Macrolides (J01FA)
From 2010 – 2011, the consumption of macrolides showed 
a small upward change of 0.03 DID (1.2%) (Table 5.2). 
Within the macrolide group, erythromycin continued 
a decreasing trend (Figure 5.10) while increases were 
observed primarily for roxithromycin (0.10 DID) but 
also for azithromycin (0.04 DID) and clarithromycin 
(0.04 DID). As in previous years, part of the increased 
roxithromycin consumption was most likely caused by an 
outbreak of M. pneumoniae (see also section 5.3.1). 
Figure 5.8. Consumption of tetracyclines in primary health care, Denmark
DANMAP 2011
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Figure 5.10. Consumption of macrolides in primary health care, Denmark
From 2002 to 2011, the consumption of roxithromycin 
increased noticeably (0.79 DID), with smaller 
increases also observed for clarithromycin (0.07 DID) 
and azithromycin (0.02 DID). The consumption of 
erythromycin decreased substantially (0.54 DID), most 
likely in response to changes in national guidelines 
which in 2004 substituted the first-choice macrolide in 
primary care from erythromycin to roxithromycin and 
subsequently also to clarithromycin in 2007. These two 
substances are now the recommended first choices for 
treatment of respiratory infections in people with penicillin 
allergy or suspected M. pneumoniae infection. During the 
whole period, azithromycin has been the recommended 
treatment for urethritis/cervicitis and epididymitis.  
  
5.3.6  Fluoroquinolones (J01MA)
The consumption of fluoroquinolones in 2011 remained 
at the same level as observed in 2010 (0.57 DID) 
(Table 5.2). Ciprofloxacin accounted for the majority 
of fluoroquinolone consumption (94%), followed by 
moxifloxacin (3.6%) and ofloxacin (1.9%) (Figure 5.12). 
During the past decade, the consumption of 
fluoroquinolones has increased by 0.40 DID (238%), 
although with a marked drop in the rate of increase from 
2009 and onwards (Table 5.2). As described in 2011 
[Jensen and Bjerrum 2011. Ugeskr Læger. 173: 2853–2856] 
the continuously increasing consumption of ciprofloxacin 
is most likely due to the introduction of generic versions 
in Denmark in December 2001, followed by subsequent 
drops in prices. From a resistance perspective, this increase 
is particular grounds for concern as ciprofloxacin is 
strongly associated with resistance.
DANMAP 2011
DANMAP 2011
Figure 5.11. Monthly consumption of macrolides and beta-lactamase sensitive penicillins and PCR positive Mycoplasma 
pneumoniae tests in primary health care, Denmark
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Figure 5.12. Consumption of leading fluoroquinolones in primary health care, Denmark
DANMAP 2011
5.4  Hospital care
5.4.1  Introduction
The consumption of antimicrobial agents in the hospital 
sector is presented as both DDD per 100 occupied bed-
days (DBD) and DDD per admissions (DAD) to account 
for hospital activity. Furthermore, data are also presented 
as DID to enable comparison with primary health care 
and to document the consumption across the entire 
hospital sector, irrespective of hospital activity. 
The hospital sector encompasses all hospitals in Denmark, 
i.e. rehabilitation centres, hospices, private-, psychiatric-, 
specialized-, and somatic hospitals. Somatic hospitals 
account for the majority (97%) of the antimicrobial 
consumption in the hospital sector. Antimicrobial 
consumption is therefore correlated only to bed-days and 
admissions in somatic hospitals and not to bed-days and 
admissions in other hospital types since psychiatric hospitals 
contribute a large proportion of bed-days and admissions but 
only a small proportion of the antimicrobial consumption. 
The hospitalization pattern in Denmark has changed 
significantly during the past decade: more people are 
admitted to somatic hospitals but average length of stay has 
been shortened (Figure 5.13, Table A5.5 in web annex) and 
outpatient treatment has increased considerably. Therefore, 
the hospital activity and subsequent selection pressure for the 
emergence of resistance were higher in 2011 than in 2002.  
Figure 5.13. Number of bed-days and admissions in somatic hospitals, Denmark
DANMAP 2011
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E-bug: Raising awareness of prudent use of antimicrobial agents in future generations
Antimicrobial resistance is related to use of antimicrobial agents and has previously 
been connected to hospitals. It is now an increasing community problem. If use of 
antimicrobial agents could be reduced through preventive hygienic methods, the tide of 
increasing resistance could be stemmed. e-Bug is a European project for the generation 
for whom the resistance problem will be very important - the children. e-Bug involves 
18 European countries and is partly funded by The Directorate-General for Health and 
Consumers (DG SANCO) of the European Commission.
The aim of e-Bug is to develop and disseminate across Europe a junior and senior school 
teaching pack and web site that teaches young people about prudent use of antimicrobial agents, microbes, 
transmission of infection, preventive hygiene and vaccines. The website (www.e-bug.eu) hosts the lesson plans 
and complementary games and is easily accessed for children, parents and teachers with access to computers 
and the internet. The overall goal of the project is to increase young people’s understanding of why prudent 
use of antimicrobial agents is so important when trying to control antimicrobial resistance, and to emphasize 
the importance of proper hand and respiratory hygiene to help reduce the spread of infection. Within the 
senior school pack the sexual transmission of infections has also been included, as the peak age of chlamydial 
infection is in 16–24 year olds.
Teachers, young people and the consortium of 18 countries were closely involved in formulating the learning 
outcomes and developing the resource activities. Young people helped create the characters and microbe 
artwork. The material builds on the theory of many learning styles and the explorative approach that creates the 
understanding of the many factors involved. The resources have been translated, adapted for and disseminated 
to schools across 10 countries in Europe, and endorsed by the relevant government departments of health and 
education. The teaching resources have already been used to promote European Antibiotic Awareness Day and 
better hand and respiratory hygiene in several participating countries. The website has been visited by people 
from more than 100 countries. In the near future, all teaching resources will be translated into all European 
Union languages.
Compared to most other European countries, bacterial resistance to antimicrobial agents in primary health 
care in Denmark is low. The goal of participating in e-Bug was to keep it that way. The Danish “Folkeskole”, 
which is the Danish municipal primary and lower secondary school, uses the principle of differentiated 
teaching, integrating information technology, and there are no recommended textbooks in the curriculum. The 
teaching is organized so that it both strengthens and develops an individual student’s ability to act and care for 
themselves and for society in general. e-Bug, in its design, was seen as a tool that could be implemented well 
in the Danish “Folkeskole”, as it fulfills the goals on teaching methods and output. During the initial phase, 
2000 e-Bug packs were printed and 100 local education authorities and 1507 school principals were contacted. 
Since then, e-Bug has been presented to important stakeholders in relevant scientific magazines and at various 
meetings for teachers and infection control members. Today, the project has been well accepted and the Danish 
website (www.e-bug.eu/dk) has approximately 350 visits per month.  
The development and implementation of e-Bug across Europe is described in detail in a series of articles in 
Journal of Antimicrobial Chemotherapy, Volume 66 Supplement, 5 June 2011. 
Jette Holt and Katrin G. Kuhn
For further information: Jette Holt (JHO@ssi.dk)
60                          
                   
DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN HUMANS5. Textbox 3
The association between increased antimicrobial consumption and demographic factors in 
Denmark, 2001 to 2010
Background: The Danish system for monitoring human consumption of antimicrobial agents is one of the 
few in the world allowing surveillance of all antimicrobial agents prescribed in the primary and hospital 
sectors. Using these data, it has previously been demonstrated that the consumption of antimicrobial agents 
in primary health care in Denmark increased by 32% from 2001 to 2010 [DANMAP 2010]. This increase in 
consumption was mirrored by a concurrent increase in the occurrence of resistant bacteria. The aim of this 
study was to investigate the demographic factors associated with the increased antimicrobial consumption in 
Denmark during the past decade.
Materials and methods: Measures of defined daily doses per 1,000 inhabitant-days (DID) for leading 
antimicrobial groups (ATC-4 level) and substances (ATC-5 level) in primary health care in 2001 and 2010 
were obtained from the Danish Medicines Agency, adjusted for population size and compared between years 
and between age and gender. Data were analysed by t-tests and a multivariate stepwise regression model. 
Consumption tendencies were assessed with reference to data on visits to a general practitioner (GP). 
Results: From 2001 to  2010, the consumption of antimicrobial agents (DID) increased for all age groups and 
both genders (Figure 1). In both years, females consumed significantly more antimicrobial agents than males. 
The most marked increases were shown for 15 – 19 year olds and persons older than 65 years. Children up to 
9 years had a significantly lower consumption compared to the rest of the population, in both 2001 and 2010. 
The increase in DIDs for this age group was also significantly lower than the increase in consumption for the 
rest of the population. The observed difference in DIDs in 2001compared to 2010 varied according to the 
group (ATC-4 level) and substance (ATC-5 level) (Figure 2). For instance, the consumption of lymecycline 
and tetracycline increased particularly in 15 – 19 year olds while increases in DIDs for pivmecillinam and 
amoxicillin/clavulanic acid were observed for people older than 65 years. A multivariate model explained 
82% of the observed variation in consumption in 2001 compared to 2010, with 15 – 19 year olds having the 
most significant effect on the difference in DID between the two years. General increases in consumption for 
all ages and both genders were shown for roxithromycin and ciprofloxacin. The overall frequency of GP visits 
increased during the period, but decreases of up to 10% were observed in some age groups (Figure 3). 
Discussion and conclusions: During 2001–2010 consumption increases were observed for several leading 
antimicrobial groups and substances, driven primarily by people older than 65 years and adolescents. The 
age-related increases observed in tetracyclines and pivmecillinam are most likely related to changes in the 
treatment of acne and urinary tract infections, respectively. Population-wide increases in the consumption 
of roxithromycin may partly be explained by the occurrence of several large Mycoplasma pneumoniae 
outbreaks, while the increase in ciprofloxacin consumption is most likely related to the introduction of generic 
versions in late 2001 [Jensen et al. 2010. J Antimicrob Chemother. 65:1286-1291]. The increases observed 
for both roxithromycin and ciprofloxacin are grounds for concern as these substances are broad-spectrum 
antimicrobial agents and thus strongly associated with selection of resistant bacteria. Although increases in 
antimicrobial consumption may generally be due to many factors, evidence suggests that increases observed 
from 2001 to 2010 are a combination of disease-specific factors and not least an inclination of GPs to 
prescribe more antimicrobial agents per visit and in larger doses. This in itself is not entirely bad news but 
could rather be a reflection of changed guidelines which advocate increased dosages for shorter periods, in 
order to decrease the likelihood of selection for resistance. Overall, however, it is important to emphasize the 
need for not prescribing antimicrobial agents without a confirmed diagnosis.
  
Katrin G. Kuhn, Anette M. Hammerum and Ulrich S. Jensen
For further information: Katrin G. Kuhn (kuh@ssi.dk)
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Figure 2. Consumption (DID) of leading antimicrobial groups (ATC-4) in Denmark, 2001 and 2010
DANMAP 2011
DANMAP 2011
Figure 1. Consumption (DID) of antimicrobial agents (ATC-2) over ten years by age and gender
DANMAP 2011
Figure 3. Prevalence of GP visits over ten years by age and gender
0
5
10
15
20
25
30
35
40
45
50
0-4y 5-9y 10-14y 15-19y 20-39y 40-64y 65-79y 80+ yN
um
be
r o
f t
re
at
ed
 p
at
ie
nt
s/
10
00
 p
op
ul
at
io
n/
 y
ea
r (
D
ID
)
Females 2001 Females 2010 Males 2001 Males 2010
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
0-4y 5-9y 10-14y 15-19y 20-39y 40-64y 65-79y 80+ y
N
um
be
r o
f G
P
 v
is
its
/1
00
0 
po
pu
la
tio
n 
/ y
ea
r
Females 2001 Females 2010 Males 2001 Males 2010
0
1
2
3
4
5
6
Te
tra
cy
cl
in
es
(J
01
AA
)
Pe
ni
ci
llin
s 
w
ith
ex
te
nd
ed
sp
ec
tru
m
(J
01
C
A)
Be
ta
-la
ct
am
as
e
se
ns
iti
ve
pe
ni
ci
lli
ns
(J
01
C
E)
Be
ta
-la
ct
am
as
e
re
si
st
an
t
pe
ni
ci
lli
ns
(J
01
C
F)
C
om
bi
na
tio
n
pe
nc
illi
ns
(J
01
C
R
)
Tr
im
et
ho
pr
im
an
d 
de
riv
at
iv
es
(J
01
EA
)
Sh
or
t-a
ct
in
g
su
lfo
na
m
id
es
(J
01
EB
)
M
ac
ro
lid
es
(J
01
FA
)
Fl
uo
ro
qu
in
ol
on
es
 (J
01
M
A
)
N
itr
of
ur
an
de
riv
at
es
(J
01
XE
)
N
um
be
r o
f t
re
at
ed
 p
at
ie
nt
s/
10
00
 p
op
ul
at
io
n/
ye
ar
 (D
ID
) Females 2001 Females 2010 Males 2001 Males 2010
62                          
                   
DANMAP 2011  
ANTIMICROBIAL CONSUMPTION IN HUMANS5.
The reported sales (consumption) of certain infusion 
substances by the hospital pharmacies to the Danish 
Medicines Agency has for several years been inaccurate 
due to merging of antimicrobial agents and infusion 
liquids. This is particularly relevant for cephalosporins 
(J01DB, J01DC, J01DD), carbapenems (J01DH), 
combinations of sulfonamides and trimethoprim (J01EE) 
and imidazole derivatives (J01XD). The consumption 
of these substances has been corrected by direct data 
collection from all Danish hospital pharmacies.  
5.4.2  Total consumption in hospital care - DDD per 
1,000 inhabitants per day (DID)
The total consumption of antimicrobial agents in the 
Danish hospital sector (as defined above) in 2011 was 1.84 
DID - a decrease of 3.7% compared to 2010 (Figure 5.14). 
Broad-spectrum agents represented 66% compared to 67% 
in 2010. 
Since 2002, the total consumption of antimicrobial agents 
has increased by 0.38 DID (26%). Broad-spectrum agents 
have increased by 0.47 DID (67%), comprising 66% of 
the total consumption in 2011 compared to 50% in 2002 
(Figure 5.14 and Table A5.6 in web annex). 
5.4.3  Somatic hospitals - DDD per 100 occupied 
bed-days (DBD)
Consumption (DBD) in somatic hospitals compared to 
2010 
The consumption of antimicrobial agents (J01) in somatic 
hospitals increased by 3.12 DBD (3.6%) from 2010 to 
2011 (Table 5.4). Five therapeutic groups dominated the 
increasing consumption: linezolid (0.10 DBD, 45.5%), 
combinations of sulfonamides and trimethoprim (1.07 
DBD, 35%), ‘combination penicillins’ (1.38 DBD, 19%), 
fluoroquinolones (0.26 DBD, 6.7%), and macrolides (0.17 
DBD, 4.7%), but upward changes of ≥ 0.10 DBD were also 
observed for aminoglycosides, glycopeptides, carbapenems 
and monobactams. These changes were due both to 
decreasing numbers of bed-days as well as increasing 
DDDs. 
In two therapeutic groups, consumption decreased ≥ 0.10 
DBD: beta-lactamase resistant penicillins (0.41 DBD, 5.3%) 
and penicillins with extended spectrum (0.20 DBD, 1.4%). 
These changes were due to a decreasing number of DDDs 
in relation to a decreasing number of bed-days.  
Cephalosporins accounted for 19% of the total 
consumption of antimicrobial agents in somatic hospitals 
(Figure 5.15), followed by penicillins with extended 
spectrum (15%), fluoroquinolones (12%) and beta-
lactamase sensitive penicillins (10%). 
Figure 5.14. Consumption of antimicrobial agents (J01) in hospital care by narrow-spectrum and broad-spectrum 
agents, Denmark
Note: “Narrow-spectrum” antibiotics includes: beta-lactamase sensitive penicillins, first-generation cephalosporins, beta-lactamase 
resistant penicillins, monobactams, trimethoprim, sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol 
derivatives, nitrofuran derivatives, and ‘other antibiotics’.
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase 
inhibitors, second-generation cephalosporins, third-generation cephalosporins, carbapenems, combinations of sulfonamides and 
trimethoprim, aminoglycosides, fluoroquinolones, and polymyxins.
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Consumption (DBD) in somatic hospitals – the last decade 
From 2002 – 2011, the total consumption of antimicrobial 
agents (J01) increased by 39.11 DBD (76%) (Table 5.4). 
This increase was due to a 26% increase in the total 
number of DDDs combined with a 31% decrease in the 
number of hospital bed-days. 
During the past decade, the consumption of broad-
spectrum antimicrobial agents in Danish somatic hospitals 
has increased by 137%, from 25.8 DBD in 2002 to 61.2 
DBD in 2011 (Figure 5.16). In 2002, consumption of 
penicillins with extended spectrum and beta-lactamase 
sensitive penicillins each represented 22% of the total 
somatic hospital antimicrobial consumption, compared 
to 16% and 10%, respectively, in 2011. In the broad-
spectrum group, the consumption of fluoroquinolones 
in somatic hospitals increased by 0.05 DBD (74%) and 
the consumption of carbapenems increased by 0.03 
DBD (283%) during the past decade. Consumption of 
cephalosporins increased by 133% from 2002–2011. 
Although broad-spectrum antimicrobial agents offer 
treatment for a wider range of pathogens, their potential 
advantage is now known to be outweighed by the fact that 
these substances are known to select for resistance (see 
chapter 8). In this context, it is noteworthy that the rate of 
increase for the consumption of both cephalosporins and 
fluoroquinolones has been considerably lower from 2009 
onwards. 
Table 5.4. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), 
Denmark          
ATC 
group(a) Therapeutic group
Year
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
J01AA                        Tetracyclines               0.32 0.30 0.32 0.33 0.39 0.63 0.78 1.04 1.09 1.18
J01CA                        Penicillins with extended spectrum 11.34 11.55 11.51 12.90 13.00 13.42 13.96 15.37 14.61 14.41
J01CE                        Beta-lactamase sensitive penicillins   11.37 11.85 12.02 12.17 10.67 10.79 9.98 9.90 9.49 9.32
J01CF                        Beta-lactamase resistant penicillins   6.24 6.54 6.78 6.71 6.51 6.70 6.81 7.40 7.71 7.30
J01CR                        Combinations of penicillins. incl. beta-lactamase inhibitors   0.31 0.49 0.84 1.16 1.83 2.95 4.00 5.65 7.13 7.13
J01DB                  First-generation cephalosporins 0.14 0.14 0.17 0.15 0.14 0.13 0.18 0.13 0.13 0.13
J01DC Second-generation cephalosporins 5.79 6.24 6.91 8.39 9.38 12.31 13.32 15.76 16.21 16.14
J01DD Third-generation cephalosporins 0.65 0.67 0.67 0.83 0.83 1.03 1.25 1.42 1.26 1.39
J01DF Monobactams 0.00 0.01 0.00 0.00 0.00 0.04 0.07 0.06 0.09 0.19
J01DH Carbapenems 0.60 0.68 0.85 1.16 1.38 2.13 2.70 3.15 4.02 4.16
J01EA                        Trimethoprim and derivatives   0.41 0.43 0.41 0.41 0.42 0.44 0.44 0.44 0.36 0.36
J01EB                        Short-acting sulfonamides       1.23 1.14 1.06 0.99 0.75 0.34 0.35 0.35 0.33 0.25
J01EE                        Combinations of sulfonamides and trimethoprim. incl. derivatives 1.46 1.54 1.86 2.11 2.12 1.52 1.95 2.28 3.04 4.11
J01FA                        Macrolides                  3.21 2.95 2.85 2.89 2.83 3.08 3.06 3.42 3.52 3.69
J01FF                        Lincosamides                0.19 0.22 0.23 0.24 0.31 0.35 0.41 0.50 0.47 0.53
J01GB Aminoglycosides 1.76 1.71 2.00 1.95 1.81 1.79 1.64 1.56 1.71 1.91
J01MA                        Fluoroquinolones            3.52 3.90 4.93 6.14 6.74 8.16 9.53 10.71 10.44 10.70
J01XA Glycopeptides 0.38 0.42 0.47 0.52 0.56 0.63 0.68 0.99 1.07 1.24
J01XB                        Polymyxins                 0.04 0.03 0.06 0.12 0.12 0.05 0.05 0.07 0.10 0.09
J01XC                        Steroid antibacterials (fusidic acid)     0.19 0.22 0.22 0.25 0.28 0.28 0.26 0.31 0.34 0.27
J01XD                 Imidazole derivatives 2.12 2.32 2.43 2.62 2.78 2.62 3.27 3.84 3.93 4.19
J01XE Nitrofuran derivatives (nitrofurantoin) 0.28 0.30 0.28 0.29 0.29 0.28 0.29 0.36 0.31 0.33
J01XX05 Methenamine 0.12 0.08 0.10 0.08 0.11 0.09 0.10 0.09 0.08 0.10
J01XX08 Linezolid 0.04 0.04 0.07 0.15 0.20 0.16 0.21 0.22 0.22 0.32
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.02 0.02 0.02
J01 Antibacterial agents for systemic use (total) 51.73 53.77 57.04 62.58 63.47 69.94 75.28 85.03 87.72 90.84
          
           
           
           
DANMAP 2011
a) From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system 
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Figure 5.15. Distribution of the total consumption of antimicrobial agents in somatic hospitals, Denmark
Note: Bold highlights indicate broad-spectrum antibacterial agents
Figure 5.16. Total somatic hospital consumption (DID) by leading groups of antimicrobial agents (J01), Denmark
DANMAP 2011
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5.4.4  Somatic hospital consumption - DDD per 100 
admissions (DAD)
The total consumption of antimicrobial agents (J01) in 
Danish somatic hospitals in 2011 remained at the same 
level as observed in 2010, when expressed as DAD (DDD 
per 100 admissions) (Table 5.5). Increases in consumption 
were partly observed for the same therapeutic groups as 
when expressed in DBD: linezolid (0.27 DAD, 37.5%), 
combinations of sulfonamides and trimethoprim (2.91 
DAD, 29.5%), ‘combination penicillins (3.32 DAD, 14.3%) 
and aminoglycosides (0.39 DAD, 6.9%). A decreased 
consumption was observed for beta-lactamase resistant 
penicillins (2.33 DAD, 9.3%), beta-lactamase sensitive 
penicillins (1.85 DAD, 6%), penicillins with extended 
spectrum (2.69 DAD, 5.7%) and second-generation 
cephalosporins (2.46 DAD, 4.7%).  
DANMAP 2011
Table 5.5. Consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), 
Denmark
a) From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system
b) The number of admissions was affectedly low in 2008 due to a major hospital strike
ATC 
group(a) Therapeutic group
Year
2002 2003 2004 2005 2006 2007 2008(b) 2009 2010 2011
J01AA            Tetracyclines               1.58 1.43 1.45 1.45 1.67 2.59 3.19 3.63 3.55 3.66
J01CA            Penicillins with extended spectrum 56.68 54.88 52.22 56.43 55.13 55.39 57.18 53.76 47.46 44.77
J01CE            Beta-lactamase sensitive penicillins  56.79 56.33 54.53 53.20 45.26 44.55 40.90 34.61 30.83 28.98
J01CF            Beta-lactamase resistant penicillins  31.18 31.11 30.77 29.33 27.60 27.64 27.89 25.86 25.04 22.71
J01CR            Comb. of penicillins. incl. beta-lactamase inhibitors   1.56 2.35 3.82 5.09 7.77 12.17 16.37 19.74 23.15 26.47
J01DB                  First-generation cephalosporins 0.72 0.67 0.76 0.67 0.60 0.55 0.72 0.46 0.43 0.41
J01DC Second-generation cephalosporins 28.95 29.66 31.36 36.70 39.76 50.81 54.55 55.12 52.65 50.19
J01DD Third-generation cephalosporins 3.25 3.17 3.06 3.62 3.53 4.24 5.10 4.98 4.10 4.33
J01DF Monobactams 0.02 0.02 0.02 0.02 0.00 0.18 0.27 0.21 0.29 0.60
J01DH Carbapenems 2.98 3.24 3.85 5.05 5.86 8.78 11.08 11.01 13.07 12.55
J01EA            Trimethoprim and derivatives   2.07 2.05 1.86 1.78 1.78 1.81 1.80 1.56 1.17 1.11
J01EB            Short-acting sulfonamides       6.16 5.44 4.82 4.32 3.18 1.41 1.43 1.21 1.09 0.78
J01EE            Comb. of sulfonamides and trimethoprim. incl. derivatives 7.31 7.32 8.44 9.21 8.98 6.28 7.98 7.96 9.88 12.79
J01FA            Macrolides                  16.03 14.03 12.92 12.64 12.01 12.70 12.53 11.97 11.45 11.47
J01FF                        Lincosamides                0.94 1.05 1.04 1.05 1.31 1.46 1.69 1.74 1.52 1.63
J01GB Aminoglycosides 8.79 8.14 9.07 8.55 7.68 7.39 6.71 5.45 5.56 5.95
J01MA            Fluoroquinolones            17.60 18.53 22.38 26.87 28.58 33.66 39.04 37.45 33.92 33.30
J01XA Glycopeptides 1.88 1.97 2.12 2.28 2.38 2.61 2.77 3.48 3.47 3.87
J01XB            Polymyxins                 0.20 0.14 0.27 0.54 0.53 0.22 0.21 0.24 0.32 0.28
J01XC            Steroid antibacterials (fusidic acid)   0.97 1.04 1.01 1.11 1.19 1.17 1.05 1.09 1.12 0.85
J01XD                 Imidazole derivatives 10.57 11.03 11.02 11.47 11.81 10.83 13.39 13.43 12.76 13.03
J01XE Nitrofuran derivatives (nitrofurantoin) 1.42 1.41 1.26 1.28 1.24 1.17 1.19 1.27 1.01 1.02
J01XX05 Methenamine 0.61 0.37 0.45 0.36 0.46 0.38 0.43 0.31 0.27 0.32
J01XX08 Linezolid 0.22 0.21 0.34 0.64 0.86 0.68 0.84 0.76 0.72 0.99
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.00 0.03 0.06 0.06 0.07 0.05
J01 Antibacterial agents for systemic use (total) 258.46 255.59 258.81 273.67 269.18 288.70 308.39 297.36 284.89 282.53
From 2002 – 2011, the consumption of antimicrobial 
agents (J01) increased by 9.3%, from 258.46 DAD in 2002 
to 284.89 DAD in 2011. As observed in previous years, 
this increase was primarily driven by a 28% increase in the 
number of DDDs but counterbalanced by a 17% increase 
in the number of hospital admissions. 
The increase in consumption observed when expressed as 
DBD contrasts the no change observed when consumption 
is expressed as DAD. This illustrates the necessity for 
using different indicators to express the consumption of 
antimicrobial agents in hospitals. 
Katrin Gaardbo Kuhn and Maja Laursen
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6. Resistance in zoonotic bacteria
Zoonoses are infections and diseases that are transmissible 
between animals and humans, either via direct contact or 
indirectly via contaminated food. Zoonotic bacteria such 
as Salmonella and Campylobacter can develop resistance to 
antimicrobial agents as a result of treatment of the animals, 
which subsequently may lead to limitation of treatment 
possibilities or treatment failure of human infections. A 
more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and 
control programmes can be found in Textbox 4 and in the 
Annual Report on Zoonoses in Denmark 2011 [www.food.
dtu.dk].
6.1  Salmonella 
Salmonella is an important zoonotic pathogen of great 
economic impact in both animals and humans. Human 
salmonellosis is typically characterised by watery, 
sometimes bloody diarrhoea, abdominal pain, fever, 
headache and nausea after an incubation period  of 12 
to 36 hours.  Extraintestinal infections or post-infection 
complications such as reactive arthritis can occur
The common reservoir of Salmonella is the intestinal 
tract of a wide range of domestic and wild animals. In 
animals, infections are often sub-clinical. Transmission 
of Salmonella to humans often happens through food 
that has been contaminated with Salmonella, which 
has subsequently been allowed to multiply due to e.g. 
inadequate storage temperatures, inadequate cooking or 
cross contamination of ready-to-eat food. In Denmark, 
as well as in the European Union, S. Enteritidis and 
S. Typhimurium are the serovars most frequently 
associated with human illness. Human cases caused by 
S. Enteritidis are most commonly associated with the 
consumption of contaminated eggs and poultry meat, 
while S. Typhimurium cases are mostly associated with the 
consumption of contaminated pork, beef as well as poultry 
meat.
Clonal dissemination plays an important role for the 
spread of antimicrobial resistant Salmonella spp., 
particularly within S. Typhimurium. Examples of this are 
the rapid, global dissemination of the monophasic variants 
of S. Typhimurium, which are resistant to ampicillin (A), 
streptomycin (S), sulfonamide (Su) and tetracycline (T), 
often referred to as the ASSuT-profile. Presumably also 
as a consequence of clonal dissemination, certain phage 
types appear to be strongly associated with particular 
resistance patterns, as is observed with the monophasic S. 
Typhimurium DT193 and DT120 strains. 
However, DT193 and DT120 are also commonly found 
in other lineages, for instance lineages derived from 
DT104 which are typically resistant to ampicillin (A), 
chloramphenicol (C), streptomycin (S), sulfonamide (Su) 
and tetracycline (T), known as the ‘classic DT104 pattern’ 
or the ACSSuT-profile. For a detailed presentation of the 
relationship between phage types and the ASSuT and 
ACSSuT resistance profiles, please see DANMAP 2010.
Table 6.1. Phage type distribution (%) among Salmonella Typhimurium(a) from pigs(b), Danish pork and human cases(c), 
Denmark
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:- 
b) Some of the isolates from pigs (n = 40) and humans (n = 4) included in the analysis of resistance was not phage typed in 2011
c) The isolate was categorised as ‘domestic sporadic’ if the patient did not travel one week prior to the infection and was not reported as being 
part of an outbreak
DANMAP 2011
Phage type
Pigs Pork Human
% Danish         %
Domestic
sporadic 
%
Domestic 
outbreak 
%
Travel 
abroad
%
Unknown 
origin 
%
DT 193 13 20 21 0 47 28
DT 120 27 24 16 100 10 16
DT 104 3 8 10 0 5 7
DT 12 14 4 3 0 1 6
DT U292 1 0 8 0 1 5
DT U302 7 2 2 0 1 0
DT 170 6 2 3 0 0 1
DT 1 0 0 2 0 5 6
DT 135 1 0 2 0 3 4
DT 17 5 4 0 0 0 1
DT 8 0 0 3 0 3 2
Other/ unspc. 23 35 27 0 23 24
Number of isolates 162 49 202 21 73 83
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Annual Report on Zoonoses in Denmark 2011
Background: The Annual Report on Zoonoses presents a summary of the trends and sources of zoonotic 
infections in humans and animals, as well as the occurrence of zoonotic agents in food and feeding stuffs 
in Denmark in 2011. The report is based on data compiled according to the zoonoses directive 03/99/EEC, 
supplemented by data obtained from national surveillance and control programmes and data from relevant 
research projects. The report is available at www.food.dtu.dk.
Surveillance of Salmonella and Campylobacter: In Denmark, all flocks of laying hens, broilers and turkeys, 
including breeder flocks, are monitored for Salmonella according to the EU requirements and the Danish 
legislation. Eggs from Salmonella positive laying hen flocks are heat treated or destroyed, and meat from 
broiler flocks found Salmonella positive at the ante-mortem control is heat treated. An extensive Salmonella 
surveillance and control programme is also running in the Danish pig production. At herd level, slaughter 
pig herds are monitored using serological testing of meat juice samples collected at slaughter, and high-risk 
herds are slaughtered under special hygienic precautions. Breeder and multiplier herds are monitored using 
serological testing of blood samples collected at farm, and fecal samples are collected in high-risk herds in order 
to assess the serotype distribution. In sow herds receiving animals from high-risk breeder and multiplier herds, 
fecal samples are collected as well. At the slaughterhouses, swabs samples from pig and cattle carcasses and neck 
skins from broiler carcasses are collected after chilling. 
Since January 2010, a mandatory surveillance of Campylobacter in broiler flocks at the farm has been in place. 
To the extent possible, positive flocks are allocated to the production of frozen products. At the slaughter houses 
and at retail level, Campylobacter in fresh broiler meat are surveyed. 
Finally, a case-by-case based control programme for Salmonella and Campylobacter in Danish and imported 
broiler meat, turkey meat, beef and pork ready for retail has been in place since 2007. Samples are collected at 
cold storages, slaughter houses, processing and catering facilities as well as at the border control.  
The occurrence of Salmonella and Campylobacter in the primary production, at the slaughter houses and in 
Danish and imported fresh meat ready for retail are presented in Table 1.  
Table 1. Occurrence of Salmonella and Campylobacter in pig, cattle and broiler production in Denmark, 2011
Source: Annual Report on Zoonoses in Denmark 2011
a) Data from slaughterhouses where 50 animals or more were slaughtered pr month (>99% of all tested carcasses). Pooled swab samples 
from five carcasses, where the percent positive carcasses was estimated using a conversion factor adjusting for the pooling
b) Slaughter pig herds are monitored using serological testing af meat juice samples collected at slaughter. If the seroprevalence during a 
three months period exceed a certain limit, herds will be classified as level 2 (medium risk) or level 3 (high risk) and defined as Salmonella 
positive 
c) Detection limit for samples tested at slaughter is <10 cfu/g and detection limit for samples for batches ready for retail is <100 cfu/g 
Primary 
production 
At 
slaughter 
Danish meat, ready 
for retail
Imported meat, ready 
for retail
herds/flocks Carcasses/samples Batches Batches
Bacteria Animal species Tested % pos Tested % pos Tested % pos Tested % pos
Salmonella Cattlea - - 7635 0.4 110 2.7 110 1.8
Pigsab 7427 4.8 22025 1.3 259 9.7 256 10.5
Broilers 3795 1.2 306 0.0 96 1.0 212 5.7
Campylobacter Broilersc 3379 14.4 1095 12.7 265 12.8 211 25.1
DANMAP 2011
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Human infections: Human salmonellosis and campylobacteriosis are notifiable in Denmark, and all cases are 
reported to the national database at SSI. 
Campylobacter is the most frequently reported foodborne pathogen in Denmark. In 2011, the number of 
human Campylobacteriosis cases (73.1 cases per 100,000 inhabitants) remained at the same level as in 2010. 
Since 2007, approximately one third of the cases have been related to travel. Consumption and handling of 
broiler meat is assumed to be the major source of human campylobacteriosis (estimated more than 50% of 
domestic sporadic cases), however other sources such as contaminated water, vegetables and direct contact to 
farm animals cattle exist.
In 2011, the number of human salmonellosis decreased by 27% compared to 2010 (from 28.7 to 21.0 cases 
per 100,000 inhabitants). Very few Salmonella outbreaks were reported and there were no outbreaks caused 
by S. Enteritidis. For the first time in more than a decade none of the Salmonella outbreaks could be related 
to meat of Danish origin. As in previous years, almost half of the human cases of salmonellosis were due to 
travel (Figure 1) and more than 70% of the S. Enteritidis cases were acquired abroad. The majority of the S. 
Typhimurium cases were still acquired in Denmark. For the sporadic cases not related to travel, Danish pork 
was estimated to be the most important source although decreasing markedly compared to the previous year, 
mainly because there were no outbreaks related to Danish pork in 2011. The relative importance of eggs as a 
source of infection continued to decrease and was the source with lowest estimated number of cases next to 
Danish produced beef. No cases were attributed to Danish broiler meat.
Helle Korsgaard and Birgitte Helwigh
For further information: Birgitte Helwigh (bhel@food.dtu.dk)
Figure 1. Estimated sources(a) of 1,166 cases of human salmonellosis, Denmark
Source: Annual Report on Zoonoses in Denmark 2011
a) Sporadic and outbreak-related cases with unknown source include all sources not in the model. E.g. one outbreak with 43 
cases where the source was tomatoes imported from Italy was included as ”outbreak-related, source unknown” 
Domestic beef (0-2.4%)
Domestic table eggs 
(0.1-1.9%)
Domestic ducks (0.4-3.2%)
Domestic pork (3.7-11.2%)
Pork of unknown origin, 
outbreak-related  (0.4%) 
Imported pork (0.5-7.0%)
Imported pork, outbreak-
related (1.9%)
Imported beef (0.9-4.1%)
Imported broilers (0.1-4.3%)
Imported turkey (0-3.2%)
Imported duck (0.7-4.7%)Travel (45.5-46.8%)
Outbreak-related, 
source 
unknown (4.3%)
Sporadic cases, source 
unknown (21.6-28.3%)
DANMAP 2011
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Some phage types (e.g. DT12 and DT66) appear to 
acquire resistance very slowly - if at all. Rather, such phage 
types appear to be displaced by resistant phage types if a 
selection pressure is applied due to changes in the use of 
antimicrobial agents. 
The distribution of S. Typhimurium phage types among the 
isolates from pigs, Danish pork and human cases included 
in the DANMAP report 2011 is presented in Table 6.1.
In this report, S. Typhimurium include the monophasic 
variants with antigenic formulas S. 4,5,12:i:- and S. 4,12:i:-, 
as recently recommended by the European Food Safety 
Authority [EFSA journal 2010. 8(10): 1826]. Isolates 
verified as monophasic variants of S. Typhimurium from 
animals, meat and humans have been included for all 
years presented in this report. If an isolate was resistant 
to three or more of the ten different antimicrobial classes 
included in the test panel, it was considered multi-resistant 
(see definition of multi-resistance and the included 
antimicrobial classes in section 10.5).
6.1.1  Salmonella in animals
For pigs and poultry, the isolates originated mainly from 
the national surveillance programmes. Comparison 
of resistance levels to previous years should be done 
cautiously, because the origin of the pig isolates collected in 
2011 differ from previous years. The number of Salmonella 
isolates from the national surveillance has decreased and 
in 2011, implementation of a new Salmonella programme 
in the pig production meant that relatively few pen-faecal 
samplings were to be conducted. New initiatives were 
commenced, and Salmonella isolates from samples taken at 
medicine- and welfare control visits as well as the samples 
collected for the DANMAP programme of healthy pigs at 
slaughter were susceptibility tested.
Among the Salmonella isolates tested for antimicrobial 
resistance in 2011, one isolate per farm was randomly 
selected and included. Insufficient numbers of S. 
Typhimurium and S. Enteritidis isolates (<15) were 
obtained for Danish broilers and layers and for Danish 
cattle; therefore the results of the susceptibility testing 
are not presented. This also applies for the susceptibility 
results for S. Enteritidis in pigs. MIC distributions among 
S. Typhimurium from pigs in 2011 are shown in the web 
annex (Table A6.1). 
In 2011, Salmonella was isolated from 420 pig herds, where 
45% were S. Typhimurium and 37% S. Derby. Considering 
the large proportion of S. Derby it is important to mention, 
that the majority of the isolates were fully sensitive and 
that relatively few human S. Derby cases are reported in 
Denmark [Annual Report on Zoonoses in Denmark 2011]. 
Only two S. Enteritidis isolates were found in pigs. 
 
Salmonella Typhimurium in pigs
In 2011, the S. Typhimurium isolates from pigs originated 
from samples taken in a number of different contexts: 1) 
from farms where the national surveillance had detected 
medium and high sero-prevalence (n = 107), 2) from the 
DANMAP samples collected from healthy pigs at slaughter 
(n = 50), 3) from control visits in herds with animal health 
problems and high antimicrobial consumption (n  = 12), 
and 4) from pig herds investigated due to clinical disease 
(n = 33). As in previous years, all available isolates (e.g. one 
isolate per farm) were included to estimate the occurrence 
of resistance in Salmonella from pigs. However, this year 
the proportion of isolates from diagnostic submissions 
or control visits was relatively high (22%). Since these 
isolates are likely to originate from animals with a history 
of antimicrobial therapy, a relatively higher frequency of 
resistance is to be expected, when compared to isolates 
from healthy animals (e.g. the DANMAP samples).
Among all the susceptibility tested S. Typhimurium 
isolates from pigs (n = 202), 32% of the isolates were 
of the monophasic variants of S. Typhimurium. Not all 
isolates had been phage typed (n = 162), but the most 
common phage types were DT120 (27%) and DT193 
(13%) (Table 6.1). Overall, 33% of the susceptibility 
tested S. Typhimurium isolates from pigs were fully 
sensitive, whereas 53% were found to be multi-resistant. 
The monophasic variants of S. Typhimurium isolates 
represented 60% (64/107) of all multi-resistant isolates . 
The highest occurrence of resistance was to streptomycin 
(57%), followed by sulfonamide (55%), tetracycline (54%) 
and ampicillin (51%) (Table 6.2).
The isolates included in the DANMAP report were 
previously obtained through the national surveillance 
in the pig production. However, 2011 was the first year 
that Salmonella was also isolated from samples collected 
specifically for DANMAP from healthy pigs at slaughter. 
The level of resistance among the isolates from randomly 
selected healthy animals (DANMAP samples, Table 6.2), 
was generally lower than the resistance level among all 
available isolates (Table 6.2). Among the S. Typhimurium 
isolates from healthy animals, 44% of the tested isolates 
were fully sensitive, whereas 42% were multi-resistant. 
Less than half (43%, 9/21) of the multi-resistant S. 
Typhimurium isolates were of the monophasic variants.
Resistance to cephalosporins, ciprofloxacin or nalidixic 
acid in Danish pigs have been reported occasionally in 
the previous years, however the last two years resistance 
towards these antimicrobial classes have not been detected. 
The levels of resistance to ampicillin, neomycin, 
sulfonamide and tetracycline were significantly higher in 
2011 than in 2010. Since 2000, there has been a parallel 
increase in resistance to ampicillin, sulfonamide and 
tetracycline (Figure 6.1). 
In 2008 and 2009, a temporary reduction in tetracycline 
resistance was observed but has not been fully explained; 
although it was partly related to a reduction in DT104 
(consequent to a national eradication programme) and 
other phage types often resistant to tetracycline. However, 
in 2010 and 2011 the level of resistance to tetracycline 
increased again (Figure 6.1 and 6.2), which is mainly 
explained by an increase in the monophasic DT193 isolates 
with the ASSuT-profile. 
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1) Data on resistance to colistin and trimethoprim were not 
available for 2007, thus the proportion of multi-resistant or fully 
sensitive were not calculated
The usage of tetracycline for pigs decreased in second 
half of 2010 and in 2011. However, the occurrence of 
tetracycline resistance in Salmonella from pigs continued 
to increase significantly, thereby supporting the theory 
that clonal spread is responsible for the current increasing 
level of resistance, particularly by the spread of the multi- 
resistant clones of the monophasic S. Typhimurium 
variants (Figure 6.3). 
Pigs Pork Human
Antimicrobial agent %
DANMAP
only
%
Danish         
%
Domestic
sporadic 
%
Domestic 
outbreak 
%
Travel 
abroad
%
Unknown 
origin 
%
Tetracycline 54 (42) 65 53 90 74 54
Chloramphenicol 8 (4) 10 14 0 28 9
Florfenicol 6 (4) 8 9 0 23 6
Ampicillin 51 (36) 71 55 0 69 52
Ceftiofur 0 (0) 0 1 0 12 0
Cefotaxime 0 (0) 0 - - - -
Sulfonamide 55 (42) 67 59 0 70 67
Trimethoprim 8 (8) 10 2 0 9 8
Apramycin 2 (0) 0 0 0 1 0
Gentamicin 2 (0) 0 2 0 14 0
Neomycin 8 (12) 6 1 0 0 1
Spectinomycin 17 (10) 22 14 0 14 11
Streptomycin 57 (44) 71 60 5 68 60
Ciprofloxacin 0 (0) 0 2 0 16 6
Nalidixic acid 0 (0) 0 1 0 7 4
Colistin 0 (0) 0 0 0 3 0
Number of isolates 202 (50) 49 203 21 74 85
DANMAP 2011
Table 6.2. Resistance (%) among Salmonella Typhimurium(a) from pigs(b), Danish pork and human cases(c), Denmark
a) Include verified monophasic S. Typhimurium-like isolates
b) In 2011, the S. Typhimurium isolates from pigs originated the national surveillance (n = 107), control visits in pig herds with animal 
health problems and high antimicrobial consumption (n = 12), clinical investigations (n = 33) and also from the DANMAP samples collected 
from randomly selected healthy pigs at slaughter (n = 50). The distribution of resistant isolates among the 50 DANMAP samples are also 
presented seperately
c) The isolate was categorised as ‘domestic sporadic’ if the patient did not travel one week prior to the infection and was not reported as being 
part of an outbreak
From 2007 to 2011, the proportion of S. Typhimurium 
isolates with the ASSuT-profile parallels the significantly 
increasing proportion of phagetypes DT120/193 and 
monophasic variants of S. Typhimurium (Figure 6.3). 
Overall during the period 2008 - 20111, the proportion of 
multi-resistant isolates increased significantly, while the 
proportion of fully sensitive isolates decreased significantly 
(Figure 6.3).
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6.1.2  Salmonella in meat
Salmonella isolates from Danish and imported broiler 
meat, turkey meat, beef and pork are collected and 
susceptibility tested as part of national surveillance and 
control programmes. One isolate was selected from each 
Salmonella positive batch of imported fresh meat or one 
carcass per herd.
In 2011, a total of 49 S. Typhimurium isolates from Danish 
pork (carcasses at slaughter) was included, and the MIC 
distributions are shown in the web annex (Table A6.2).
Insufficient numbers of S. Typhimurium isolates (<15) 
were available for Danish broiler meat, Danish beef, 
imported beef, imported turkey and imported pork and 
the results of the susceptibility testing are not presented in 
this report. Also due to a low number of isolates, resistance 
data for S. Enteritidis in meat were also excluded. 
The vast majority of Danish turkeys are exported for 
slaughter; therefore, no Salmonella isolates were available 
for susceptibility testing from Danish turkey meat in 2011.
Figure 6.1. Resistance (%) in Salmonella Typhimurium(a) 
from pigs, Denmark
a) The numbers of isolates varies between years (n = 216–736). 
Include monophasic variants of S. Typhimurium with antigenic 
formulas S. 4,[5],12:i:-. 
b) Presents the distribution of resistance in isolates from healthy 
pigs at slaughter in 2011 (n = 50).  Please note that the occurrence 
of tetracycline and sulfonamide is identical
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Salmonella Typhimurium in pork
Among the 49 susceptibility tested S. Typhimurium isolates 
available from Danish pork, the most dominant phage 
types were DT120 (24%) and DT193 (20%) and 43% of the 
isolates were of the monophasic variant of S. Typhimurium 
(Table 6.1 and Figure 6.3). 
Overall, 14% of the susceptibility tested S. Typhimurium 
isolates from Danish pork were fully sensitive, whereas 67% 
were found multi-resistant. Resistance to ampicillin (71%), 
streptomycin (71%), sulfonamide (67%) and tetracycline 
(65%) was most common (Table 6.1). In 2011, the 
monophasic variants of S. Typhimurium represented 64% 
(21/33) of all multi-resistant isolates and 67% (14/21)of the 
total number of isolates with the ASSuT-profile. 
As in 2010, none of the S. Typhimurium isolates 
from Danish pork were resistant to cephalosporins or 
fluoroquinolones. Cephalosporin resistance in pork has not 
been reported since 2008, where it was found in one isolate.
When comparing the occurrence of resistance in S. 
Typhimurium from Danish pork in 2011 to the level in 
2010, significant increases were found for tetracycline, 
ampicillin, sulfonamide, streptomycin, spectinomycin 
and trimethoprim. In 2011, the level of resistance 
towards tetracycline, ampicillin and sulfonamide in the 
isolates from Danish meat was comparable to the levels 
found in imported pork during the period 2007–2010. 
This comparison could not be made in 2011 data, due 
to insufficient numbers of S. Typhimurium isolates 
from imported pork. However, in previous years the 
S. Typhimurium isolates from Danish pork have had 
significantly lower resistance to these three antimicrobial 
agents compared to isolates from imported pork (Figure 
6.2).
The proportion of S. Typhimurium isolates from Danish 
pork with the ASSuT-profile was significantly higher in 
2011 (43%) than in 2007 (17%) (Figure 6.3). This coincided 
with a significant increase in the occurrence of phagetypes 
DT120 and DT193 as a result of a significantly increasing 
proportion of monophasic variants of S. Typhimurium 
(Figure 6.3). As for the isolates from pigs, the proportion of 
fully sensitive isolates decreased over the period 2008–2011 
(Figure 6.3). From 2010 to 2011, there was a significant 
increase in the proportion of multi-resistance (from 35% 
to 67%) as a concequence of the increased occurrence of 
monophasic variants of S. Typhimurium (8% to 43%).
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a)  The number of isolates varies between years (pigs n = 202–581, Danish pork: n = 26–103, imported pork: n = 26–68, domestic sporadic 
human cases: n = 98–269 and travel related human cases: n = 55–117). Include isolates verified as monophasic variants of S. Typhimurium with 
antigenic formulas S. 4,[5],12:i:-. Data for imported pork in 2011 was not presented due to insufficient number of isolates
b) The isolate was categorised as 'domestically acquired' if the patient did not travel one week prior to the infection and as 'travel abroad 
reported' if the patient travelled one week prior to the infection
DANMAP 2011
Figure 6.3. Occurrence (%) of multi-resistance(a b), phagetypes DT120/193(c) and monophasic variants(d) in Salmonella 
Typhimurium in pigs, pork and human cases(e), Denmark
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Note: The number of isolates varies between years (pigs: n = 202–581, Danish pork: n = 26–103, domestic sporadic human cases: n = 98–269). 
Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-.
a) An isolate was assumed multi-resistant if resistant to three or more of the ten different antimicrobial classes included in the test panel, see 
definition in section 10.5. Data on resistance to colistin and trimethoprim were not available for 2007, thus the proportion of multi-resistant or 
fully sensitive were not calculated
b) 'ASSuT' isolates are resistant to ampicillin, streptomycin, sulfonamide and tetracycline, but can also include resistant to other antimicrobial 
agents except chloramphenicol
c) Presenting the proportion of DT 120/193 among phage typed isolates. Only in 2011, some of the isolates from pigs (n = 40) and humans (n = 
4) was not phage typed  
d) The recording of monofasic strains in the databases were not fully implemented in 2007 and 2008, thus data are not presented
e) The isolate was categorised as 'domestically acquired' if the patient did not travel one week prior to the infection
DANMAP 2011
Figure 6.2. Resistance (%) in Salmonella Typhimurium(a) in pigs, pork and human cases(b), 
Denmark
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6.1.3  Salmonella in humans
In 2011, 1,166 cases of human salmonellosis 
(corresponding to 21.0 cases per 100,000 inhabitants) 
were reported, representing a decrease of 27% compared 
to 2010. The estimated sources of human salmonellosis in 
2011 are presented in Textbox 4. 
SSI collected travel information from the patients 
diagnosed with salmonellosis by phone interviews. The 
patients were asked about the date of disease onset and 
whether they had travelled abroad within a seven-day 
period before getting ill. Patients who had travelled were 
also asked about their destinations. Depending on the 
available information, patients were divided into three 
categories: 1) domestically acquired, 2) travel abroad 
reported and 3) unknown origin. The latter category were 
cases, where no travel information had been reported to 
the general practitioners, and where no phone interview 
was conducted. In 2011, travel information was obtained 
for 80% of the Salmonella cases. 
 
Outbreaks of human salmonellosis are reported in the 
‘Annual Report on Zoonoses in Denmark in 2011’ [www.
dtu.food.dk]. All human cases associated with a detected 
outbreak were considered ‘outbreak-related’ in this report. 
MIC distributions among S. Typhimurium and S. 
Enteritidis from human cases in 2011 are shown in the web 
annex (Tables A6.3 and A6.4). 
Salmonella Typhimurium in humans
Among the reported human S. Typhimurium isolates 
with valid results from susceptibility testing of all 
antimicrobial agents included in the test panel (n = 383), 
19% were categorised as travel-related and 58% as being 
domestically acquired. In 2011, there was one outbreak 
of S. Typhimurium DT120 including 21 cases; so of the 
domestically acquired cases, 10% was outbreak related and 
90% were of sporadic origin. The origin of the remaining 
23% of the S. Typhimurium isolates was unknown (Table 
6.2). 
Irrespectively of the origin of the infection, the 
most commonly reported phage types in human S. 
Typhimurium isolates were DT193 and DT120 (Table 6.1).
Among the human sporadic domestic cases (n = 203), 38% 
of the S. Typhimurium isolates were fully sensitive whereas 
57% were multi-resistant. The monophasic variants of 
S. Typhimurium represented 59% (68/116) of all multi-
resistant isolates. For the travel-related cases (n = 74) and 
cases of unknown origin (n = 85), 15% and 27% of the S. 
Typhimurium isolates were fully sensitive, whereas 68% 
and 56% were multi-resistant, respectively.
Resistance to cephalosporins was only found among 
isolates from nine travel-associated cases (12%) and 
one sporadic domestic case (1%). As observed in 2010, 
a marked difference in ciprofloxacin resistance was 
found between domestically acquired infections (2%) 
and travel related infections (16%). The higher level 
of ciprofloxacin resistance in the travel-associated S. 
Typhimurium infections may reflect a higher consumption 
of fluoroquinolones in production animals in the countries 
of destination. 
The pattern of resistance in the human S. Typhimurium 
isolates in 2011 continued the trend observed the previous 
years. As observed in human isolates from the rest of 
Europe, resistance to ampicillin, streptomycin, sulfonamide 
and tetracycline were dominating (the ASSuT-profile). The 
occurrence of resistance to these four antimicrobial agents 
was similar among travel-related cases and cases with 
unknown origin. In the domestic sporadic cases resistance 
was markedly lower for all four antimicrobial agents than 
what was observed in the travel-related cases and the cases 
of unknown origin (Figure 6.2). 
As a consequence of the significantly increasing occurrence 
of monophasic variants of S. Typhimurium, the proportion 
of fully sensitive human S. Typhimurium isolates of 
domestic sporadic origin has decreased significantly from 
50% in 2008 to 38% in 2011, and the proportion of multi-
resistant isolates increased significantly from 36% to 57% 
(Figure 6.3). 
Salmonella Enteritidis in humans
Among the reported human S. Enteritidis isolates with 
valid results from susceptibility testing of all antimicrobial 
agents included in the test panel (n = 288), 58% of the 
infections were associated with travelling abroad, 23% was 
domestically acquired infections and the remaining 19% 
had an unknown origin. No S. Enteritidis outbreaks were 
recorded in 2011, wherefore all cases with domestically 
acquired infections were considered to be of sporadic 
origin (Table 6.3). 
The level of resistance among the human S. Enteritidis 
isolates was generally lower than observed in human 
S. Typhimurium isolates. The majority of S. Enteritidis 
isolates originating from domestic sporadic cases (74%), 
travel-related cases (56%) and cases of unknown origin 
(58%) were fully sensitive, whereas one (2%) domestic 
sporadic case, ten (6%) travel-related cases and two (4%) 
case of unknown origin were multi-resistant. Resistance to 
cephalosporins was only found in one of isolates from the 
travel-associated cases. 
 
Overall in 2011, 18% of the domestic sporadic isolates were 
ciprofloxacin and nalidixic acid resistant. This is a 10% 
increase compared to 2010, meaning that the occurrence 
of fluoroquinolone resistance in the domestic sporadic 
isolates is approaching the level observed in isolates from 
the travel-related cases (24%) and of unknown origin 
(27%) (Table 6.3). The major source of S. Enteritidis is 
poultry, however fluoroquinolones have not been used 
in Danish table egg production (parents and layers) since 
2004, and the prevalence of Salmonella is low in Danish 
layers [Textbox 4].
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Table 6.3. Resistance (%) in Salmonella Enteritidis from 
human cases(a), Denmark
DANMAP 2011
a) The isolate was categorised as ‘domestically acquired’ if the patient 
did not travel one week prior to the infection, and as ‘travel abroad 
reported’ if the patient travelled one week prior to the infection
Antimicrobial agent
Humans
Domestic
sporadic
%
Travel 
abroad 
%
Unknown 
origin
%
Tetracycline 3 6 5
Chloramphenicol 0 0 0
Florfenicol 0 0 0
Ampicillin 5 7 13
Ceftiofur 0 1 0
Cefotaxime - - -
Sulfonamide 2 4 4
Trimethoprim 2 2 2
Apramycin 0 1 0
Gentamicin 0 0 0
Neomycin 0 0 0
Spectinomycin 2 1 2
Streptomycin 0 3 2
Ciprofloxacin 18 24 27
Nalidixic acid 18 22 27
Colistin 0 1 0
Number of isolates 66 167 55
6.1.4  Salmonella in a farm to fork perspective
In 2011, the occurrence of resistance in the Salmonella 
isolates from pigs, Danish pork and humans were 
markedly influenced by increased occurrence the 
monophasic variants of S. Typhimurium, carrying the 
ASSuT resistance profile. Figure 6.3 shows the distinct 
association between the occurrence of the ASSuT-profile, 
the phagetypes DT120/DT193 and the monophasic 
variants of S. Typhimurium. This tendency is observed 
throughout the farm to fork pathway, where the proportion 
of multi-resistance has increased dramatically, while the 
number of fully sensitive isolates has decreased. 
Despite the reduced consumption of tetracycline in 
pigs in 2011, the occurrence of tetracycline resistance 
in Salmonella from pigs and Danish pork continued to 
increase significantly due to the increased occurrence 
of the multi-resistant clones of the monophasic S. 
Typhimurium variants. 
S. Typhimurium isolates sampled from healthy pigs at 
slaughter is assumed more representative of the general 
Danish population of finishers than the overall collection 
of pig isolates. However, significantly higher occurrence 
of resistance was found for ampicillin, streptomycin, 
sulfonamide and tetracycline in S. Typhimurium isolates 
from Danish pork compared to isolates from Danish pigs 
(healthy pigs at slaughter only).
The Salmonella source attribution model (Textbox 4) 
estimated that 7% (86 sporadic cases) of the human 
salmonellosis cases in 2011 could be attributed to Danish 
pork. Of the 75 S. Typhimurium cases attributed to pork, 
53% were of the monophasic variant, almost exclusively 
multi-resistant phagetypes DT120 and DT193. All of the 
37 sporadic S. Typhimurium cases attributed to imported 
pork (86% of all sporadic cases attributed to imported 
pork) were estimated to be of multi-resistant monophasic 
variants (all DT120 or DT193). Additionally, seven S. 
Typhimurium cases were attributed to poultry, all of the 
monophasic variant.   
Tina Struve, Lars Stehr Larsen, 
Eva Møller Nielsen and Helle Korsgaard
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Whole Genome Sequencing of Salmonella Typhimurium from Danish pigs for identification of acquired 
antimicrobial resistance
Background: The cost of Whole Genome Sequencing (WGS) continues to decline, making it increasingly available 
in routine diagnostic laboratories and as a supplement for traditional methods for resistance gene identification. The 
use of a genotypic method for diagnostic purposes may have the disadvantages that unknown mechanisms or point 
mutation are not detected, on the other hand a genotypic method may detect resistance genes not expressed in the 
bacteria. For the traditional susceptibility testing methods the result depends on testing condition and interpretation 
criteria and a high level of standardisation is required. One limitation for diagnostic laboratories to use WGS is 
interpretation of the sequence results. The aim of this study was to compare analyses of WGS data with traditional 
phenotypic determination of antimicrobial resistance among S. Typhimurium from Danish pigs.
Materials and methods: Antimicrobial susceptibility tests were made on S. Typhimurium isolates from Danish 
pigs (n = 50) as part of the DANMAP program. The isolates originate from different farms and were collected 
randomly in the first half of 2011. Total DNA was purified from the isolates and sequenced on the Illumina 
platform, paired-end reads. The reads was assembled de novo prior to prediction of the resistance profile and 
N50 values of the assembly were used for quality control of the DNA sequences. The web-server ResFinder [www.
genomicepidemiology.org] was used to identify acquired antimicrobial resistance genes in the WGS data. A threshold 
equal to 98% identity was selected and results were compared with the phenotypic antimicrobial susceptibility testing 
results. 
Results: One isolate was excluded from the study because of poor WGS data (N50 = 196), making it impossible to 
test in ResFinder. The rest of the isolates were assembled to draft genomes with high N50 values (average 238,833 
±  12,079, 95% CI). ResFinder identified resistance genes in 32 (65%) of the isolates, all genes were found with a 
>99% identity match to resistance genes in the database. The susceptibility tests found that the same 32 isolates were 
phenotypically resistant and their resistance profiles matched the ResFinder results 100% (Table 1).
Antimicrobial agent
Total no. of isolates 
with phenotypic 
resistance
% Isolates with matching 
resistance gene found with 
ResFinder
Genes found by ResFinder (n)
Apramycin 0 - -
Gentamicin 0 - -
Neomycin 4 100 aph(3’)-Ia (2), aph(3’)-Ic (2)
Spectinomycin 8 100 aadA1 (5), aadA2 (2), aadA13 (1)
Streptomycin 25 100 strA/strB (19), aadA1 (5), aadA2 (2), aadA13 (1)
Amoxicillin/clavulanic 
acid 0 - -
Ampicillin 23 100 blaTEM-1(21), blaCARB-2(2)
Ceftiofur 0 - -
Cefotaxime 0 100 -
Chloramphenicol 2 100 floR (2)
Florfenicol 2 100 floR (2)
Ciprofloxacin 0 - -
Nalidixan 0 - -
Sulfamethoxazole 26 100 sul1 (9), sul2 (20)
Tetracycline 22 100 tet(B) (19), tet(G) (2), tet(A) (1)
Trimethoprim 2 100 dfrA1 (1), dfrA14 (1)
Colistin 0 - -
Table 1. Number of isolates with phenotypic resistance according to the antimicrobial agent DANMAP 2011
In most cases only one resistance gene was found for each of the detected resistances except for three isolates that 
contained various genes conferring the same resistance (streptomycin, spectinomycin and sulfamethoxazole). All 
three isolates contained both sul1 and sul2, in all three cases both genes were found with a 100% identity match 
and were located at different positions in the genome. In addition, two of the three isolates contained both strA/
strB (streptomycin resistance) and aadA1 (streptomycin and spectinomycin resistance). The rest of the isolates with 
streptomycin and spectinomycin resistance (n = 8) did not contain the strA/strB genes, but only an aadA gene.
The results indicate that ResFinder based on WGS can predict the resistance profile for at least nine of the tested 
antimicrobial agents and did not produce false positives for the last eight tested. WGS may be a useful tool for 
diagnostic and surveillance purposes in the future.
Ea Zankari, Martin Vestergaard, Anne Mette Seyfarth, Yvonne Agersø and Henrik Hasman
For further information: Ea Zankari (east@food.dtu.dk)
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Tentative colistin epidemiological cut-off value for Salmonella spp.
Background: The interpretive criteria are crucial when determining bacteria as either resistant or sensitive to an 
antimicrobial drug. The European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2011) presents 
a clinical breakpoint and an epidemiological cut-off value of >2 mg/L for colistin, based on a few isolates whereas 
Salmonella isolates with a Minimal Inhibitory Concentration (MIC) ≤2 mg/L should be reported as sensitive or 
wildtype. The epidemiological cut-off value is defined based on MIC population distributions of Salmonella spp. 
[EUCAST 2011, www.EUCAST.org]. 
In a study we determined MIC population distributions for colistin for Salmonella on subtype level. Furthermore, 
also if differences in MIC for colistin could be explained by mutations in pmrA or pmrB encoding proteins 
involved in processes that influence the binding of colistin to the cell membrane [Agersø et al 2012. Foodborne 
Pathog Dis. 2012 9:367-9].
Materials and methods: During 2008–2011, Salmonella isolates of human (n = 6,583) and of animal/meat origin 
(n = 1,931) were collected. The isolates were serotyped and susceptibility tested towards colistin (range 1 -16 
mg/L). Moreover, 37 isolates were tested for mutations in pmrA and pmrB by PCR and DNA sequenced. 
Results: MIC distribution for colistin at serotype level showed that S. Dublin followed by S. Enteritidis  were 
less susceptible than ’other’ Salmonella serotypes originating from humans and S. Typhimurium of animal and 
meat origin. Among the human isolates, MIC was ≤1 mg/L for 98.9% of ‘other’ Salmonella serotypes, 61.3% of S. 
Enteritidis and 12.1% of S. Dublin isolates. Among the animal and meat isolates, MIC was ≤1 mg/L for 99.4% of 
S. Typhimurium, (Figure 1). 
Interestingly, S. Dublin and S. Enteritidis belong to the same O-group (O:1, 9,12) suggesting that surface 
lipopolysaccharides (LPS) of the cell (O-antigen) play a role in colistin susceptibility. 
The epidemiological cut-off value >2 mg/L for colistin suggested by EUCAST is placed inside the distribution 
for both S. Dublin and S. Enteritidis. All tested S. Dublin isolates, regardless of MIC colistin value, had identical 
pmrA and pmrB sequences. Missense mutations were found only in pmrA in one S. Reading isolates and in pmrB 
in one S. Concord isolate both with MIC≤1 for colistin. 
In conclusion, our study indicates that missense mutations are not necessarily involved in increased MICs for 
colistin. Increased MICs for colistin seemed to be linked to specific serotypes (S. Dublin and S. Enteritidis). 
Therefore, we recommend that Salmonella with MIC >2 mg/L for colistin are evaluated on serovar level.
Yvonne Agersø, Mia Torpdahl, Camilla Zachariasen, 
Anne Mette Seyfarth, Anette M. Hammerum, Eva Møller Nielsen
For further information: Yvonne Agersø (yvoa@food.dtu.dk)
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Figure 1. MIC distribution (%) of colistin determined for all Salmonella serovars(a), Denmark
a) Total number of Salmonella isolates include isolates from humans, animals and meat (n = 198)
DANMAP 2011
Figure 2. MIC distribution (%) of Salmonella serovars(a) from humans and animals/meat, Denmark
Note: Number of isolates included: S. Dublin = 198, S. Enteritidis = 1,247,  S. Typhimurium from animals and meat = 
1,795 and ‘other’ Salmonella serovars from humans = 5,274. Other Salmonella serovars of human origin constitutes all 
included serovars except S. Dublin and S. Enteritidis
DANMAP 2011
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6.2  Campylobacter
Campylobacter are the most commonly reported cause 
of gastrointestinal bacterial infections in humans in 
Denmark as well as in the European Union (see Textbox 
4). 
Human campylobacteriosis is caused by thermotolerant 
Campylobacter spp. The species most commonly 
associated with human infections is C. jejuni followed 
by C. coli, but other species are also known to cause 
infections in humans. In Denmark, 85-95% of the human 
campylobacteriosis cases are caused by C. jejuni. 
The incubation period is typically two to five days and 
common clinical symptoms include watery, sometimes 
bloody diarrhoea, abdominal pain, fever, headache and 
nausea. Usually, infections are self-limiting and last only 
a few days. Infrequently, extraintestinal infections or 
post-infection complications such as reactive arthritis and 
neurological disorders may occur. C. jejuni has become 
the most recognized antecedent cause of Guillain-Barré 
syndrome, which is a polio-like form of paralysis that 
can result in respiratory failure and severe neurological 
dysfunction and even death.
Thermotolerant Campylobacter are widespread in nature 
and the most important reservoirs are the alimentary tract 
of wild and domesticated birds and mammals. They are 
prevalent in production animals such as poultry, cattle, 
pigs and sheep; in pets, including dogs and cats; in wild 
birds and environmental water sources. The bacteria can 
readily contaminate various foodstuffs. Among sporadic 
human cases, contact with live poultry, consumption 
of poultry meat, drinking water from untreated water 
sources, and contact with pets and other animals have been 
identified as the major sources of infection. Furthermore, 
source attribution models have attributed the majority of 
human cases to the broiler reservoir. The main focus of 
this chapter is therefore C. jejuni isolates obtained from the 
broilers and broiler meat.
An isolate was considered multi-resistant if it was found 
resistant to three or more of the six different antimicrobial 
classes included in the test panel (see definition of multi-
resistance and the included antimicrobial classes in Section 
10.5).
6.2.1  Campylobacter jejuni in animals
Samples from healthy animals were collected at slaughter 
for the DANMAP programme and all analyses were 
performed at the National Food Institute. Only one isolate 
per farm was included in the report.  C. jejuni from pigs 
were not included due to the very low number of isolates 
found in pigs. 
MIC distributions among C. jejuni from cattle and broilers 
in 2011 are shown in the web annex (Table A6.5). 
DANMAP 2011
Table 6.4. Resistance (%) in Campylobacter jejuni from animals, Danish broiler meat, imported broiler meat and in 
domestic and travel related human cases, Denmark 2011
Antimicrobial agent
Cattle Broilers Broiler meat Humans
Danish Danish Danish Imported Domestically acquired
Travel
abroad
% % % % % %
Tetracycline 4 19 10 36 27 62
Chloramphenicol 0 0 0 1 0 1
Erythromycin 0 0 0 6 0 3
Gentamicin 0 0 0 0 1 1
Streptomycin 0 5 2 1 4 5
Ciprofloxacin 20 23 11 57 33 84
Nalidixic acid 20 23 11 57 33 84
Number of isolates 95 43 61 70 104 79
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In isolates from Danish broilers, the highest levels 
of resistance were found for ciprofloxacin (23%) and 
tetracycline (19%). A significant increase in resistance to 
ciprofloxacin and tetracycline has been observed over the 
last decade from less than 10% resistant isolates in 2001 to 
23% and 19% in 2011, respectively (Figure 6.4). 
Since 2009, fluoroquinolones have not been used in 
rearing and parent flocks for the broiler production and 
considerable decreases have also been observed in the 
consumption of amoxicillin, penicillins, sulfonamides 
and macrolides in these types of flocks. In broiler flocks, 
the consumption of tetracycline increased considerably 
from 2008 to 2010, but decreased from 2010 to 2011.
However, the use of tetracycline remains higher than 
before 2008. Second to amoxicillin, tetracycline was the 
most commonly used antimicrobial agent in Danish 
broilers in 2010 and 2011; this may be an explanation for 
the increasing tetracycline resistance in C. jejuni from 
Danish broilers. In contrast to what was observed for the 
broiler rearing flocks, the consumption of amoxicillin and 
penicillins in broiler flocks increased importantly from 
2010 to 2011 (Figure 4.10).
Figure 6.4. Resistance (%) in Campylobacter jejuni(a) from broilers, broiler meat and human cases(b), Denmark
DANMAP 2011
Cattle
For cattle, 95 C. jejuni isolates were susceptibility tested; 
78% of the C. jejuni isolates from cattle were fully sensitive 
to the antimicrobial agents tested and no isolates were 
multi-resistant.
Resistance to ciprofloxacin among C. jejuni from cattle 
has remained virtually unchanged since 2008, at a level 
around 20% (Figure 6.5). As described in previous 
DANMAP reports, a significant increase in the level of 
fluoroquinolone resistance occurred in 2005 despite low 
consumption of fluoroquinolones in cattle since 2003. 
As in previous years, only few of the fluoroquinolone 
resistant isolates were also resistant to tetracycline in 
2011, indicating that co-selection by tetracycline (one 
of the major drugs for treatment of calves) was not the 
explanation for the high occurrence of fluoroquinolone 
resistance. It has been discussed [DANMAP 2007] 
that clonal spread, particularly between farms, could 
be an explanation for the observed resistance to 
fluoroquinolones. Initially, fluoroquinolone resistant C. 
jejuni isolates came from cattle farms in Southern Jutland, 
but the occurrence of resistance has been moving north 
since 2007, and in 2011, 95% of the ciprofloxacin resistant 
C. jejuni isolates originated from farms distributed 
throughout Jutland.
Broilers
A total of 43 C. jejuni from broilers were isolated and 
susceptibility tested (Table 6.4). Of these, 74% were fully 
sensitive to the antimicrobial agents tested and only one 
isolate was found multi-resistant. 
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Figure 6.5. Resistance (%) in Campylobacter jejuni from 
cattle, Denmark
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In 2011, the Danish Veterinary and Food Administration 
(DVFA) collected samples for Campylobacter testing from 
meat sold at wholesale and retail outlets. The isolates were 
species identified in the regional laboratories of DVFA and 
tested for antimicrobial susceptibility at the National Food 
Institute. 
MIC distributions among C. jejuni from broiler meat in 
2011 are shown in the web annex (Table A6.6). 
Broiler meat
From broiler meat, 131 C. jejuni isolates (61 Danish, 
70 imported) were susceptibility tested. One isolate per 
sample was reported (Table 6.4). The percentage of isolates 
that were fully sensitive to the antimicrobial agents tested 
increased among the isolates from Danish broiler meat 
from 2010 to 2011(from 75% to 87%). In contrast, the 
percentage of fully sensitive isolates from imported meat 
decreased from 37% in 2010 to 27% in 2011, making the 
difference in antimicrobial resistance between Danish 
and imported meat even more pronounced than in 2010. 
Multi-resistance was found in only one isolate obtained 
from imported broiler meat.
The observed resistance to ciprofloxacin and tetracycline 
has fluctuated over the last five years, and in 2011, the 
Since 2005, the level of resistance to tetracycline has 
fluctuated, but overall a general increase in the resistance 
to tetracycline has been observed in isolates obtained from 
cattle (Figure 6.5).
resistance increased to approximately 11% and 10%, 
respectively, returning to the same levels as reported in 
2007. As in previous years, resistance to ciprofloxacin 
and tetracycline was significantly higher in C. jejuni from 
imported broiler meat compared to Danish broiler meat 
(Figure 6.4). Erythromycin resistance has remained at a 
very low level in both domestic and imported broiler meat 
for almost a decade.
6.2.3  Campylobacter jejuni in humans
Campylobacter continued to be the most frequent cause 
of bacterial intestinal infections in 2011. A total of 4,068 
human laboratory confirmed cases of campylobacteriosis 
were reported (73.1 per 100,000 inhabitants), similar to 
the year before [Annual report on Zoonoses in Denmark 
2011]. For surveillance of antimicrobial resistance among 
human cases, isolates from three out of five geographical 
regions in Denmark (North Denmark Region and the 
regions of Southern Denmark and Zealand) were selected 
and tested in 2011. 
Since 2007, SSI has collected information on travel history 
through phone interviews. Patients were asked about 
the date of disease onset and whether they had travelled 
abroad within a seven-day period prior to the onset of 
disease. Furthermore, patients who had been abroad were 
asked about their destinations. Cases were categorised as 
“domestically acquired” if the patients had not travelled 
within the last week prior to the onset of infection.
MIC distributions among C. jejuni from humans in 2011 
are shown in the web annex (Table A6.7). 
In 2011, 183 Campylobacter jejuni isolates were 
submitted to SSI for susceptibility testing continuously 
over the year. The isolates were randomly selected from 
all Campylobacter isolated from stool samples in the 
geographical regions mentioned above. Among the tested 
isolates, 104 (57%) were from travel-associated cases and 
79 (43%) were considered to be domestically acquired. 
Among the isolates from domestically acquired infections, 
82% were fully sensitive to the antimicrobial agents 
tested, while the percentage of fully sensitive isolates was 
much lower (9%) among isolates from travel associated 
cases (Table 6.4). Multi-resistance was found in three 
domestically acquired infections (4%) and five (5%) 
infections associated with travel.
In 2011, the level of resistance to ciprofloxacin in C. jejuni 
isolates from domestically acquired human infections 
remained in between the level of resistance for isolates 
obtained from Danish broiler meat and imported broiler 
meat. The consumption of imported broiler meat has 
continued to increase in Denmark, from 17% in 2003 to 
45% in 2010. However, while, the overall consumption of 
broiler meat increased in 2011, the percentage of imported 
meat decreased slightly to 35% (Table 3.2). Imported 
broiler meat contributes to the relatively high occurrence 
of ciprofloxacin resistance in C. jejuni isolates (33%) from 
domestically acquired human infections, however, the 
extent of this contribution is unknown. 
6.2.2  Campylobacter jejuni in meat
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The occurrence of resistance to ciprofloxacin and 
tetracycline continued to be significantly higher in travel 
associated C. jejuni isolates (84% and 62%, respectively) 
compared to isolates from domestically acquired infections 
(27% and 33%, respectively) (Figure 6.4). For the other 
antimicrobial agents tested, no significant differences 
in resistance levels were observed. Ciprofloxacin or 
other fluoroquinolones are often used for empiric 
treatment of adults with severe bacterial gastroenteritis. 
Fluoroquinolones are also used in animal husbandry. 
In Denmark, however, fluoroquinolones are rarely used 
in animal husbandry (except for pet animals) since 
the implementation of legal restrictions in 2002-2003 
[DANMAP 2010]. Travelling to, or eating meat, from 
countries where fluoroquinolone restrictions are not 
implemented can be associated with a higher risk of 
acquiring infection with ciprofloxacin resistant C. jejuni.
6.2.4  Campylobacter coli  in animals
For animals, antimicrobial resistance among C. coli 
is reported only for pig isolates in this report. MIC 
distributions and the occurrence of antimicrobial 
resistance among C. coli from pigs are shown in the web 
annex (Table A6.8).
In 2011, 102 randomly selected C. coli isolates were 
susceptibility tested. Only one isolate per herd was tested; 
36% were found fully sensitive and four isolates were 
found multi-resistant. As in the previous three years, no 
significant changes in fluoroquinolone resistance were 
observed among C. coli from pigs from 2010 to 2011. 
Fluoroquinolone resistance was detected in approximately 
7% of the tested isolates (Figure 6.6) despite low 
consumption of fluoroquinolones in pigs since 2003 (web 
annex, Table A4.2). 
A continuous decrease in erythromycin resistance in C. 
coli was observed after withdrawal of the growth promoter 
tylosin from the Danish pig production in 1998–1999. 
Between 2006 and 2010, the level of erythromycin 
resistance remained stable between 10-15%, but from 
2010 to 2011, erythromycin resistance in C. coli from 
pigs decreased significantly from 15% to 7% (Figure 
6.6). In contrast, an increasing trend has been observed 
in the occurrence of resistance to tetracycline in C. coli 
from Danish pigs over the past decade, especially during 
2004–2011. Overall, the consumption of tetracycline has 
also increased from 2001 to 2009 (web annex, Table A4.1). 
The dramatic decrease in use of tetracyclines in the pig 
production in 2011 (by 27%) has not affected the level of 
tetracycline resistance in C. coli isolates from pigs.
In 2011, streptomycin resistant C. coli isolates from pigs 
remained at the same high level as in 2010 (61% in 2011 
compared with 62% in 2010). The increase observed since 
2009 may reflect that isolates coincidentally originated 
Figure 6.6. Resistance (%) in Campylobacter coli from 
pigs, Denmark 
DANMAP 2011
6.2.5  Campylobacter coli  in meat
From samples of meat, only one isolate per sample was 
susceptibility tested and reported. In 2011, 20 C. coli 
isolates were obtained from imported broiler meat.  Due 
to an insufficient number of samples (< 15), no C. coli 
isolates from Danish broiler meat were included in this 
report. Only two isolates from imported broiler meat were 
fully sensitive to the antimicrobial agents tested, while five 
of the isolates were multi-resistant. The MIC values are 
shown in the web annex (Table A6.9). 
6.2.6  Campylobacter coli  humans
No C. coli isolates from human cases were included in the 
DANMAP report 2011, since only a small number of C. 
coli were received at SSI.
Birgitte Borck Høg, Lars Stehr Larsen, 
Eva Møller Nielsen and Anne Mette Seyfarth
from producers with high prevalences of diseases typically 
treated with streptomycin (limb, joint, CNS and skin). It is, 
however, noteworthy that the consumption of penicillin-
streptomycin combinations for finisher pigs also increased 
during 2009-2010. It should also be noted that the increase 
in streptomycin consumption represents only a very small 
fraction of the total consumption (web annex, Table A4.2).
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7. Resistance in indicator bacteria
Indicator bacteria (Enterococcus faecium, Enterococcus 
faecalis and Escherichia coli) have been included in the 
DANMAP programme since 1995. These bacteria were 
selected as indicators for prevalence of antimicrobial 
resistance for several reasons. They are ubiquitous, and 
present as major commensals in both the animal and 
human reservoirs. They may acquire antimicrobial 
resistance as response to selective pressures. Furthermore, 
they have the potential for transferring resistance to 
pathogenic bacteria. 
Most of the antimicrobial agents that were used for 
growth promotion in Denmark (banned successively from 
1994–1999) had an effect on Gram-positive bacteria such 
as enterococci. Today, many of the antimicrobial agents 
used in veterinary clinical therapy are broad spectrum 
agents that are also active against Gram-negative bacteria, 
such as Salmonella and E. coli. Exceptions are penicillins, 
lincosamides, macrolides and pleuromutilins that are 
most active against Gram-positive bacteria.
Enterococci are included in the DANMAP programme 
to monitor the persistence of resistance after the 
ban of growth promoters and to monitor changes in 
antimicrobial resistance in Gram-positive bacteria. E. 
coli are included to monitor resistance in Gram-negative 
bacteria.
7.1  Enterococci
 
Enterococcus faecium and Enterococcus faecalis were 
isolated from healthy broiler and pigs at slaughter for the 
DANMAP programme. More over, enterococci were also 
isolated from meat sold at wholesale and retail outlets. 
If an isolate was resistant to three or more of the ten 
different antimicrobial classes included in the test panel, 
it was considered multi-resistant (see definition of multi-
resistance and the included antimicrobial classes in section 
10.5).
The MIC distributions and occurrence of resistance among 
E. faecium and E. faecalis are presented in the web annex 
(Tables A7.1, A7.2, A7.3 and A7.4).
7.1.1  Enterococcus faecium in animals
For samples from pigs and broilers, only one isolate per 
farm was included. A randomly selected subsample of 
isolates from broilers (n = 107) and pigs (n = 116) were 
susceptibility tested and reported (Table 7.1).
Table 7.1. Resistance (%) among Enterococcus faecium from animals and meat  of Danish and imported origin, 
Denmark 2011 DANMAP 2011
Antimicrobial agent
Broilers Pigs Broiler meat Beef meat Pork meat
Danish  
 %
Danish  
 %
Danish
%
Imported
%
Imported
%
Danish
%
Tetracycline 5 62 10 34 0 7
Tigecycline 0 0 0 0 0 0
Chloramphenicol 0 0 0 0 0 0
Penicillin 3 23 2 28 0 0
Ampicillin 3 10 2 27 0 0
Erythromycin 15 33 19 61 0 15
Gentamicin 0 1 0 0 0 0
Kanamycin 1 25 0 16 0 4
Streptomycin 4 41 0 28 0 4
Ciprofloxacin 0 0 0 0 0 0
Vancomycin 0 1 0 0 0 0
Quinupristin/dalfopristin 1 2 1 12 0 0
Salinomycin 55 0 54 25 0 0
Linezolid 0 0 0 0 0 0
Teicoplanin 0 1 0 0 0 0
Number of isolates 107 116 83 64 16 27
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Figure 7.1. Resistance (%) in indicator Enterococcus faecium from broilers, broiler meat and pigs, Denmark 
Note: The number of isolates varies between years (broilers: n = 43–119, Danish broiler meat: n = 83–164, imported broiler meat:  n = 64–230, 
pigs: n = 116–153). Data from broiler meat was not available from 2007 and data from pork was excluded due to few isolates
Broilers
Among the E. faecium isolates from broilers, 38% were 
fully sensitive to the antimicrobial agents tested and four 
isolates (4%) were multi-resistant. The highest occurrence 
of resistance was found for salinomycin (55%) followed by 
erythromycin (15%) and tetracycline (5%) (Table 7.1).
Salinomycin is widely used as a coccidiostat in the broiler 
production. Presently, no cut-off value is recommended 
by EUCAST for salinomycin, and the value used here is 
equivalent to the one used in DANMAP 2010. Significant 
reductions in resistance to salinomycin (from 75% to 55%) 
and to streptomycin (from 13% to 4%) have been seen over 
the past five years (Figure 7.1). 
From 2010 to 2011, the antimicrobial resistance to 
erythromycin among E. faecium isolated from broilers 
decreased significantly from 26% to 15% (Figure 7.1), 
while the overall consumption of macrolides decreased 
by 30% (web annex, Table A4.4). Resistance towards the 
growth promoter virginiamycin (quinupristin/dalfopristin 
resistance) persisted at a low level (1%), even though the 
usage has been banned for more than a decade.
Pigs
Among the E. faecium isolates from pigs, 31% were fully 
sensitive to the antimicrobial agents tested and 32% were 
multi-resistant. The highest occurrence of resistance was 
found for tetracycline (62%), followed by streptomycin 
(41%), erythromycin (33%) and kanamycin (25%) (Table 
7.1). Both streptomycin and kanamycin belong to the 
aminoglycosides. 
From 2010 to 2011, significant increases in antimicrobial 
resistance among isolated E. faecium from pigs were seen 
for ampicillin and penicillin; both belonging to the beta-
lactams. The increase in resistance to the beta-lactams 
(ampicillin and penicillin) did not correlate with the usage 
of beta-lactams in pigs.
Despite usage of streptogramins and avoparcin as growth 
promoters has been banned since 1994, resistance to 
vancomycin and quinupristin/dalfopristin remained at a 
low level among E. faecium isolated from pigs (Table 7.1).
Of the streptomycin resistant isolates, 98% (46/47) were 
also resistant to tetracycline, indicating co-resistance 
between these antimicrobial agents.. 
In 1995, the consumption of tetracyclines in pigs was 
reduced markedly, but has since then increased gradually 
until 2010 (web annex, Figure A7.1). During this period, 
the level of tetracycline resistance was not directly linked 
to the tetracycline consumption. In contrast, the level of 
erythromycin resistance among E. faecium isolates from 
pigs was strongly correlated with the marked decrease in 
consumption of macrolides in 1999 (web annex, Figure 
A7.2). 
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7.1.2  Enterococcus faecium in meat
E. faecium were isolated from broiler meat (83 Danish, 64 
imported), pork (27 Danish and 16 imported) and beef (16 
imported) sampled at wholesale and retail outlets in 2011. 
Only one isolate per positive sample was susceptibility 
tested and reported (Table 7.1). 
Broiler meat
Among the E. faecium isolates from Danish and imported 
broiler meat, 33% and 20% were fully sensitive to the 
antimicrobial agents tested, whereas 1% and 38% were 
found multi-resistant, respectively. For Danish broiler 
meat, the highest occurrence of resistance was found for 
salinomycin (54%), erythromycin (19%) and tetracycline 
(10%), whereas resistance to erythromycin (61%), 
tetracycline (34%) and beta-lactams (penicillin 28% and 
ampicillin 27%) was most common among the isolates from 
imported broiler meat. 
From 2010 to 2011, a significant increase in antimicrobial 
resistance towards salinomycin was seen among isolates 
from imported broiler meat (Figure 7.1). 
When comparing E. faecium isolates from Danish and 
imported broiler meat, significantly higher resistance 
to tetracycline, penicillin, ampicillin, erythromycin, 
kanamycin and streptomycin was found in isolates 
from imported broiler meat. In contrast, resistance to 
salinomycin was higher among isolates from Danish broiler 
meat compared to isolates from imported broiler meat. 
These significant differences have also been observed in 
previous years (Figure 7.1).
Pork and beef
The number of samples from Danish pork (n = 27) and 
imported beef (n = 16) was quite low, however among 
isolates from Danish pork, resistance to erythromycin 
was most common (15%) followed by resistance towards 
tetracycline (7%). The isolates from imported beef were 
fully susceptible to all antimicrobial agents tested.  
7.1.3  Enterococcus faecalis in animals
For samples from pigs and broilers, only one isolate per 
farm was included. A randomly selected subsample of 
isolates from broilers (n = 110) and pigs (n = 117) were 
susceptibility tested and reported (Table 7.1).
Broilers
Among E. faecalis isolates from broilers, 76% were fully 
sensitive to the antimicrobial agents tested and four isolates 
(4%) were multi-resistant. The highest occurrence of 
resistance was observed for tetracycline (17%) followed by 
erythromycin (15%), streptomycin (4%) and salinomycin 
(3%) (Table 7.2). As for E. faecium isolates from broilers, 
resistance to erythromycin among the E. faecalis isolates 
decreased significantly from 2010 to 2011. During this 
period, the overall consumption of macrolides decreased 
by 30%, even though the consumption already was at a low 
level (web annex, Table A4.4).
As in previous years, the level of salinomycin resistance 
was significantly lower in E. faecalis than in E. faecium 
isolates from broilers.
As for streptomycin resistance among E. faecium 
isolated from pigs, high (100%) co-resistance between 
streptomycin, tetracycline and erythromycin was detected 
among E. faecalis from broilers (only four isolates).
Pigs
Among E. faecalis isolates from pigs, 13% were fully 
sensitive to the antimicrobial agents tested and 42% were 
multi-resistant. The highest occurrence of resistance was 
observed for tetracycline (85%) followed by erythromycin 
(54%), streptomycin (37%), kanamycin (32%) and 
gentamicin (21%) (Table 7.2). From 2010 to 2011, 
antimicrobial resistance to the aminoglycosides gentamicin 
and kanamycin increased significantly. This increase could 
not be related to increased use of aminoglycosides.  
All chloramphenicol resistant isolates (27/27) were co-
resistant to both tetracycline and erythromycin, while 
94% (35/37) of the kanamycin resistant isolates and 96% 
(24/25) of the gentamicin resistant isolates were resistant 
to tetracycline and erythromycin. For isolates resistant to 
both aminoglycosides, 100% (22/22) were resistant to both 
tetracycline and erythromycin.
The level of tetracycline resistance among E. faecalis 
isolates from pigs did not reflect the general changes in 
in tetracycline consumption during 1995 to 2011 (web 
annex, Figure A7.1). In contrast, the level of erythromycin 
resistance among E. faecalis isolates from pigs was strongly 
correlated with the marked decrease in consumption of 
macrolides in 1999. During the following decade, the 
consumption of macrolides to pigs increased slowly, and 
a corresponding significant increase in erythromycin 
resistance was observed (web annex, Figure A7.2).
7.1.4  Enterococcus faecalis in meat
E. faecalis was isolated from pork (133 Danish, 45 
imported), broiler meat (34 Danish, 69 imported) and beef 
(20 Danish, 30 imported). Only one isolate per sample was 
susceptibility tested and reported (Table 7.2).
Broiler meat
Among the susceptibility tested E. faecalis isolates from 
Danish and imported broiler meat, 68% and 29% were fully 
sensitive to the antimicrobial agents tested, whereas 6% (n 
= 2) and 35% were found multi-resistant, respectively. The 
highest occurrence of resistance was found for tetracycline 
(26% and 67%) and erythromycin (18% and 49%) among 
the isolates from Danish and imported broiler meat, 
respectively.  
When comparing E. faecalis isolates from Danish and 
imported broiler meat from 2011, a significantly lower 
occurrence of resistance to tetracycline, erythromycin, 
kanamycin and streptomycin was observed. This tendency 
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Table 7.2. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, 
Denmark 2011
Antimicrobial agent
Broilers Pigs Broiler meat Beef Pork meat
Danish    
%
Danish    
%
Danish
%
Imported
%
Danish
%
Imported
%
Danish
%
Imported
%
Tetracycline 17 85 26 67 20 17 17 36
Tigecycline 0 0 0 0 0 0 0 0
Chloramphenicol 0 23 0 6 5 3 4 7
Penicillin 0 0 0 0 0 0 0 0
Ampicillin 0 0 0 0 0 0 0 0
Erythromycin 15 54 18 49 5 7 8 11
Gentamicin 0 21 0 1 0 3 2 4
Kanamycin 0 32 0 29 10 7 5 7
Streptomycin 4 37 6 33 10 10 5 7
Ciprofloxacin 0 0 0 4 0 0 0 0
Vancomycin 0 0 0 0 0 0 0 0
Salinomycin 3 0 0 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0
Number of isolates 110 117 34 69 20 30 133 45
was also observed in previous years in isolates from Danish 
broiler meat (Figure 7.2). 
Pork
Among E. faecalis isolates, 83% of the isolates from Danish 
pork were fully sensitive to the antimicrobial agents tested, 
while 44% of the isolates from imported pork were fully 
sensitive. For both Danish and imported pork, 7% of the 
isolates were found multi-resistant. Also, for E. faecalis 
from pork, the highest occurrence of resistance was found 
for tetracycline (17% and 36%) and erythromycin (8% and 
11%) among the isolates from Danish and imported origin, 
respectively.  
Compared to 2010, a significantly higher occurrence of 
antimicrobial resistance to erythromycin and streptomycin 
was observed in E. faecalis isolates from Danish pork. 
In contrast, no significant changes in levels of resistance 
were observed in E. faecalis isolates from imported 
pork. Compared to Danish pork, a significantly higher 
occurrence of resistance to tetracycline was found in E. 
faecalis from imported pork. 
Beef
The number of samples from Danish and imported beef 
was relatively low, resulting in a low number of isolates 
available for susceptibility testing. Most of the isolates 
(80%) from both Danish and imported beef were fully 
sensitive to the antimicrobial agents tested, whereas very 
few isolates (1 and 3, respectively) were multi-resistant. 
Resistance to tetracycline was most common and found in 
20% of the Danish isolates and 17% of imported isolates.
7.1.5  Comparison of resistance in animals
Among isolates from pigs, significantly higher levels 
of resistance were seen in E. faecium (tetracycline, 
penicillin, ampicillin, erythromycin, and kanamycin) and 
E. faecalis (tetracycline, chloramphenicol, erythromycin, 
gentamicin, kanamycin and streptomycin) than in isolates 
from broilers. However, a higher level of resistance to 
salinomycin was found in E. faecium from broilers. 
These differences probably reflect the relatively higher 
consumption per live biomass, and thus the higher 
selection pressure, in pigs compared to broilers (Figure 
4.3).
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Figure 7.2. Resistance (%) in Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Note: The number of isolates varies between years (broilers: n = 49–112, Danish broiler meat: n = 34–102, imported broiler meat:  n = 69–288, 
pigs: n = 117–157, Danish pork: n = 84–144, imported pork:  n = 45–250). Data from meat was not available from 2007, and broiler data from 
2009 was excluded due to few isolatesfrom 2007, and broiler data from 2009 was excluded due to few isolates
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7.1.6  Enterococcus in a farm to fork perspective
The level of resistance in E. faecium and E. faecalis 
from Danish broiler meat reflects the levels observed in 
the Danish broiler flocks, as there were no significant 
differences between the observed antimicrobial resistance 
in isolates from animals and meat. In contrast, significantly 
lower occurrence of resistance was found for tetracycline, 
kanamycin and streptomycin in E. faecium and E. 
faecalis isolates from Danish pork compared to isolates 
from Danish pigs. Significantly lower occurrence of 
antimicrobial resistance was also found for penicillin in E. 
faecium isolates and for chloramphenicol and gentamicin 
in E. faecalis isolates from Danish pork compared to 
Danish pigs. 
The level of antimicrobial resistance in E. faecium and 
E. faecalis isolates was significantly higher in imported 
broiler meat compared to Danish broiler meat. This 
includes tetracycline, erythromycin, kanamycin and 
streptomycin for both E. faecium and E. faecalis, and in 
addition ampicillin and penicillin for E. faecium. Only E. 
faecium from Danish broiler meat had a higher occurrence 
of resistance to salinomycin than what was observed 
among the isolates from imported meat. These significant 
differences have also been observed in previous years.
Lars Bogø Jensen and Lars Stehr Larsen
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Figure 7.5. Resistance (%) in indicator Escherichia coli from broilers and pigs and meat thereof, Denmark 
Note: The number of isolates varies between years (broilers: n = 114–152, Danish broiler meat: n = 113–148, imported broiler meat: 
n = 140–304, pigs: n = 150–160, Danish pork: n = 66–108, imported pork: n = 30–96)
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7.2  Indicator Escherichia coli
E. coli isolates from healthy animals originated from faecal 
samples collected for the DANMAP programme at the 
time of slaughter. E. coli from meat originated from meat 
sampled at wholesale and retail outlets, collected randomly 
in all regions of Denmark by the Danish Veterinary and 
Food Administration Regional Laboratories in a centrally 
coordinated programme. Samples from healthy humans 
have not been collected since 2008. If an isolate was 
resistant to three or more of the ten different antimicrobial 
classes included in the test panel, it was considered 
multi-resistant (see definition of multi-resistance and the 
included antimicrobial classes in section 10.5).
 
7.2.1  Indicator Escherichia coli in animals  
Only one isolate per farm was susceptibility tested, and a 
random selection of isolates from broilers (n = 134), cattle 
(n = 93) and pigs (n = 157) , were included in the report.
MIC distributions among E. coli from broilers, cattle and 
pigs are shown in the web annex (Table A7.5). Trends in 
resistance to selected antimicrobial agents in isolates from 
production animals during 2002–2011 are presented in 
Figure 7.5. 
In 2011, resistance levels were generally higher in isolates 
from pigs compared to broilers and cattle; however, 
resistance to quinolones (nalidixic acid and ciprofloxacin) 
was higher in isolates from broilers (9%) than from cattle 
or pigs (0-1%) (Table 7.3). 
Broilers 
Among E. coli isolates from broilers, 57% were fully 
sensitive and 16% were multi-resistant, similar to levels 
in 2010. No significant changes in the occurrences of 
resistance were observed in 2011 compared to 2010 (Figure 
7.5). The highest occurrence of resistance in broiler isolates 
was seen for ampicillin (20%, Table 7.3), a resistance that 
confers cross-resistance to amoxicillin which has been 
the most frequently used antibacterial agent in the broiler 
production for at least a decade (Figure 4.10).
 
Among the E. coli isolates from broilers, one isolate was 
resistant to ceftiofur. 
In 2011, 9% of the E. coli isolates from broilers were 
resistant to fluoroquinolones, and the occurrence has 
varied between 7% and 13% during the last 10 years. 
Until 2007, fluoroquinolone consumption in poultry 
was relatively higher than for the other animal species 
in Denmark, because the number of antimicrobial 
agents approved for poultry were limited. In the broiler 
production (including parent flocks), the highest 
fluoroquinolone consumption per broiler was observed 
during 2004–2007, reaching a maximum in 2006. Since 
2008, the fluoroquinolone usage in the poultry production 
has been very low. 
The highest occurrence of ciprofloxacin resistance in E. 
coli from broilers was observed in 2007, but the level of 
resistance has not changed significantly over the past 
decade (Figure 7.5). 
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Table 7.3. Resistance (%) among Escherichia coli from and meat of Danish and imported origin, Denmark 2011
Antimicrobial agent
Broilers Cattle Pigs Broiler meat Beef Pork meat
Danish   
%
Danish  
%
Danish
%
Danish   
%
Imported   
%
Danish    
%
Imported  
%
Danish    
%
Imported  
%
Tetracycline 10 5 29 19 52 5 14 33 40
Chloramphenicol 0 2 4 2 19 0 7 2 20
Florfenicol 0 2 0 0 1 0 2 0 3
Ampicillin 20 2 27 23 57 5 9 29 33
Cephalothin - - - - - - - - -
Ceftiofur 1 0 1 2 7 0 0 0 3
Cefpodoxime - - - - - - - - -
Cefotaxime 1 0 1 2 7 0 0 0 3
Sulfonamide 16 3 28 22 56 0 5 27 33
Trimethoprim 10 0 21 12 38 0 5 24 30
Apramycin 0 0 0 0 1 0 0 0 0
Gentamicin 0 0 0 0 3 0 0 0 0
Neomycin 1 0 3 4 12 0 0 2 3
Spectinomycin 3 0 20 2 31 0 2 15 10
Streptomycin 11 5 36 11 46 3 9 37 30
Ciprofloxacin 9 0 1 6 41 0 5 0 10
Nalidixic acid 9 0 1 6 39 0 5 0 10
Colistin 0 0 0 0 4 0 0 0 0
Number of isolates 134 93 157 122 140 37 44 92 30
DANMAP 2011
Cattle 
Among the included animal species, the level of resistance 
in indicator E. coli was lowest in isolates from cattle, where 
92% of the isolates were fully sensitive and only 3% (n = 3) 
were multi-resistant, a level comparable to 2010. In isolates 
from cattle, the level of resistance was similar to previous 
years. The most frequent types of resistance (Table 7.3) 
were resistance to tetracycline (5%) and streptomycin 
(5%). 
In 2011, none of the E. coli isolates from cattle were 
resistant to fluoroquinolones and cephalosporins. 
Pigs 
From pigs, 49% of the E. coli isolates were fully sensitive 
and 32% were multi-resistant, a level comparable to 
2010. In E. coli from pigs, resistance to ampicillin (27%), 
streptomycin (36%), sulfonamide (28%) and tetracycline 
(29%) was common (Table 7.3), and 11% of the included 
isolates had the ASSuT resistance profile (resistant to 
ampicillin, streptomycin, sulfonamide and tetracycline).
 
For a decade, the total consumption of antimicrobial agents 
for pigs has increased, but since 2009, large decreases have 
been observed for the consumption of tetracyclines (32%), 
penicillins with extended spectrum (23%), streptomycin 
(12%) and sulfonamides (12%) (Figure 4. 4). However, a 
time lapse is often seen between changes in consumption 
and a consequent change in resistance in E. coli [Jensen et 
al. 2006. J Antimicrob Chemother. 58: 101–107]. 
Streptomycin resistance in E. coli isolates from pigs 
decreased significantly in 2011 compared to 2010 (47% 
vs. 36%, Figure 7.5). Co-resistance between streptomycin  
and tetracycline and/or sulfonamide resistance is very 
frequently observed. In 2010, this co-resistance occurred 
in 99% (74/75) of the streptomycin resistant isolates from 
pigs, whereas this proportion was reduced to 75% (42/56) 
in 2011, coinciding with an overall (non-significant) 
reduction in tetracycline and/or sulfonamide resistance. 
The decrease in resistance to streptomycin in indicator E. 
coli from pigs may therefore be an effect of the dramatic 
decrease (by 27%) in use of tetracyclines in the pig 
production in 2011 (Figure 4.5).
 
Among the E. coli isolates from pigs, two isolates were 
resistant to both ceftiofur and cefotaxime.
The low level of fluoroquinolone resistance in E. coli 
from Danish pigs and cattle probably reflects the low 
consumption of fluoroquinolones since 2002–2003, when 
the use in production animals was restricted by law.
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7.2.2  Indicator Escherichia coli in meat 
Broiler  meat 
Indicator E. coli were isolated from broiler meat (158 
Danish, 177 imported), beef (32 Danish, 39 imported) and 
pork (68 Danish, 70 imported) sampled at wholesale and 
retail outlets in 2011. Only one isolate per positive sample 
was susceptibility tested and reported (Table 7.3).
 
MIC distributions and occurrence of antimicrobial 
resistance in E. coli isolates collected from broiler meat, 
beef and pork are presented in the web annex (Table A7.6). 
Among the E. coli isolates from Danish and imported 
broiler meat, 56% and 16% were fully sensitive, 
whereas 18% and 61% were found to be multi-resistant, 
respectively. For E. coli from Danish broiler meat, the 
observed resistance to trimethoprim increased significantly 
from 4% in 2010 to 12% in 2011 (Figure 7.5). The level 
of resistance in isolates from Danish broiler meat was 
zero or very low-moderate for all tested agents, with the 
highest level found for ampicillin (23%) (Table 7.3).  The 
increasing trend in resistance to sulfonamide observed 
from 2009 (8%) to 2010 (15%) continued through 2011 
(19%).
In imported broiler meat, the level of resistance was 
significantly higher for 11 of the 16 tested antimicrobial 
agents as compared to E. coli from Danish broiler meat 
(tetracycline, chloramphenicol, ampicillin, colistin, 
sulfonamide, trimethoprim, neomycin, spectinomycin, 
streptomycin, ciprofloxacin and nalidixic acid) (Table 7.3). 
In 2011, three ceftiofur resistant isolates (2%) were found 
in Danish broiler meat, as compared to 2010 when the 
first isolate was found in broiler meat by the non-selective 
methods. Consequently, the level found in Danish broiler 
meat was no longer significantly lower than in imported 
broiler meat (7%). Occurrence determined by non selective 
methods is an indicator of the prevalence in the bacterial 
population, whereas occurrence shown by selective 
methods is an indicator of the presence at sampling level 
(e.g. in the animals or meat samples). See Textbox 7 for 
results using selective methods.
The occurrence of fluoroquinolone resistance in broiler 
meat was unchanged. The level of fluoroquinolones 
resistance was significantly higher in imported meat (41%) 
than in Danish broiler meat (6%) (Table 7.3). 
Pork 
Among indicator E. coli isolates from Danish and imported 
pork, 49% and 30% were fully sensitive whereas 35% and 
33% were found to be multi-resistant, respectively. From 
2010 to 2011, no significant changes in resistance in E. 
coli from Danish pork were observed. In imported pork, a 
decrease in occurrence of resistance to streptomycin from 
56% in 2010 to 30 % in 2011 was observed (Figure 7.5). 
In 2011, significantly lower resistance to chloramphenicol, 
ciprofloxacin and nalidixic acid was found in isolates from 
Danish pork compared to imported pork (Table 7.3).
 
In imported pork, 10% of the E. coli isolates were resistant 
to fluoroquinolone, and 3 % were resistant to ceftiofur in 
2011 (Table 7.3). Fluoroquinolone resistance remained 
low (none observed in 2011) in Danish pork, probably due 
to the low fluoroquinolone consumption in Danish pigs 
since 2002 (see web annex, Table A4.2). The occurrence 
of cephalosporin resistant isolates in Danish pork has 
remained at a very low level (see also Textbox 7). 
In contrast, the use of both fluoroquinolones and 
cephalosporins has been increasing for animal production 
in some European countries during 2005–2009 [European 
Medicines Agency, 2011] and internationally, the 
occurrence of cephalosporin resistance (ESBL) in food is 
increasing [European Food Safety Agency, 2011]. 
Beef 
Among the susceptibility tested indicator E. coli isolates 
from Danish and imported beef, 92% and 80% were fully 
sensitive whereas 3% (one isolate) and 7% were found to 
be multi-resistant, respectively. No significant changes in 
resistance levels were observed from 2010 to 2011 and no 
significant differences were found between imported and 
Danish beef. In imported beef, two indicator E. coli isolates 
(5%) were found resistant to fluoroquinolones, whereas no 
fluoroquinolone resistant isolates were found in Danish 
beef (Table 7.3). 
7.2.3  Indicator E. coli in a farm to fork perspective 
For most of the tested antimicrobial agents, the level of 
resistance in Danish meat reflected the level of resistance 
in the corresponding animal species with one exception: 
The occurrence of tetracycline resistance among E. coli 
from Danish broiler meat (19%) was significantly higher 
than what was found among Danish broilers (10%). This 
difference might be caused by contamination from other 
sources at the slaughterhouse. In Denmark, the level 
of resistance is generally very low among broilers, and 
therefore contamination is likely to cause an increase in 
resistance level. 
Vibeke Frøkjær Jensen and Lars Stehr Larsen
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Occurrence of Extended spectrum beta-lactamase (ESBL)-producing Escherichia coli after selective 
enrichment with ceftriaxone in meat and food producing animals
Background: Extended spectrum beta-lactamase (ESBL)-producing bacteria is one of the fastest emerging 
resistance problems worldwide. This resistance type seems to be related to food producing animals and may 
spread to humans via food. In July 2010, the use of cephalosporins in the Danish pig production was discontinued, 
but it is still used for systemic and intramammary treatment in cattle. Cephalosporins have not been used in the 
Danish broiler production for at least a decade. The aim of this study was to investigate the occurrence of ESBL-
producing E. coli in pigs at farm level, in pigs and cattle at slaughter and in meat at retail (see section 11.2 for 
definition of ESBL).
Materials and methods: During February 2011 through October 2011, pools of five stool samples (n = 78) were 
collected in pig farms and fecal samples were taken from pigs (n=777) and cattle (n=186) at slaughter. From 
January through November 2011, samples of broiler meat (132 Danish, 152 imported), beef (122 Danish, 115 
imported) and pork (225 Danish, 99 imported) were collected randomly in retail stores and outlets in all regions 
of Denmark. The samples were randomly selected; and for pig farms each farm was sampled only once. For cattle 
and pigs sampled at slaughter, one animal represented one farm and no herds were sampled more than once in 
the same month. E. coli was isolated from 1 g of pooled stool sample, 1 g of feces or 5 g of meat after selective 
enrichment in McConkey media with ceftriaxone (1 µg/ml). The genetic background for ESBL resistance was 
revealed by use of PCR, micro array and DNA sequencing.
Results: None (0/78) of the pig stool samples contained ceftriaxone resistant E. coli and this was significantly lower 
than in 2010 (Figure 1). For pigs at slaughter 3.6% (28/777) contained ceftriaxone resistant E. coli, which were 
significantly lower than in 2009 and 2010. The most commonly detected gene was CTX-M-1 but also CTX-M-14 
and CTX-M-15 genes often detected in E. coli causing human infections were found. In cattle, the prevalence 
of ceftriaxone resistant E. coli were at the same level (10.2% , 19/186), as in 2010 and CTX-M-1 followed by 
CTX-M-14 was most frequently found (Figure 1). 
From meat samples, the highest prevalence of ceftriaxone resistant E. coli was found among imported broiler 
meat (48%, 73/152). But the prevalence in Danish broiler meat (44%, 58/132) had increased significantly when 
compared to 2010 (8.6%) now being at the same level as imported broiler meat. The most commonly detected 
gene in broiler meat was, as found in previous years, CMY-2 followed by CTX-M-1. The prevalence of ceftriaxone 
resistant E. coli was 4% in imported pork and remained even lower in beef and Danish pork [0-0.9%] (Figure 2).
Discussion and conclusions: The results showed that the voluntary ban of cephalosporin usage in the Danish 
pig production had an effect on reducing ceftriaxone resistant E. coli in the pigs at farm level and at slaughter. The 
prevalence of ceftriaxone resistant E. coli in cattle was unchanged in 2011 compared to 2010, probably because 
3rd and 4th generation cephalosporins are still used for intramammary and systemic treatment in cattle. The 
high prevalence of ceftriaxone resistant E. coli found in Danish broiler meat was surprising since cephalosporins 
are not used in the Danish broiler production. However, this high prevalence may be due to extended spectrum 
penicillins being increasing used for treatment in the Danish broiler production as extended spectrum penicillins 
may select for ceftriaxone resistant E. coli being introduced via breeding animals. 
CTX-M-1 was the most common ESBL-gene in pigs and cattle, but also CTX-M-14 and CTX-M-15 was found; 
these genes are often found in ESBL E. coli causing human infections. A more detailed analysis of CTX-M-14 and 
CTX-M-15 isolates from pigs and pork showed isolates from porcine origin to belong to STs that had previously 
given rise to infections in humans. Furthermore, the genes were transferable to a ST131 E. coli recipient of pork 
origin suggesting that pigs and pork can be a reservoir of human pathogenic ESBL-producing E. coli and a 
reservoir of transferable CTX-M-14 and CTX-M-15 genes [Hammerum et al, 2012, J. Antimicrobial Chemother., 
Ahead of print].
Broiler meat from both Danish and imported sources seemed to be the most important meat sources and CMY-
2 was the most common type in broiler meat. CMY-2 was also found in ESBL E. coli causing human infections 
(See Textbox 9) but it is unknown whether the prevalence of E. coli with CMY-2 causing human infections has 
increased.
Yvonne Agersø
For further information: Yvonne Agersø (yvoa@food.dtu.dk)
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Figure 1.  Occurrence (%) of ESBL-producing Escherichia coli and genes in pigs and cattle from samples(a) 
collected at farm and slaughterhouse level, Denmark
DANMAP 2011
DANMAP 2011
Figure 2. Occurrence (%) of ESBL-producing Escherichia coli and genes in meat(ab), Denmark
a) E. coli was isolated after selective enrichment with ceftriaxone (1 μg/ml). The genetic background for ESBL resistance was 
revealed by use of PCR, micro array and DNA sequencing
a) E. coli was isolated after selective enrichment with ceftriaxone (1 μg/ml). The genetic background for ESBL resistance was 
revealed by use of PCR, micro array and DNA sequencing
b) Each year, approximately 1,000 samples are collected evenly distributed between the six categories of meat
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8. Resistance in human clinical bacteria
8.1  Escherichia coli
Escherichia coli is part of the normal intestinal flora of both 
humans and animals but also cause infections. In humans, 
E. coli cause a variety of intestinal and extra-intestinal 
infections such as diarrhoea, urinary tract infections, 
meningitis, and bloodstream infections. For E. coli, this 
report includes data from 12 Departments of Clinical 
Microbiology (DCM), representing 95% of the Danish 
population. Data on antimicrobial resistance in blood and 
urine isolates of E. coli in hospitals were obtained from 12 
of the 13 Danish DCM working with hospital isolates; 11 
DCM of the 12 DCM working with primary health care 
isolates contributed data on antimicrobial resistance in 
urine isolates of E. coli from primary health care (Table 
8.1).
E. coli blood isolates obtained from hospitalised patients
The antimicrobial susceptibility of approximately 3,600 E. 
coli isolates from blood was reported in 2011 (Table 8.1 
and Figure 8.1).
In 2011, cefuroxime (2nd generation cephalosporin) 
resistance was 9% (min. 6%, max. 24%) the same as 
reported in 2010. Likewise, 8% (min. 6%, max. 21%) of 
the isolates were resistant to 3rd generation cephalosporin 
(reported as resistance to ceftazidime, ceftriaxone, 
cefpodoxime or cefotaxime) similar to the level in 2010. 
The occurrence of 3rd generation cephalosporin resistance 
reported from the DCM corresponded to the prevalence 
of ESBL in 368 E. coli blood isolates from hospitalised 
patients (7%) as observed in a nation-wide prevalence 
study of ESBL-producing bacteria performed in October 
2011 [Textbox 9]. Third generation cephalosporin 
resistance can be due to production of ESBL or AmpC 
enzymes; ESBL-producing E. coli blood isolates from 
October 2011 were investigated for the genetic background 
of their ESBL-production, see Textbox 9.
In 2011, ciprofloxacin resistance was 14% (min. 12%, max. 
31%) and nalidixic acid resistance was 21% (min. 17%, 
max. 24%), which is the same level as in 2010. 
The level of fluoroquinolone and 3rd generation 
cephalosporin resistance in Denmark was above the level 
reported to EARS-Net by the other Nordic countries 
and corresponded to the occurrence reported by other 
European countries in 2010 [EARS-Net 2010]. 
Aminoglycoside (gentamicin) resistance was 6% (min. 2%, 
max. 15%) in 2011, which is at the same level as in 2010. 
This was above the level reported to EARS-Net by the other 
Nordic countries in 2010 [EARS-Net 2010]. Mecillinam 
resistance was 10% (min. 5%, max. 17%) in 2011, which is 
at the same level as in 2010.
Over the last decade, resistance to cefuroxime has 
increased from 2% in 2002 to 9% in 2011. Resistance to 
3rd generation cephalosporins has only been reported 
since 2008. Resistance to fluoroquinolones has also 
increased over the last ten years; ciprofloxacin resistance 
increased from 3% in 2002 to 14% in 2011, and nalidixic 
acid resistance from 6% in 2002 to 21% in 2011. 
Aminoglycoside (gentamicin) resistance has increased 
from 1% in 2002 to 6% in 2011. The increased frequency 
of resistance in E. coli blood isolates parallels the increased 
consumption of broad spectrum antimicrobial agents 
[Textbox 8].
DANMAP 2011
Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark 2011
*) An asterisk indicates a significant increase from 2010 to 2011
#) A number sign indicates a significant decrease from 2010 to 2011
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary health care
% % %
Ampicillin 48 42 41
Mecillinam 10 7 6
Sulfonamide 35 35 #
Gentamicin 6 4 * 3
Ciprofloxacin 14 13 * 11
Nalidixic acid 21 17 * 15
Cefuroxime 9 5 3
3rd generation cephalosporins a) 8 5 3
Meropenem 0
Max. number of isolates tested 3636 36389 32117
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In 2011, carbapenem (meropenem) resistance was not 
observed in E. coli blood isolates. 
E. coli urine isolates obtained from hospitalised patients 
The antimicrobial susceptibility of approximately 36,000 
E. coli isolates obtained from hospitalised patients with a 
urinary tract infection was reported in 2011 (Table 8.1 and 
Figure 8.2).
In 2011, cefuroxime (2nd generation cephalosporin) 
resistance was 5% (min. 4%, max. 9%) the same as reported 
in 2010. The occurrence of 3rd generation cephalosporin 
resistance (reported as resistance to cefpodoxime or 
cefotaxime) was 5% (min. 4%, max. 8%) similar to the level 
in 2010. The occurrence of 3rd generation cephalosporin 
resistance reported from the DCM corresponded to the 
prevalence of ESBL in 4068 E. coli urine isolates from 
hospitalised patients (5%) as observed in a nation-wide 
prevalence study of ESBL-producing bacteria performed in 
October 2011 [Textbox 9]. Third generation cephalosporin 
resistance can be due to production of ESBL or AmpC 
enzymes; ESBL-producing E. coli blood isolates from 
October 2011 were investigated for the genetic background 
of their ESBL-production, see Textbox 9.
Fluoroquinolone resistance increased significantly from 
2010 (ciprofloxacin 12%, nalidixic acid 15%) to 2011 
(ciprofloxacin 13%, nalidixic acid 17%). Over the last 
decade, an increase in the occurrence of fluoroquinolone 
resistance has also been seen; ciprofloxacin resistance has 
increased from 2% in 2002, nalidixic acid resistance has 
increased from 6% in 2002. 
Aminoglycoside (gentamicin) resistance increased 
significantly from 3.7% in 2010 to 4.4% in 2011.
 
Carbapenem resistance is not mandatory reportable in 
Denmark and only one DCM reported data on all isolates; 
therefore no calculation of the occurrence of carbapenem 
resistance could be made. In 2011, carbapenem 
(meropenem) resistance was observed in five E. coli 
urine isolates from hospitalised patients. The mechanism 
behind the carbapenem resistance in these isolates is not 
known since the isolates were not sent to SSI for further 
investigation. 
E. coli urine isolates obtained from primary health care
The antimicrobial susceptibility of approximately 32,000 
E. coli isolates obtained from patients with a urinary tract 
infection from primary health care was reported in 2011 
(Table 8.1 and Figure 8.3).
In 2011, cefuroxime (2nd generation cephalosporin) 
resistance was 3% (min. 3%, max. 5%) the same as reported 
in 2010. The occurrence of 3rd generation cephalosporin 
resistance (reported as resistance to cefpodoxime or 
cefotaxime) was 3% (min. 3%, max. 5%) similar to the level 
in 2010. The occurrence of 3rd generation cephalosporin 
resistance reported from the DCM corresponded to the 
prevalence of ESBL in 4037 E. coli urine isolates from 
hospitalised patients (3%) as observed in a nation-wide 
prevalence study of ESBL-producing bacteria performed in 
October 2011 [Textbox 9]. Third generation cephalosporin 
resistance can be due to production of ESBL or AmpC 
enzymes; ESBL-producing E. coli blood isolates from 
October 2011 were investigated for the genetic background 
of their ESBL-production, see Textbox 9.
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2011
DANMAP 2011
Figure 8.1. Resistance (%) in Escherichia coli blood isolates from humans, Denmark
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Figure 8.2. Resistance (%) in Escherichia coli urine isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2011
DANMAP 2011
Figure 8.3. Resistance (%) in Escherichia coli urine isolates from humans in primary health care, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2011
DANMAP 2011
Over the last decade, the occurrence of resistance to 
fluoroquinolones has increased; ciprofloxacin resistance 
from 1% in 2001 to 11% in 2011, and nalidixic acid 
resistance from 5% in 2001 to 15% in 2011, respectively.
The occurrence of sulfonamide resistance decreased 
significantly from 37% in 2010 to 35% in 2011. 
In 2011, carbapenem (meropenem) resistance was 
observed in three E. coli urine isolates from primary health 
care. The carbapenem resistant isolates were not further 
investigated. The presence of antimicrobial resistance 
in this species is not mandatory reportable, and no 
calculation of the occurrence of carbapenem resistance 
could be made since the DCM reported data on selected 
isolates only.
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
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Increasing consumption of antimicrobial agents in Denmark parallels increasing resistance in 
Escherichia coli bloodstream isolates
Background: Escherichia coli is one of the most important causes of nosocomial infections. In hospitals, E. 
coli bloodstream infections are often treated with beta-lactams (mainly cephalosporins and carbapenems) 
and fluoroquinolones. However, resistance to these compounds has been reported with increasing frequency 
in Europe in recent years. Until 2006, the occurrence of 3rd generation cephalosporin resistant E. coli from 
bloodstream infections in Denmark was low [EARRS Annual Report 2006]. To monitor the ESBL-prevalence 
in Danish patients, three studies have been carried out; these results are presented in Textbox 9. In 2009, we 
reported on the consequences of the increased antibacterial consumption in Danish hospitals (2001–2007) 
[Jensen et al. 2009. J Antimicrob Chemother. 63: 812-5]. We recently reported on the development of 
antimicrobial consumption in Danish hospitals (2007–2010) and resistance among E. coli from bloodstream 
infections (2008–2010) [Skjøt-Rasmussen et al. 2012. Int J Antimicrob Agents, 40: 86–8]. 
Materials and methods: From 2008 through 2010, data on gentamicin, ciprofloxacin, 3rd generation 
cephalosporin (ceftazidime, ceftriaxone, or cefotaxime) and carbapenem resistance in E. coli blood isolates 
were collected from 9 of 14 Departments of Clinical Microbiology (DCM) in Denmark (DCM at Hvidovre, 
Rigshospitalet, Hillerød, Odense, Esbjerg, Vejle, Aarhus, Viborg and Aalborg Hospital). An average of 2300 
E. coli blood isolates per year was collected from the catchment area representing approximately 2/3 of the 
Danish population (3.7 million people). 
Consumption data for the included hospitals were obtained from Statens Serum Institut (formerly the Danish 
Medicines Agency). Since an increase in the level of resistance is often observed after the consumption of 
antimicrobial agents takes place, consumption data from 2007 were included in our study. 
Results: The level of resistance to gentamicin, ciprofloxacin and 3rd generation cephalosporins increased 
significantly from 2008 through 2010 (Figure 1a). Resistance to gentamicin increased significantly from 4.3% 
to 6.5%, ciprofloxacin from 9.7% to 13.6%, and 3rd generation cephalosporins from 3.9% to 7.5%. The level 
of multi-resistance (gentamicin, ciprofloxacin, 3rd generation cephalosporins) increased significantly from 
1.3% in 2008 to 2.4% in 2010 (Figure 1a). None of the isolates were carbapenem resistant.
From 2007–2010, the consumption of broad spectrum antimicrobial agents also increased (Figure 1b). 
This was seen for 2nd generation cephalosporins (12.01 to 15.35 DDD/100 bed-days in 2007 compared 
to 2010), 3rd generation cephalosporins (1.13 to 1.46 DDD/100 bed-days in 2007 compared to 2010) 
and fluoroquinolones (8.60 to 11.08 DDD/100 bed-days in 2007 compared to 2010). Furthermore, the 
consumption of carbapenems increased from 2.53 DDD/100 bed-days in 2007 to 4.81 DDD/100 bed-days in 
2010.
Discussion and conclusions: The hospital consumption of antimicrobial agents would be expected to 
significantly influence only those isolates that were nosocomial or hospital-associated. We do not know the 
exact number of hospital-associated or community-acquired isolates in our study. However, the interaction 
between consumption of antimicrobial agents inside and outside hospitals is complex. Ciprofloxacin is used 
in hospitals as well as in primary health care in Denmark (see Table 5.2), therefore the ciprofloxacin resistant 
E. coli could also be selected outside the hospitals; however, 2nd and 3rd generation cephalosporins and 
carbapenems are almost exclusively used in hospitals. Cephalosporinase-producing E. coli can be detected in 
meat and animals in Denmark [Textbox 7]; we do not know if the isolates in our study has an animal origin. 
Further studies are needed to quantify the risk of E. coli of animal origin in relation to human health.
The increased frequency of resistance in E. coli blood isolates parallels the increased consumption of broad 
spectrum antimicrobial agents. An increase in multi-resistant E. coli infections might explain part of the 
increased consumption of carbapenems. The increasing resistance in E. coli is not merely a Danish problem; 
an alarming increase in antimicrobial resistance in E. coli is observed in all of Europe [Gagliotti et al. 2011. 
Euro Surveill. 16: pii:19819]. Global efforts to reduce the use of broad spectrum antibiotics are warranted. 
A recent study has shown that bloodstream infections caused by 3rd generation cephalosporin resistant E. 
coli are associated with excess mortality and prolongation of hospital stay, posing a considerable burden on 
patients and health care systems [De Kraker et al. 2011. PloS Med. 8: e1001104].
Line Skjøt-Rasmussen, Stefan S. Olsen, Ulrich S. Jensen and Anette M. Hammerum 
on behalf of the DANRES Study Group
For further information: Line Skjøt-Rasmussen (lbs@ssi.dk)
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Figure 1. Data on antimicrobial resistance in Escherichia coli blood isolates and antimicrobial consumption in 
hospitals from nine Danish Departments of Clinical Microbiology. All data were obtained as part of the DANMAP 
programme. (a) The percentage of gentamicin, ciprofloxacin and 3rd generation cephalosporin resistant and 
multi-resistant (gentamicin, ciprofloxacin and 3rd generation cephalosporin) E. coli blood isolates (2008–2010) 
with 95% confidence intervals
DANMAP 2011
DANMAP 2011
Figure 2. The consumption (DDD/100 bed-days) of 2nd generation cephalosporins, 3rd generation 
cephalosporins, carbapenems, aminoglycosides and fluoroquinolones in hospitals (2007–2010). 
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8.2  Klebsiella pneumoniae
Klebsiella pneumoniae is part of the intestinal flora in 
humans but is often the cause of extra-intestinal infections 
such as urinary tract-, respiratory tract-, wound- and 
bloodstream infections. Many of these infections are 
hospital acquired and can be life threatening, especially 
if the strains are resistant to antimicrobial agents. K. 
pneumoniae is intrinsically resistant to aminopenicillins 
(e.g. ampicillin). Therefore, infections caused by K. 
pneumoniae are treated with broad spectrum antimicrobial 
agents such as ciprofloxacin, gentamicin, cephalosporins 
and carbapenems. Data on antimicrobial resistance in 
blood and urine isolates of K. pneumoniae in hospitals were 
obtained from 12 of the 13 Danish DCM working with 
hospital isolates; 11 of the 12 DCM working with primary 
health care isolates contributed data on antimicrobial 
resistance in urine isolates of K. pneumoniae from primary 
health care.
 
K. pneumoniae blood isolates obtained from hospitalised 
patients
The antimicrobial susceptibility of approximately 900 K. 
pneumoniae isolates from blood was reported in 2011 
(Table 8.2).
Until 2007, the occurrence of antimicrobial resistance in K. 
pneumoniae was low and at the same level as in the other 
Nordic countries (e.g. for 3rd generation cephalosporins 
<5%). However, since 2007 a steady increase in resistance 
has been observed until 2009. In general, the level of 
antimicrobial resistance in 2011 was similar to 2010.
In 2011, 3rd generation cephalosporin resistance (reported 
as resistance to ceftazidime, ceftriaxone, cefpodoxime or 
cefotaxime) was 10% (min. 0%, max. 16%); this was at 
the same level as in 2010 (9%). In 2011, 3rd generation 
cephalosporin resistance was above the level reported to 
EARS-Net by the other Nordic countries and corresponded 
to the occurrence reported by several other European 
countries in 2010 [EARS-Net 2010]. Third generation 
cephalosporin resistance can be due to production of 
ESBL or AmpC enzymes. The genetic background was not 
reported for the 3rd generation cephalosporin resistant 
K. pneumoniae isolates in 2011. However, the occurrence 
of 3rd generation cephalosporin resistance reported from 
the DCM corresponded to the prevalence of ESBL in 83 
K. pneumoniae blood isolates from hospitalised patients 
(7%), as observed in a nation-wide prevalence study of 
ESBL-producing bacteria performed in October 2011 
[Textbox 9]. Thus, 3rd generation cephalosporin resistance 
among K. pneumoniae in Denmark is mostly due to ESBL-
producing isolates and in the majority of the cases it was 
encoded by CTX-M-15.
The occurrence of fluoroquinolone resistance 
(ciprofloxacin 12%, nalidixic acid 18%) and 
aminoglycoside (gentamicin) resistance (6%) was above 
the level reported from the other Nordic countries and 
the same as reported to EARS-Net by other European 
countries in 2010 [EARS-Net 2010]. 
In 2011, one carbapenem (meropenem) resistant K. 
pneumoniae blood isolate was found. The mechanism 
behind the carbapenem resistance in this isolate is not 
known since the isolate was not sent to SSI for further 
investigation.
K. pneumoniae urine isolates obtained from hospitalised 
patients
The antimicrobial susceptibility of approximately 5,700 K. 
pneumoniae isolates obtained from hospitalised patients 
with a urinary tract infection was reported in 2011 (Table 
8.3).
The occurrence of 3rd generation cephalosporin resistance 
(reported as cefpodoxime or cefotaxime) decreased 
significantly from 12% in 2010 to 10% in 2011. The 
occurrence of 3rd generation cephalosporin resistance 
reported from the DCM corresponded to the prevalence 
of ESBL in 650 K. pneumoniae urine isolates from 
hospitalised patients (10%), as observed in a nation-wide 
prevalence study of ESBL-producing bacteria performed 
in October 2011 [Textbox 9]. The occurrence of 2nd 
generation cephalosporin (cefuroxime) resistance also 
decreased from 13% in 2010 to 11% in 2011.
Fluoroquinolone (ciprofloxacin) resistance decreased 
significantly from 14% in 2010 to 11% in 2011.
In 2011, carbapenem (meropenem) resistance was 
observed in five K. pneumoniae urine isolates from 
hospitalised patients. One of the five isolates was tested for 
the presence of genes encoding carbapenemases and it was 
positive for KPC-2. The origin of this KPC-2 producing K. 
pneumoniae was unknown [Textbox 11]. The mechanism 
behind the carbapenem resistance in the other four isolates 
was not tested. The presence of antimicrobial resistance in 
this species is not mandatory reportable and no calculation 
of the occurrence of carbapenem resistance could be made 
since only one DCM reported data on all isolates. 
Table 8.2. Resistance (%) in Klebsiella pneumoniae 
isolates from blood, Denmark
a) Susceptibility to gentamicin was tested in 908 isolates, ciprofloxacin 
susceptibility in 888 isolates, nalidixic acid susceptibility in 367 
isolates, cefuroxime susceptibility in 852 isolates, 3rd generation 
cephalosporin susceptibility in 906 isolates, and meropenem 
susceptibility in 589 isolates
b) Tested 3rd generation cephalosporins were ceftazidime, 
ceftriaxone, cefpodoxime and cefotaxime
Substance 2008 2009 2010 2011
(a)
% % % %
Gentamicin 7.6 9.0 6.0 5.8
Ciprofloxacin 16.1 18.1 11.3 11.7
Nalidixic acid 22.2 21.8 17.4 18.3
Cefuroxime 15.2 17.1 12.8 14.0
3rd gen. cephalosporins (b) 9.6 12.0 9.2 9.6
Meropenem <1 0 0 <1
Max. number of isolates tested 788 886 799 908
DANMAP 2011
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Sulfonamide resistance increased from 29% in 2010 to 33% 
in 2011. Mecillinam resistance decreased from 14% in 2010 
to 12% in 2011.
K. pneumoniae urine isolates obtained from primary 
health care
The antimicrobial susceptibility of approximately 3,400 K. 
pneumoniae isolates obtained from patients with a urinary 
tract infection from primary health care was reported in 
2011 (Table 8.4). 
The occurrence of 3rd generation cephalosporin resistance 
(reported as cefpodoxime or cefotaxime) decreased 
significantly from 7% in 2010 to 5% in 2011. The 
occurrence of 3rd generation cephalosporin resistance 
reported from the DCM corresponded to the prevalence 
of ESBL in 450 K. pneumoniae urine isolates from general 
practice patients (7%), as observed in a nation-wide 
prevalence study of ESBL-producing bacteria performed 
in October 2011 [Textbox 9]. Resistance to 3rd generation 
cephalosporins in K. pneumoniae from urine from 
general practice patients was significantly lower than the 
occurrence of resistance detected in isolates from both 
blood and urine from hospitalised patients.
Table 8.3. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in hospitals, Denmark
a) Susceptibility to mecillinam was tested in 5746 isolates, 
sulfonamide susceptibility in 2683 isolates, gentamicin susceptibility 
in 3899 isolates, ciprofloxacin susceptibility in 4827 isolates, nalidixic 
acid susceptibility in 2065 isolates, cefuroxime susceptibility in 4720 
isolates, and 3rd generation cephalosporin susceptibility in 4595 
isolates
b) Tested 3rd generation cephalosporins were cefpodoxime and 
cefotaxime
Substance 2009 2010 2011
(a)
% % %
Mecillinam 13.3 14.3 11.9
Sulfonamide 27.0 28.6 33.4
Gentamicin 7.3 6.4
Ciprofloxacin 17.3 13.9 11.5
Nalidixic acid 21.9 19.6 18.8
Cefuroxime 12.8 10.9
3rd gen. cephalosporins (b) 12.8 12.0 9.6
Max. number of isolates tested 6394 5740 5746
DANMAP 2011 DANMAP 2011
Table 8.4. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in primary health care, Denmark
Substance 2009 2010 2011
(a)
% % %
Mecillinam 15.1 16.3 12.5
Sulfonamide 30.2 33.9 34.9
Gentamicin 3.5 2.3
Ciprofloxacin 13.2 11.9 8.6
Nalidixic acid 19.9 19.7 14.1
Cefuroxime 8.6 6.8
3rd gen. cephalosporins (b) 8.1 7.0 5.3
Max. number of isolates tested 3200 3200 3489
a) Susceptibility to mecillinam was tested in 3489 isolates, 
sulfonamide susceptibility in 2510 isolates, gentamicin 
susceptibility in 1342 isolates, ciprofloxacin susceptibility in 3198 
isolates, nalidixic acid susceptibility in 1338 isolates, cefuroxime 
susceptibility in 2183 isolates, and 3rd generation cephalosporin 
susceptibility in 2777 isolates
b) Tested 3rd generation cephalosporins were cefpodoxime and 
cefotaxime
The occurrence of fluoroquinolone resistance 
(ciprofloxacin 9%, nalidixic acid 14%) decreased 
significantly from the level observed in 2010 (ciprofloxacin 
12%, nalidixic acid 20%). Ciprofloxacin and nalidixic 
acid resistance in K. pneumoniae from urine from 
general practice patients was significantly lower than the 
occurrence of resistance detected in isolates from urine 
from hospitalised patients.
In 2011, carbapenem (meropenem) resistance was 
observed in one K. pneumoniae urine isolate from 
primary health care. The carbapenem resistant isolate was 
not further investigated. The presence of antimicrobial 
resistance in this species is not mandatory reportable, and 
no calculation of the occurrence of carbapenem resistance 
could be made since the DCM reported data on selected 
isolates only.
Sulfonamide resistance was 35% (min. 27%, max. 47%). 
Mecillinam resistance decreased significantly from 16% in 
2010 to 12% in 2011. 
Line Skjøt-Rasmussen, Stefan S. Olsen
and Anette M. Hammerum
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Extended spectrum beta-lactamase producing bacteria in patients, October 2011
Background: Extended Spectrum Beta-Lactamase (ESBL)-producing bacteria are found in the intestinal flora 
of hospitalised patients and otherwise healthy persons in the community. Being an ESBL carrier is a risk factor 
for subsequent clinical infection with the same ESBL-producing bacterium. The bacteria are transmitted via 
the faecal-oral route and risk of infection is enhanced by the presence of catheters and other foreign bodies. In 
the community, ESBL-producing bacteria are often associated with urinary tract infections while in hospital 
settings they may also cause pneumonia and bloodstream infections. ESBL-producing enterobacteria, particularly 
Klebsiella pneumoniae, have a distinct tendency to cause nosocomial outbreaks. In Denmark, clonal spread has 
been detected at hospitals in Zealand [Lester et al. 2011. Int J Antimicrob Agents. 38: 180-2]. ESBL-producing E. 
coli are also detected in meat and faecal samples from animals [Textbox 7]. 
Materials and methods: In October 2011, 12 of the 13 Danish Departments of Clinical Microbiology screened 
all E. coli and K. pneumoniae urine and blood isolates for ESBL-production using a cephalosporin disc/tablet on 
the primary plate. Results were confirmed by demonstrating inhibition with clavulanic acid in combination with 
a 3rd or 4th generation cephalosporin using the disc-combination method or by gradient test. The majority of the 
isolates were sent to SSI for further confirmation and genotyping. Polymerase chain reaction (PCR) amplification 
and sequencing were performed with primers specifically to identify blaTEM, blaCTX-M, blaOXA, blaSHV and blaAmpC 
β-lactamase genes.
The prevalence of ESBL-producing bacteria was calculated from the total number of the same species tested at 
each site. These figures only include “true” ESBL-producing bacteria; i.e. excluding AmpC-producing bacteria. 
Several laboratories sent AmpC-producing isolates to SSI for genotyping, but it was not possible to calculate an 
AmpC-prevalence.
Results and discussion: The prevalence of ESBL-producing Escherichia coli and K. pneumoniae isolated from 
blood and urine, the latter divided into hospital- or community derived urine cultures, is shown in Table 1. The 
ESBL-prevalence obtained in 2011 was compared to data from similar studies performed in 2007 and 2009 [Table 
1]. From October 2009 to October 2011, the prevalence of ESBL-producing E. coli increased significantly in urine 
samples from community and hospitals. 
DANMAP 2011
Table 1. Prevalence of Extended Spectrum Beta-Lactamase (ESBL)(a) in Escherichia coli and Klebsiella 
pneumoniae isolated from blood and urine cultures, September-October 2007, October 2009 and 
October 2011
a) AmpC producing isolates were not included
b) NA: Not applicable. For the study in 2007, no information was provided on the distribution of the in all 47,504 urine cultures 
performed in hospitals and general practices
c) A significant increase was detected from 2009 to 2011
Sample type Period No. of tested cultures No. of E. coli 
ESBL E. coli
(%)
No. of K. 
pneumoniae 
ESBL K. 
pneumoniae
(%)
Blood 2007 18259 625 4.2 160 5.0
2009 11532 356 7.0 89 14.6
2011 12891 368 7.3 83 7.2
Urine, hospitals 2007 NA(b) 6791 2.3 1078 6.6
2009 16536 4004 3.8 675 11.1
2011 19780 4068 4.7(c) 650 9.7
Urine, general practice 2007 NA(b) 4966 1.5 513 2.7
2009 12574 3392 2.3 385 6.8
2011 16984 4037 3.2(c) 450 7.1
DANMAP 2011
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Table 2. ESBL enzymes detected in the ESBL-producing E. coli and K. pneumoniae isolates from the ESBL-
prevalence study, October 2011(a)
a) AmpC producing  isolates (incl. CMY-2) were not included
ESBL enzyme 
E. coli from 
urine
(%)
E. coli from 
blood
(%)
K. pneumoniae 
from urine
(%)
K. pneumoniae from 
blood
(%)
CTX-M-1 7.3 8.0 1.3
CTX-M-14 16.7 4.0 10.0
CTX-M-15 59.3 68.0 75.0 60.0
CTX-M-27 8.7 12.0 1.3
Other types 8.0 8.0 11.3 40.0
Number of isolates 275 25 80 5
DANMAP 2011
As in previous years, CTX-M-15 dominated among ESBL-producing E. coli and K. pneumoniae isolates from urine 
and bloodstream infections from human patients, while CTX-M-1 and CTX-M-14 were present in a limited number 
of the human isolates only [Table 2]. CMY-2 was detected in some of the submitted AmpC producing E. coli isolates 
from both urine and blood, but it was not possible to calculate the prevalence of this enzyme since not all isolates 
were submitted to SSI. The most common ESBL-type among pig E. coli isolates was CTX-M-1 and only a small 
number of isolates were CTX-M-15 [Textbox 7]. Among the E. coli isolates from imported and Danish broiler meat, 
CMY-2 was most prevalent [Textbox 7]. The distribution of ESBL-types among animals and humans was therefore 
not consistent. However, CTX-M-15 producing E. coli from Danish pigs has been shown to belong to sequence 
types which have previously been detected in human patients [Hammerum et al. 2012. J Antimicrob Chemother. 67: 
2049–51]. Further studies are needed to quantify this risk of ESBL-producing E. coli of animal origin in relation to 
human health. 
Prior antimicrobial consumption is a risk factor for development of an infection with ESBL-producing 
bacteria. Consumption of ciprofloxacin and 2nd and 3rd generation cephalosporins has increased constantly 
in Danish hospitals for the last 10 years, further promoting the selection pressure for ESBL-producing bacteria 
in the hospitals [Textbox 8]. A reduction in antimicrobial consumption can lead to a reduction in resistant K. 
pneumoniae [Textbox 8, DANMAP 2010].
Infection with ESBL-producing bacteria frequently results in prolonged hospital stays with ensuing human and 
financial costs. Furthermore, empirical treatment on suspicion of septicaemia might be changed to a carbapenem 
(meropenem) [Textbox 8]. Carbapenems are the last resort antimicrobial agents for treatment of multi-resistant 
enterobacteria, and we should not expect new and more effective antibiotics to be introduced in the next decade. 
Furthermore, patients colonised or infected with carbapenem resistant enterobacteria have already been observed 
in Denmark [Textbox 11]. Consequently, infections may occur in Denmark for which no or limited treatment 
options exist. 
Dennis S. Hansen, Frank Hansen, Kurt Fuursted, Ulrik S. Justesen, Helga Schumacher, Claus Østergaard, 
Helle Krogh Johansen, Pia Littauer, Susanne H. Harzen, Jurgita Samulioniene, 
Ole Heltberg, Magnus Arpi and Anette M. Hammerum
 
For further information: Anette M. Hammerum (ama@ssi.dk)
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Klebsiella pneumoniae isolates from the Eastern part of Denmark (Zealand) is more resistant to 3rd 
generation cephalosporin, ciprofloxacin and gentamicin than isolates from the Western part (Funen 
and Jutland) 
Background: Extended-spectrum-lactamase (ESBL)-producing Klebsiella pneumoniae has been increasingly 
detected in Europe, Africa, America and Asia. Before 2007, the occurrence of 3rd generation cephalosporin 
resistance was low among K. pneumoniae isolated from bloodstream infections in Danish patients [EARRS 2007]. In 
the following years, 3rd generation cephalosporin resistant K. pneumoniae has been increasingly seen in Denmark 
[Textbox 9]. In the present study, the resistance pattern of K. pneumoniae isolates from different regions in Denmark 
was investigated.
Methods: Data on gentamicin, ciprofloxacin and 3rd generation cephalosporin (ceftazidime, ceftriaxone, 
cefpodoxime and cefotaxime) resistance in K. pneumoniae bloodstream and urine isolates from hospitalised patients 
in 2011 were collected from 12 of 13 Departments of Clinical Microbiology (DCM) in Denmark; 11 DCM working 
with primary health care isolates contributed data on antimicrobial resistance in urine isolates of K. pneumoniae 
[8.2 Klebsiella pneumoniae].
Results: The level of resistance to 3rd generation cephalosporin, ciprofloxacin and gentamicin was significantly 
higher in K. pneumoniae isolates from bloodstream infections and urinary tract infections from hospitalised patients 
in the Eastern part of Denmark (Zealand) than in the Western part (Funen and Jutland) (Figure 1a and Figure 
1b). The same tendency was observed in K. pneumoniae urine isolates from primary health care patients, where 
resistance to 3rd generation cephalosporins and fluoroquinolones (ciprofloxacin and nalidixic acid) was significantly 
higher in isolates from the Eastern part of Denmark (Zealand) than the Western part (Funen and Jutland).
Figure 1. The percentage of 3rd generation cephalosporin, ciprofloxacin and gentamicin resistance in 
Klebsiella pneumoniae blood (a) and urine (b) isolates from hospitalised patients at Zealand, and at Funen 
and in Jutland, respectively, in 2011 (with 95% confidence intervals).
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Discussion: The 3rd generation cephalosporin resistant K. pneumoniae isolates from October 2011 were 
investigated for ESBL-encoding genes as a part of the ESBL-prevalence study [Textbox 9]. The majority of the 
isolates in the ESBL-prevalence study were CTX-M-15 producing, but none of the isolates in the present study 
was further typed by molecular methods [Textbox 9]. In an earlier study, K. pneumoniae bloodstream isolates 
from 2008 were investigated for the presence of ESBL-genes, multi-locus sequence typed and PFGE typed [Lester 
et al. 2011, Int J Antimicrob Agents. 38: 180-2]. In the study by Lester et al. it was shown that the spread of 3rd 
generation cephalosporin resistant K. pneumoniae from bloodstream infections was mostly due to spread of two 
clones (ST15 and ST16) producing the ESBL-enzyme CTX-M-15 among hospitals in Zealand. Both clones were 
co-resistant to ciprofloxacin and the majority of the isolates belonging to the ST15 clones were also gentamicin 
resistant. The ST16 clone was first detected in Zealand in 2006 and seems to persist for very long [Lester et al. 2011, 
Int J Antimicrob Agents. 38: 180-2]. Further studies are needed to investigate if the high occurrence of resistance 
in K. pneumoniae isolates from Zealand in 2011 is due to persistence of the same clones as in 2008. An intervention 
study at Bispebjerg Hospital in 2010 showed that a reduction in the number of resistant K. pneumoniae isolates is 
possible when the prescription of antimicrobial agents is changed [Textbox 8, DANMAP 2010].
Line Skjøt-Rasmussen, Stefan S. Olsen and Anette M. Hammerum
Further information: Anette M. Hammerum (ama@ssi.dk)
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Carbapenemase producing enterobacteria
Background: Carbapenems is one of the only classes of antimicrobial agents that can be used for treatment of 
infections with multi-resistant bacteria such as ESBL-producing Klebsiella pneumoniae. Frequently, none or only 
suboptimal antimicrobial agents are available for the treatment of infections with carbapenemase producing 
enterobacteria (CPE). Resistance is caused by the presence of various carbapenemases of which the most frequently 
occurring are K. pneumoniae carbapenemase (KPC), Oxacillinase β-lactamase (OXA), Verona integron-encoded 
metallo-β-lactamase (VIM) and New Delhi metallo-β-lactamase (NDM). Recently, major outbreaks were reported 
from Holland (OXA-48), Italy (KPC-2) and Poland (KPC-2). Additionally, VIM- and KPC-producing bacteria 
occur endemically in Greece. The occurrence of NDM is particularly high in Pakistan and India, but cases have been 
reported from nearly all parts of the world. CPE (and other multi-resistant enterobacteria) comprise a particular 
problem as they can be carried in the intestine without causing symptoms. Antimicrobial treatment may contribute 
to the sustaining of the carrier state and lead to multiplication and increased excretion. Particularly in hospitals and 
nursing homes this may cause problems. The ECDC (European Centre for Disease Prevention and Control) and the 
CDC (Centers for Disease Control and Prevention) in the USA recommend CPE-screening of patients transferred 
from hospitals abroad and patients suspected of forming part of an outbreak. 
In recent years, Danish Departments of Clinical Microbiology (DCM) have, on a voluntary basis, submitted CPE 
isolates for verification and genotyping at Statens Serum Institut. We recently described 15 Danish CPE cases 
[EPI-NEWS No. 2012]. Data from this DANMAP report indicate that more cases might be present since several 
carbapenem resistant E. coli and K. pneumoniae isolates were detected in 2011. Currently, Denmark does not 
systematically screen for and monitor CPE. CPE are not reportable in Denmark.
 
Danish CPE cases (Table 1): The first case of VIM-producing K. pneumoniae was detected in Denmark in 2008 
[Hasman et al. 2010. Int J Antimicrob Agents. 36: 468–9] and in 2010 the second case was seen. Both patients had 
previously been admitted to hospitals in Greece. In 2009, the first cases of KPC-2-producing K. pneumoniae in 
Denmark were observed [Hammerum et al. 2010. Int J Antimicrob Agents. 35: 610–2]. These patients had also 
been admitted to Greek hospitals. In 2010, the first Danish case of NDM-1 was seen [Hammerum et al. 2010. 
Lancet Infect Dis.10: 829–30]. The patient had been admitted to a hospital in Bosnia-Herzegovina and was one of 
the first NDM-1 cases in Europe to be linked to Balkan. In 2011, two cases of NDM-1 were found; one was linked 
to Egypt, the other to Pakistan [Nielsen et al. 2012. J Antimicrob Chemother. 67: 2049–51]. Furthermore, seven 
cases of OXA-48 in patients from Libya were observed in 2011. During the stay in Denmark, one patient developed 
sepsis and meningitis with the OXA-48-producing K. pneumoniae in the blood and spinal fluid. The patient was 
treated with colistin and fosfomycin with full resolution of symptoms and recovery [Hammerum et al. 2012. Int J 
Antimicrob Agents. 40: 191–2]. With the exception of one case, the known Danish CPE cases were all imported. 
There is no knowledge of secondary spreading at Danish hospitals or nursing homes.
Table 1. The 15 known Danish cases of carbapenemase-producing enterobacteria
Enzyme Species No. cases Origin Year
VIM K. pneumoniae 1 Greece 2008
VIM K. pneumoniae 1 Greece 2010
KPC-2 K. pneumoniae 2 Greece 2009
KPC-2 K. pneumoniae 1 Unknown origin 2011
NDM-1 K. pneumoniae 1 Bosnia-Herzegovina 2010
NDM-1 K. pneumoniae 1 Egypt 2011
NDM-1 E. coli 1 Pakistan 2011
OXA-48 K. pneumoniae 7 Libya 2011
DANMAP 2011
Conclusion: Of the 15 CPE cases observed in Denmark 2008–2011, 10 were detected in 2011 and most of these 
were imported from Libya from patients sent to Denmark to receive medical assistance for injuries during the 
Libyan conflict. The increasing occurrence of CPE in Europe and now also in Denmark is worrying. Not only 
are these infections extremely difficult to treat with antimicrobial agents, the bacteria also have the potential to 
establish and spread endemically at hospitals and in the community. This is in line with what was previously seen 
for ESBL-producing bacteria. Due to the seriousness of this issue, the ECDC encourages systematic monitoring of 
these bacteria in all European countries. It is essential to be particularly aware of any occurrence of multi-resistant 
enterobacteria in patients transferred after admission to hospitals abroad. 
Anette M. Hammerum 
For further information: Anette M. Hammerum (ama@ssi.dk)
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8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen of 
immunocompromised individuals. P. aeruginosa typically 
infects the pulmonary tract, urinary tract, burns, wounds, 
and also causes other bloodstream infections. It is the 
most frequent coloniser of medical devices (e.g. catheters). 
P. aeruginosa infection is a serious problem in patients 
hospitalised with cancer, cystic fibrosis and burns. The 
case fatality rate in these patients is high. P. aeruginosa 
is intrinsically resistant to the majority of antimicrobial 
agents. The antimicrobial classes which can be used for 
treatment include some fluoroquinolones (e.g. ciprofloxacin 
and levofloxacin), aminoglycosides (e.g. gentamicin, 
tobramycin and amikacin), some beta-lactams (piperacillin-
tazobactam, ceftazidime, and carbapenems) and colistin.
P. aeruginosa blood isolates obtained from hospitalised 
patients
For P. aeruginosa, this report includes data from 12 
Departments of Clinical Microbiology (DCM), representing 
95% of the Danish population. The antimicrobial 
susceptibility of approximately 400 P. aeruginosa isolates 
from blood was reported in 2011. Resistance to all the 
tested antimicrobial agents was at the same level as in 
2010 (Figure 8.4). The occurrence of resistance was low 
compared to most of the other countries reporting to 
EARS-Net [EARS-Net 2010].
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
8.4  Streptococci 
Streptococci are part of the normal commensal flora of 
the mouth, skin, intestine, and upper respiratory tract of 
humans, but streptococci also cause infections such as 
otitis media, tonsillitis, bacterial pneumonia, bacteremia/
sepsis, endocarditis and meningitis.
In this report, data on resistance in invasive (from 
blood or cerebrospinal fluid) streptococcal isolates were 
obtained from the Neisseria and Streptococcus Reference 
laboratory covering all DCM in Denmark. In Denmark, 
penicillins and macrolides are often used for treatment 
of infections caused by streptococci. All invasive non-
duplicate Streptococcus pneumoniae and group A, B, C 
and G streptococci were susceptibility tested against 
erythromycin and penicillin. 
Streptococcus pneumoniae
Streptococcus pneumoniae is a leading cause of bacterial 
pneumonia, otitis media, bacteraemia and meningitis. In 
2011, susceptibility testing was performed on 901 non-
duplicate S. pneumoniae isolates from invasive infections 
(Figure 8.5).
Macrolide resistance in S. pneumoniae isolates from 
blood and cerebrospinal fluid was 4.9% (n = 44) in 2011 
compared to 4.2% in 2010. As can be seen in Figure 8.5 
macrolide resistance has been fluctuating but relatively 
stable around 6% from 2000 to 2008, then decreased 
significantly from 6.6% in 2008 to 3.6% in 2009 and 
now increasing again. The 44 macrolide resistant S. 
pneumoniae from 2011 belonged to 11 different serotypes 
and the most commonly found serotypes were type 19A 
(36.4%), 15A (20.5%) and 6C (15.9%). 
The percentage of S. pneumoniae invasive isolates being 
non-susceptible (resistant and intermediary resistant) to 
penicillin was 4.8% (n = 43) in 2011 compared to 3.5% 
in 2010. The 43 penicillin non-susceptible S. pneumoniae 
from 2011 belonged to 10 different serotypes, and the 
most commonly found serotypes were type 19A (46.5%), 
15A (16.3%) and 6C (9.3%). One of the 901 tested isolates 
(0.2%) was resistant to penicillin (MIC > 2 μg/ml).
The occurrence of resistance to erythromycin and 
penicillin was similar to the occurrence in other 
Scandinavian countries but much lower than reported in 
many of the other European countries reporting to EARS-
Net [EARS-Net 2010]. 
Group A streptococci
In 2011, 164 invasive GAS (Streptococcus pyogenes) 
isolates were susceptibility tested. As in previous years, 
no resistance to penicillin in GAS isolates from invasive 
infections was reported in 2011. Erythromycin resistance 
was detected in two isolates (1.2%) as compared to two of 
155 (1.3%) in 2010.
Group B, C and G streptococci
As in previous years, no resistance to penicillin was 
reported in isolates from group B, C or G invasive 
infections in 2011. In 2011, 124 invasive group B 
Figure 8.4. Resistance (%) in Pseudomonas aeruginosa 
blood isolates from humans, Denmark
DANMAP 2011
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2011
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streptococci (Streptococcus agalactiae) isolates from 
invasive infections were tested. Erythromycin resistance 
was detected in 20 isolates (20.2%) compared to 12.7% in 
2010.
Forty-nine isolates of invasive group C streptococci 
were tested in 2011. One isolate (2.0%) was resistant to 
erythromycin compared to one isolate (1.9%) in 2010.
Eleven (8.0%) of the tested 138 invasive group G 
streptococci were resistant to erythromycin compared to 
12% in 2010.
Lotte M. Lambertsen
Figure 8.5. Resistance (%) in Streptococcus pneumoniae 
blood and spinal fluid isolates from humans, Denmark
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8.5  Enterococci
Enterococci are part of the normal intestinal flora of 
both humans and animals but can also cause infections. 
Important clinical infections caused by Enterococcus 
species include urinary tract infections, bacteraemia 
and bacterial endocarditis. E. faecalis and E. faecium can 
cause life-threatening infections in humans, especially 
in the hospital environment. The naturally high level of 
antimicrobial resistance found in E. faecalis and E. faecium 
makes infections difficult to treat. Antimicrobial therapy 
for serious enterococcal infections requires the use of 
synergistic combinations of a cell-wall-active agent such as 
penicillin (ampicillin) and an aminoglycoside (gentamicin) 
or a glycopeptide (vancomycin). 
For E. faecalis and E. faecium, data from 12 of the 13 DCM 
were obtained, representing 95% of the Danish population. 
Enterococcus faecium and Enterococcus faecalis blood 
isolates obtained from hospitalised patients
In 2011, 619 E. faecium isolates and 513 E. faecalis isolates 
from blood were tested for antimicrobial susceptibility.
As in previous years, most of the E. faecium isolates from 
bloodstream infections were ampicillin resistant. In 2011, 
93% of the E. faecium isolates were resistant to ampicillin. 
Treatment with fluoroquinolones, cephalosporins or 
carbapenems has been described as a risk factor for 
development of an E. faecium infection. An increasing 
consumption of these antimicrobial agents has been 
observed in hospitals in Denmark during the past 
years. The antimicrobial selection pressure in a hospital 
environment might be a reason for the high level of 
ampicillin resistant E. faecium as a cause of bloodstream 
infections.
 
One of the DCM (Aalborg Hospital) tested all enterococcal 
blood isolates for high-level gentamicin resistance 
(HLGR). Among the tested E. faecalis isolates at DCM 
Aalborg, 31% were HLGR, whereas 74% of the tested E. 
faecium isolates were HLGR. The occurrence of HLGR E. 
faecalis and HLGR E. faecium was similar to or higher than 
the occurrence detected in many countries reporting to 
EARS-Net in 2010 [EARS-Net 2010].
In 2011, vancomycin resistance was detected in 1.3% of the 
E. faecium isolates (n = 8), whereas none of the E. faecalis 
isolates from bloodstream infections were vancomycin 
resistant. Four of the vancomycin resistant E. faecium 
isolates were detected at DCM Aarhus and these isolates 
were part of an outbreak of vancomycin resistant (vanA) 
E. faecium. The occurrence of vancomycin resistant E. 
faecium and vancomycin resistant E. faecalis was at the 
same level or lower compared to most other countries in 
Europe [EARS-Net 2010].
Since 2005, presumable vancomycin resistant enterococcal 
isolates from invasive and non-invasive infections have 
been sent from the DCM to SSI for national surveillance 
on vancomycin resistant enterococci. Besides the vanA E. 
faecium isolates from the outbreak at Aarhus University 
hospital, 17 vanA E. faecium, and 2 vanB E. faecalis isolates 
were received during 2011. 
As described above, most of the E. faecium isolates from 
bloodstream infections were resistant to ampicillin; these 
infections can therefore not be treated with ampicillin but 
will often be treated with vancomycin or linezolid instead. 
This might in part, together with the increased number 
of MRSA infections, explain the increased consumption 
of glycopeptides (vancomycin) and linezolid in hospitals, 
which has been observed during the last years. 
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
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8.6  Staphylococcus aureus 
Staphylococcus aureus is part of the normal flora from 
skin and mucosa in approximately 50% of humans. Some 
people only carry S. aureus intermittently whereas others 
carry S. aureus for longer time. However, in addition S. 
aureus also cause infections ranging from superficial skin 
infections i.e. impetigo and boils, to invasive infections 
such as post-operative wound infections, infections 
related to intravenous catheters and prosthetic devices, 
bacteraemia, osteomyelitis, endocarditis and arthritis. 
In Denmark, Methicillin Resistant S. aureus (MRSA) 
has been both laboratory and clinical notifiable since 
November 2006. In recent years, MRSA belonging 
to clonal complex 398 (CC398), has attracted special 
attention as this type has been closely connected to 
livestock animals, especially pigs, and increasingly affects 
people in direct contact with pigs.  
Surveillance of bacteraemia
In 2011, 1,525 S. aureus bacteraemia cases corresponding 
to 24.6 per 100,000 inhabitants were reported from 
the Departments of Clinical Microbiology (DCM) in 
Denmark. Twenty-one (1.4%) of the cases were caused 
by MRSA. This is at the same level as in previous 
years and very low compared to most of the other 
countries participating in EARS-Net [EARS-Net 2010]. 
Antimicrobial resistance in S. aureus bacteraemia isolates 
from 2006–2011 are presented in Table 8.5. The highest 
frequency of resistance other than to penicillins was 
observed for fusidic acid (13.2%), erythromycin (6.5%), 
clindamycin (5.8%) and norfloxacin (3.6%). Susceptibility 
to all tested antimicrobials was at the same level as in 
2010. Resistance to at least 1, 2 or 3 other antimicrobials 
in addition to penicillin was demonstrated in 15%, 6% and 
1% of the cases, respectively. 
Surveillance of Methicillin Resistant S. aureus 
In 2011, 1,292 new MRSA cases were detected (23.3 per 
100,000 inhabitants). This is the highest number of cases 
observed in over 25 years (Figure 8.6).  A case was a person 
found positive for the first time with a specific MRSA 
strain regardless whether the patient was infected or 
colonised. 
In 2011, the number of MRSA increased by 18% and 
thereby continued the large increase seen from 2009 to 
2010 (34%). In 2011, eleven persons were found with their 
second case of MRSA (i.e. MRSA of a new subtype) and 
one person with a third case. At the time of diagnosis, 681 
(53%) of the new cases were found due to infection, this 
proportion was lower than in 2010 (646 cases (59%)). The 
proportion of bloodstream infections with MRSA was 1.4% 
in 2011 (see surveillance of S. aureus bacteraemia). The 
incidence rate of new MRSA cases per year for each DCM 
in the last four years is shown in Table 8.6. The incidence 
varied from 13.5 per 100,000 inhabitants in Århus to 38.1 
per 100,000 inhabitants in the greater Copenhagen area 
(Greater Copenhagen was served by three DCM, and is 
shown as one).
Table 8.5. Resistance (%) in isolates from Staphylococcus aureus bacteraemia cases, Denmark DANMAP 2011
Antimicrobial agent 2006%
2007
%
2008
%
2009
%
2010
%
2011
%
Methicillin 1.4 0.6 1.3 1.6 1.4 1.4
Penicillin 80 78 77 77 75 77
Erythromycin 5 4 5 7 5 7
Clindamycin 4 3 4 6 4 6
Tetracycline 3 2 3 2 3 2
Fusidic acid 10 9 9 9 13 13
Rifampicin <1 <1 <1 <1 <1 <1
Norfloxacin 2 1 2 2 3 4
Kanamycin 1 <1 1 1 1 <1
Linezolid 0 0 0 0 0 0
Mupirocin 0 <1 <1 <1 <1 <1
Trimethoprim-sulfamethoxazole nt nt nt nt nt <1
Number of isolates 1329 1345 1344 1480 1418 1525
nt = not tested
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Figure 8.6. Number of MRSA cases, with a three years moving average, Denmark
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Table 8.6. Incidence rate of new MRSA cases per 100,000 inhabitants per Department of Clinical Microbiology, Denmark
a) Rigshospitalet (national referral hospital), Hvidovre and Herlev
b) Statens Serum Institut is no longer serving former Roskilde County
c) Including isolates from former Roskilde County
Department of Clinical Microbiology 2008 2009 2010 2011
Greater Copenhagen(a) 23.6 26.9 30.9 38.1
Hillerød 21.8 16.5 27.0 18.7
Statens Serum Institut(b) 17.6 17.6 – –
Slagelse(c) 19.3 15.1 17.9 28.6
Næstved 12.1 8.8 19.8 18.1
Odense 12.9 8.9 16.3 14.0
Sønderborg 11.1 12.8 25.8 23.8
Esbjerg 8.8 6.2 11.8 18.0
Vejle 20.0 11.6 10.6 16.3
Herning 7.7 7.3 15.1 13.7
Århus 6.0 10.1 11.6 13.5
Viborg 18.5 9.1 11.0 17.3
Aalborg 10.7 7.6 16.6 21.0
Denmark total 15.5 14.7 19.8 23.3
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Table 8.7. Epidemiological classification of new MRSA cases, Denmark
Epidemiologic classification Exposure 2010 2011
No. of cases(a) No. (%) of cases with infections No. of cases
No. (%) of cases 
with infections 
Imported (IMP) 247 163 (66) 253 145 (57)
Hospital-acquired (HA) 62 34 (55) 61 32 (53)
Health-care associated, 
community onset (HACO) with health care risk 169 187
      with known exposure 40 16 (40) 44 10 (23)
      without known exposure 129 116 (90) 143 122 (85)
Health care worker 35 8 (23) 40 7 (18)
Community-acquired (CA) without health care risk 578 751
      with known exposure 331 100 (30) 454 111 (24)
      without known exposure 247 210 (85) 297 254 (86)
Unclassified 0 0 (0) 0 0 (0)
DANMAP 2011
The total number of cases and the number of cases 
presenting with infection according to epidemiological 
classification are shown in Table 8.7. Most of the cases 
(80%) were acquired in Denmark. The epidemiological 
classification of MRSA infections 2006–2011 is shown 
in Figure 8.7. Only 10 of the HACO infections could be 
associated with a known exposition, 4 from hospitals, 4 
from nursing homes and the remaining 2 from other social 
institutions. The remaining 122 cases of infection classified 
as HACO were registered with a possible association to 
health-care institutions (within the last 12 months) but 
without known exposition; of these, 69 cases were with an 
association to hospitals and 37 cases with an association 
to nursing homes and private home care. The remaining 
16 cases were associated to other social institutions. The 
number of infections classified as community-acquired 
(CA) was 365 in 2011 (Figure 8.7). The proportion of 
CA-infections with known exposure was at the same level 
(30%) as in 2010.
Molecular typing of the MRSA strains
In total, spa typing revealed 193 different strain types. 
The number of isolates belonging to the 10 dominating 
spa types isolated in 2011 is shown in Table 8.8. They 
constituted 57% of the total number of MRSA isolates. 
Seven spa types constituted 49% of the 681 clinical 
infections with MRSA (out of 154 different spa types 
associated with clinical infection). Most prevalent spa 
types causing clinical infections at time of presentation 
were t008, t019, t002, t034, t024, t044 and t127. Of the 438 
strains isolated from asymptomatic carriers, t034 was the 
most prevalent spa type (n = 62), followed by t002 (n = 48), 
t008 (n = 36), t304 (27) and t019 (n = 25). The PVL gene 
was demonstrated in 42% of the infections and in 25% of 
the asymptomatic carriers.
Figure 8.7. Number of MRSA infections according to epidemiological classification, Denmark
DANMAP 2011
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a) CC = Clonal complex
DANMAP 2011
Table 8.8. The ten most prevalent spa types demonstrated 
in MRSA cases, Denmark 2011
spa type CC group(a) No. of cases
No. causing infections 
(%)
t034 CC398 130 49 (38)
t008 CC8 122 74 (61)
t002 CC5 119 56 (47)
t019 CC30 97 59 (61)
t024 CC8 68 36 (53)
t044 CC80 58 34 (59)
t127 CC1 46 27 (59)
t304 CC8 37 8 (22)
t032 CC22 32 15 (47)
t223 CC22 29 14 (48)
Live-stock associated MRSA
There was no targeted screening for CC398 in 2011. The 
total number of CC398 isolates increased to 164 (42 in 
2009, 111 in 2010). The most frequent spa type related 
to CC398 was type t034 (n = 130). Forty-nine t034 cases 
presented with infections (Table 8.8).  MRSA isolates 
carrying the new mecA homologue mecAlga251, now 
proposed called mecC, were demonstrated in 37 cases (9 
in 2009, 21 in 2010). The preliminary data from 2012, 
however, indicate that the number is stabilizing/declining. 
The livestock association for mecC MRSA may not be 
as strong as for CC398 MRSA but two of the cases were 
considered associated with livestock contact. In addition, 
screening of animals in close contact with mecC positive 
patients in Region Zealand confirmed a possible bovine 
and ovine association in two cases.
Eleven (0.7%) of the bacteraemia cases belonged to CC398. 
None of these were MRSA and association to pig farming 
is not known. The corresponding numbers were eleven in 
2010, ten in 2009, six in 2008 and five in 2007.
Resistance among MRSA isolates
The occurrence of resistance to erythromycin and 
clindamycin decreased when comparing all MRSA isolates 
in 2011 with all MRSA isolates in 2010 (Table 8.9). The 
resistance pattern varied considerably between spa types 
(Table 8.9). In 2011, 100% of CC398 spa type t034 isolates 
were resistant to tetracycline and 93% of CC8 spa type 
t008 were resistant to erythromycin and clindamycin. In 
contrast, the majority of t019, a primarily community-
acquired spa type, continued to be susceptible to all tested 
antimicrobial agents except for beta-lactams. Even though 
differences in antimicrobial resistance were demonstrated 
between spa types, the success of antimicrobial treatment 
cannot be predicted based on spa type or epidemiological 
classification. Resistance to at least 1, 2 or 3 other 
antimicrobials in addition to cefoxitin/penicillin was 
demonstrated in 69%, 53% and 34% of the cases, 
respectively. The most common resistance patterns and any 
frequent spa types are shown in Table 8.10.
Andreas Petersen, 
Robert L. Skov and Anders Rhod Larsen
DANMAP 2011
Table 8.9. Resistance (%) in the six most prevalent spa types demonstrated in MRSA cases compared with all MRSA 
cases, Denmark 2011
spa type t034 t008 t002 t019 t024 t044 All cases
Clonal complex CC398 CC8 CC5 CC30 CC8 CC80
% % % % % % %
Erythromycin 35 60 41 0 93 3 37
Clindamycin 82 16 32 0 93 3 34
Tetracycline 100 4 16 1 3 60 28
Fusidic acid 0.8 7 25 0 32 90 13
Rifampicin 0 0 2 1 1 0 1
Norfloxacin 34 59 34 2 43 5 28
Kanamycin 3 62 24 0 1 93 28
Linezolid 0.8 0 0 0 0 0 <<1
Mupirocin 0 2 0.8 0 0 0 0.4
Trimethoprim-sulfamethoxazole 0 0 0 0 0 0 1
Number of isolates 130 122 119 97 68 58 1292
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Table 8.10. Resistance markers in addition to cefoxitin demonstrated in MRSA cases, Denmark 2011
a) T=tetracycline, N=norfloxacin, F=fusidic acid, K=kanamycin, E=erythromycin, C=clindamycin, R=rifampicin
No. of markers No. of cases Frequent patterns (no of isolates) Any frequent spa type (no of isolates)
0 403 – –
1 208 N(57) t032(17)
T(55) t034(18)
F(45) t002(13), t008(8)
K(43) t355(11)
2 239 E,C(83) t024(31)
C,T(35) t034(32)
N,K(27) t008(9)
3 286 E,N,K(65) t008(36), t657(19)
E,C,T(64) t034(30)
E,C,N(47) t002(13), t032(13)
T,F,K(33) t044(29)
4 128 E,C,T,K(35) t127(19), t437(7)
E,C,N,K(29) t008(12)
E,C,F,N(21) t024(17)
5 22 E,C,T,N,K(12) t008(3), t045 (3)
6 4 E,C,T,R,N,S(2) t4866(2)
7 2 E,C,T,F,R,N,K,S(2) t037(2)
116                       
                   
DANMAP 2011  
RESISTANCE IN HUMAN CLINICAL BACTERIA8. Textbox 12
Adaptive evolution of livestock-associated methicillin-resistant Staphylococcus aureus CC398
Background: Recent reports of methicillin-resistant Staphylococcus aureus (MRSA) CC398 carriage in livestock, 
particularly pigs, and carriage/infections among people with close and frequent livestock contact has provided 
evidence of the existence of a true MRSA reservoir in livestock. This livestock-associated MRSA (LA-MRSA) 
CC398 clone is efficiently transmitted to people with close and frequent livestock contact but is a poor long-term 
colonizer of humans and is significantly less transmissible to and between people with no exposure to livestock. In 
Denmark, ~90% of LA-MRSA CC398 carriage/infections in humans can be linked to livestock production, whereas 
~10% of the cases have no direct or indirect contact to livestock.
Methicillin-susceptible S. aureus (MSSA) CC398 has also been identified in people with no prior exposure to 
livestock, including communities in New York, Caribbean islands, and the Amazonian forest of French Guiana.
These observations suggest that distinct S. aureus CC398 strains circulate in livestock and humans and that 
adaptation to different hosts has occurred. 
To test this hypothesis, we investigated the evolutionary relationships among 90 S. aureus CC398 isolates recovered 
from livestock and humans around the world.
Materials and methods: A detailed phylogenetic (family) tree of the 90 isolates was constructed based on whole-
genome sequence data, and potential genetic markers of adaptation were mapped onto the tree.
Results and discussion: The 90 S. aureus CC398 isolates clustered into two major groups: one consisting of 
mainly MSSA isolates from humans and the other comprising MRSA and MSSA isolates from both humans 
and livestock. The phylogeny supports that livestock-associated S. aureus CC398 strains are the descendants of a 
human-to-animal host jump by an MSSA CC398 strain. In the livestock reservoir, MSSA CC398 underwent rapid 
diversification accompanied by loss of several genes that encode modulators of human innate immunity (e.g., scn) 
and acquisition of the tetracycline resistance gene tet(M). Importantly, the phylogeny suggests that the methicillin-
resistant phenotype was acquired after adaptation to livestock through local acquisition of the mecA gene by 
geographically distinct MSSA CC398 strains. The different stages in the adaptive evolution of S. aureus CC398 are 
illustrated in Figure 1.
Figure 1. Stages in the adaptive 
evolution of S. aureus CC398. The 
original MSSA CC398 strains were, 
and still are, circulating in the human 
population (stage 1). The human-to-
animal host jump by an MSSA strain 
was accompanied by loss of scn and 
acquisition of tet(M) (stage 2). In the 
livestock reservoir, geographically 
distinct MRSA CC398 strains have 
emerged through acquisition of the 
methicillin resistance gene mecA (stage 
3). LA-MRSA CC398 strains are able 
to reacquire the scn gene, which may 
be a first step in the adaption back to 
humans (stage 4).
Human-to-animal host 
jump by MSSA ST398 -
loss of scn and 
acquisition of tet(M)
Emergence of LA-MRSA ST398 -
acquisition of mecA
2
Human-adapted 
MSSA ST398
1
3
Animal-to-human host 
jump by MRSA ST398-
acquisition of scn?
4
The loss of several functions associated with human adaptation may explain why LA-MRSA CC398 has lost part of 
its colonization and transmission ability in humans. On the other hand, our findings show that LA-MRSA CC398 
is able to reacquire the same genes (e.g., scn), probably as a result of lateral gene transfer from a bacterial member 
of the human microbiome. Additional studies accessing the risk for spread of scn-positive LA-MRSA CC398 strains 
from the livestock reservoir into the community are currently under way.
Lance Price, Marc Stegger, Henrik Hasman, Maliha Aziz, Andrew Waters, Ajmes Schupp,  Elizabeth Driebe, 
Cindy Liu, Jesper Larsen, Paal Skytt Andersen, Robert L. Skov and Frank M. Aarestrup et al.
For further information: Robert L. Skov (rsk@ssi.dk) and Frank M. Aarestrup (fmaa@food.dtu.dk)
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Methicillin resistant Staphylococcus aureus (MRSA) in Danish pig herds, in pigs and cattle at slaughter, 
and in Danish and imported retail meat 
Background: Methicillin resistant Staphylococcus aureus (MRSA), especially belonging to the clonal complex 
CC398, has since 2003 emerged in livestock worldwide. In 2009, the prevalence in Danish pigs at slaughter was 13% 
[DANMAP 2009]. As MRSA can be transmitted between animals during transportation and prior to slaughter, the 
prevalence found in the slaughter house may not be equivalent to the prevalence of MRSA positive farms [Broens et 
al., Vet. J. 2011. 189: 302–5]. Therefore, the prevalence in the pig herds was investigated in 2010 and a prevalence of 
16% was found. A mecA homologue LGA251 has been found in cattle and sheep in Denmark [García-Álvarez et al., 
2011. Lancet Infect Dis.11: 595–603] but the prevalence among these species are unknown.
In 2011, the prevalence of MRSA was investigated in pig herds, pigs and cattle at slaughter and in retail meat. The 
aim was to investigate the prevalence of MRSA at the pig farm level and compare to previous years. The prevalence 
in cattle at slaughter was also investigated. Meat samples were collected to follow changes in prevalence when 
compared to data from previous years.
Materials and methods: During February through October 2011, pools of five nasal swab samples (n = 79) were 
taken from five slaughter pigs in five different pens in 79 farms in Denmark and nasal swabs were collected from 
777 pigs at slaughter, as previously described [DANMAP 2009 and DANMAP 2010]. Cattle, mainly young bulls (n 
= 179), were tested at slaughter by taking skin swabs between leg and udder/testis, representing at least 160 different 
farms as previously described [DANMAP 2010]. From January through November 2011, samples of broiler meat 
(133 Danish, 147 imported), beef (122 Danish, 114 imported) and pork (226 Danish, 103 imported) meat samples 
were collected randomly in retail stores and outlets in all regions of Denmark. 
The samples were randomly selected; for pig farms, each farm was sampled only once. For cattle and pigs sampled at 
slaughter, one animal represented one farm and no herds were sampled more than once in the same month.
MRSA was isolated from each pool of nasal swabs, single swabs, skin swabs or from 25 g of meat after pre-
enrichment in Mueller-Hinton medium with 6.5% NaCl followed by selective enrichment in tryptone soya broth 
supplemented with 4 mg/L cefoxitin and 75 mg/L aztreonam. Ten µl were transferred to brilliance MRSA agar and 
colonies with S. aureus morphology were verified by PCR and selected isolates were spa typed.
Results and discussion: Thirteen (16%) of the pig farms were positive for MRSA, this was at the same level as in 
2010. Six isolates were spa typed and all except one isolate had spa types corresponding to CC398. Surprisingly, the 
prevalence of MRSA in pigs at slaughter (44%) was significant higher than in 2009 (13%) and also significant higher 
than in the pig herds. One hundred and sixty-eight isolates from pigs at slaughter were spa typed and most isolates 
belonged to CC398 (94%) as found previously. 
Figure 1. Occurrence (%) of MRSA in meat, Denmark
DANMAP 2011
Note: ND (Not determined) indicate that the isolates were not spa typed
a) Each year, approximately 1,000 samples are collected evenly distributed between the six categories of meat
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No MRSA was found among the 179 cattle at slaughter including the mecA homologue LGA251. The absence of 
MRSA in cattle may be due to the sampling method or that the cattle at slaughter mainly being young bulls as 
described in DANMAP 2010. The prevalence was highest in imported broiler meat (31%) and had increased 
significantly when compared to previous years, followed by Danish pork (10%), imported pork (5%), imported 
beef (4%) and Danish beef (0.8%). For the first time MRSA was detected in Danish broiler meat, the isolate could 
originate from broilers, but an investigation of MRSA in broilers in 2010 did not detect any [DANMAP 2010]. 
Forty-six of the isolates from meat were spa typed (Figure 1). Even though spa types corresponding to CC398 
were most prevalent, other spa types corresponding to other clonal complexes were observed such as CC127 
in Danish pork a clonal complex often found in pork in Italy but also found in Danish pigs at slaughter in 2009 
[Battisti et al. 2010. Vet Microbiol. 142: 361–6]. 
MRSA CC398 was found in 164 human cases in 2011, the majority in persons with close contact to pigs or being 
a household member. In 24 cases no such direct contact could be established even when specifically asked. The 
majority of the 24 cases were in persons living in rural areas with known occurrence of MRSA CC398 in pigs. 
There are still no sign of spread of CC398 to urban areas.
Conclusions:  The prevalence of MRSA in Danish pig farms (16%) was at the same level as in 2010, but the 
level in pigs at slaughter had dramatically increased which could reflect a higher in herd prevalence increasing 
the transmission between pigs during transportation and before slaughter. This was further supported by an 
increasing occurrence in Danish pork suggesting the pork production chain being more contaminated compared 
to previous years. In meat, MRSA in imported broiler meat was found in a significantly higher prevalence 
compared to 2010, but so far meat is not considered a source for human infection. The relatively frequent 
occurrence of MRSA in meat combined with very few cases in urban areas makes it safe to conclude that there is 
very little if any risk for meat being a risk for contracting MRSA CC398.
Pigs still seem to be the most important reservoir for MRSA CC398 and the in herd prevalence may have 
increased.
Yvonne Agersø, Anne Mette Seyfarth and Andreas Petersen
For further information: Yvonne Agersø,  E-mail: yvoa@food.dtu.dk
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Resistance in diagnostic submissions from animals
The DANMAP programme monitors antimicrobial 
susceptibility in Escherichia coli O149 and Staphylococcus 
hyicus from diagnostic submissions from pigs, as well as in 
E. coli F5 (K99) from diagnostic submissions from cattle. 
E. coli was isolated from faecal samples, typically from pigs 
or calves with diarrhoea, and Staphylococcus hyicus was 
isolated from clinical submissions from skin infections in 
pigs.
Most isolates from diagnostic submissions originated from 
animals in antimicrobial therapy or with a history of recent 
antimicrobial therapy. A higher frequency of resistance 
is therefore expected in bacteria from these diagnostic 
submissions compared to bacteria originating from healthy 
animals sampled at slaughter.
In 2011, 31 E. coli O149 isolates from pigs were collected. 
Since relatively few E. coli F5 (K99) isolates from cattle 
and Staphylococcus hyicus isolates from pigs are available 
each year, the overall results of the susceptibility testing 
are presented for two and three year periods, respectively. 
During 2010–2011, 25 E. coli F5 (K99) isolates from cattle 
were collected, and 30 Staphylococcus hyicus isolates from 
pigs were collected during the period 2009–2011.
E. coli isolates resistant to three or more of the ten 
different antimicrobial classes included in the test panel 
were considered multi-resistant (see definition of multi-
resistance and the included antimicrobial classes in section 
10.5).
 
The distribution of MICs among E. coli O149 and 
Staphylococcus hyicus from pigs and E. coli F5 (K99) from 
cattle are presented in the web annex (Table A9.1, A9.2 and 
A9.3). 
9.1  Escherichia coli
Pigs
Trends in resistance to the selected antimicrobial agents in 
E. coli O149 isolates from pigs are presented in Figure 9.1. 
The isolates were mainly from weaners with diarrhea (>7.5 
to 30 kg). 
In 2011, only one isolate (3%) was fully susceptible, 
where as 96% of the isolates were multi-resistant. As in 
previous years, high levels of resistance were found to 
tetracycline (71%), sulfonamide (74%) and streptomycin 
(87%) (Figure 9.1). Sulfonamide and streptomycin are 
not used for weaning pig diarrhoea, and the consumption 
in weaners has been stable at a low level (Figure 4.4).  
However, the resistance to these agents may be co-selected 
with tetracycline resistance, and tetracyclines are the 
most common antimicrobial agents used for weaning pigs 
(Figure 4.4). 
The consumption of quinolones has been at a very low 
level in the pig production since 2003 (web annex, Table 
A4.2), and from 2010 to 2011 resistance towards nalidixic 
acid decreased significantly from 21% to 3% (Figure 
9.1).  In contrast, a significant increase in the proportion 
of isolates resistant to trimethoprim (51% to 77%) was 
observed from 2010 to 2011 (data not presented).
In 2011, none of the 31 E. coli O149 isolates were resistant 
to cefotaxime and ceftiofur. 
Figure 9.1. Resistance (%) in Escherichia coli O149 from 
diagnostic submissions from pigs, Denmark
DANMAP 2011
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Cattle
In cattle, E. coli F5 (K99) was almost entirely isolated from 
diagnostic submissions from calves with diarrhea.
In 2010–2011, only one isolate (<1%) was fully susceptible 
to all antimicrobial agents included in the test panel, where 
as 72% of the isolates were multi-resistant.
There were no significant changes in the level of resistance 
to any of the antimicrobial agents included in the panel 
among isolates from 2010–2011 compared to the isolates 
from 2009.  As in previous years, high levels of resistance 
were found to tetracycline (80%) and ampicillin (96%) but 
also resistance to sulfonamide (52%) and streptomycin 
(60%) were common (Table 9.2). The most important 
antimicrobial agents used for systemic treatment in calves 
were tetracyclines and macrolides (Figure 4.7). 
 
The usage of quinolones to calves has remained at a very 
low level since 2003 (web annex, Table AP4.3). The level of 
quinolone resistance decreased from 2009 (31%), to 2010–
2011, where 20% of the diagnostic E. coli isolates from 
cattle were resistant to nalidixic acid and ciprofloxacin. A 
similar decrease in quinolone resistance was observed in 
the diagnostic E. coli O149 isolates from pigs.
During 2010–2011, none of the E. coli F5 (K99) isolates 
were resistant to ceftiofur, whereas two isolates (4%) were 
resistant to cefotaxime (Table 9.2).
Table 9.2. Resistance (%) among Escherichia coli F5 (K99) 
from diagnostic submissions from cattle, Denmark
Antimicrobial agent
2009 2010–2011
% %
Tetracycline 83 80
Chloramphenicol 17 24
Florfenicol 2 0
Ampicillin 92 96
Ceftiofur 0 0
Cefotaxime 2 4
Trimethoprim 33 20
Sulfonamide 52 52
Streptomycin 52 60
Gentamicin 0 4
Neomycin 12 20
Apramycin 0 4
Ciprofloxacin 31 20
Nalidixic acid 31 20
Colistin 0 0
Spectinomycin 17 28
Number of isolates 48 25
DANMAP 2011
9.2  Staphylococcus hyicus from pigs
During the period 2009–2011, Staphylococcus hyicus 
was isolated from 30 clinical submissions from skin 
infections in pigs. The level of resistance in the pooled 
data from 2009 to 2011 is comparable to the occurrence 
observed in the isolates collected in 2008 (Table 9.1). 
Overall, for the period 2009–2011, only 10% of the 
isolates were fully susceptible to all antimicrobial agents 
included in the test panel and among the resistant isolates 
most (18/27) were resistant to three or more of the 
antimicrobial agents included in the panel. Resistance to 
penicillin (60%), trimethoprim (50%) and tiamulin (47%) 
was most common, but also resistance to tetracycline 
(43%), erythromycin (33%), streptomycin (40%) and 
spectinomycin (37%) frequently occurred (Table 9.1). 
Since 2008, none of the 61 Staphylococcus hyicus isolates 
were resistant to cefoxitin, sulfonamide, gentamicin or 
ciprofloxacin. 
Helle Korsgaard and Lars Stehr Larsen
DANMAP 2011
Table 9.1. Resistance (%) among Staphylococcus hyicus 
from diagnostic submissions from pigs, Denmark
Antimicrobial agent
2008 2009–2011
% %
Tetracycline 29 43
Chloramphenicol 3 0
Florfenicol 3 0
Penicillin 68 60
Cefoxitin 0 0
Trimethoprim 48 50
Sulfonamide 0 0
Erythromycin 35 33
Streptomycin 48 40
Gentamicin 0 0
Ciprofloxacin 0 0
Spectinomycin 29 37
Tiamulin 42 47
Number of isolates 31 30
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10. Materials and methods
10.1 General information
For the DANMAP 2011 report, population sizes and 
geographical data were obtained from Statistics Denmark 
[www.dst.dk] and data on general practitioners from the 
Danish Medical Association [www.laeger.dk]. 
The epidemiological unit for pigs and cattle was defined 
as the individual farm, meaning that only one isolate per 
bacterial species per farm was included in the report. The 
same epidemiological unit was applied for broilers, except 
for Salmonella where the individual flock of broilers was 
defined as the epidemiological unit. For humans, the 
epidemiological unit was defined as the individual patient 
and the first isolate per patient per year was included. 
For food, the epidemiological unit was defined as the 
individual meat sample. 
10.2 Data on antimicrobial consumption  
Antimicrobial agents used for humans and animals in 
Denmark are presented in Table 3.
10.2.1 Antimicrobial consumption in animals   
Since 2001, consumption data presented in this report were 
obtained from the national monitoring program VetStat, 
a database hosted by the Danish Veterinary and Food 
Administration. Prior to 2001, data were based on national 
sales figures from the pharmaceutical industry (web annex, 
Table 4.1). 
Data registration
In Denmark, all therapeutic drugs are prescription-only 
and VetStat collects data on all medicines prescribed by 
veterinarians for use in animals, except in some instances 
medicines prescribed on special license (ie. medicines not 
approved for marketing in Denmark). In addition, data 
on consumption of coccidiostatics as feed additives (non-
prescription) and antimicrobial growth promoters (no use 
since 2000) are collected by VetStat. Data on coccidiostatic 
agents are presented in the web annex (Table A4.5). 
Until 2007, antimicrobial agents could only be purchased at 
the pharmacy or in medicated feed from the feed mills. 
From April 2007, the monopoly was suspended and private 
companies (two in 2011) can now, on certain conditions 
(identical to the pharmacies), sell prescribed veterinary 
medical products for animals. In addition, price setting was 
liberalised, which allowed for discounts corresponding to 
lower administration cost related to sale of large quantities 
to the veterinarians. 
The pharmacy or company either sells the medicines 
to veterinarians for own use in practice or for re-sale to 
farmers, or sells the medicines directly to the animal 
holder on presentation of a prescription. By law, the profit 
that veterinarians may make on the sale of medicine is very 
small (5%), thereby limiting the economic incentive to sell 
medicine. Hence, in 2010, only 10% of the antimicrobial 
agents used for animals were used or distributed by 
veterinarians.
In 2011, the animal owners and veterinarians purchased 
the antimicrobial agents almost equally from the 
pharmacies (43%) and the veterinary drug trading 
companies (55%), while only 2% was purchased from the 
feed mills. 
In 2011, sales from feed mills comprised antimicrobial 
agents for aquaculture and zinc chloride for the pig 
production, both on veterinary prescription, and non-
prescription sales of coccidiostatic agents for domestic fowl 
(Gallus gallus). 
Data on all sales of veterinary prescription medicine 
from the pharmacies, private companies, feed mills 
and veterinarians are sent electronically to VetStat. 
Veterinarians are required by law to report to VetStat all 
use and prescriptions for production animals (monthly 
submissions). For most veterinarians, the registration of 
data is linked to the writing of invoices. For the DANMAP 
report, the amounts of antimicrobial agents reported by 
the veterinary practitioners are validated against pharmacy 
data on the total sales of therapeutic drugs for use in 
practice. The electronic registration of the sales at the 
pharmacies is linked to the billing process, which ensures 
a very high data quality regarding amounts and identity of 
drugs.
The VetStat database contains detailed information about 
source and consumption for each prescription item: 
date of sale, identity of prescribing veterinarian, source 
ID (identity of the pharmacy, feed mill, or veterinarian 
practice reporting), package identity code and amount, 
animal species, age-group, disease category and code 
for farm-identity (CHR - Danish Central Husbandry 
Register). The package code is a unique identifier, relating 
to all information on the medicinal product, such as active 
ingredient, content as number of unit doses (e.g. number 
of tablets), package size, and code of the antimicrobial 
agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the 
presentation of consumption data in Defined Animal Daily 
Doses (ADD). The ADD system is a national veterinary 
equivalent to the international Defined Daily Doses (DDD) 
system applied in the human field [www.whocc.no]. See 
further description of the ADD system in the DANMAP 
2009 report. 
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Denominators
The consumption is reported in relation to the size of the 
population sizes of the different animal species or the 
volume of produced meat. Three different denominators 
used in the DANMAP report: 1) production in kg meat, 2) 
number of animals produced or 3) standing live biomass. 
Due to a relative high number of pigs exported around 30 
kg (26% of pigs produced in 2011), an adjusted measure 
of consumption per pig was calculated. The adjustment is 
based on the assumption that pigs exported at 30 kg, on 
average received the same amount of antimicrobial agents 
before export, as other pigs from farrowing to 30 kg: 
Antimicrobial use per pig produced (adjusted) = 
[ADDs * (Nf/Nw) + ADDw * (Nf/Nw) + ADDf] / Nf,
where ADDs = amount of antimicrobial agents used 
in sows (ADDkg), ADDw = amount of antimicrobial 
agents used in weaners (ADDkg), ADDf  = amount 
of antimicrobial agents used in finishers (ADDkg), 
Nw  = number of pigs produced to 30 kg bodyweight, 
including pigs exported at 15-50 kg (mostly at 30 kg), Nf 
= number of pigs produced to slaughter, whether exported 
domestically or exported.
The estimation of standing live biomass depends on the 
available data sources for each species:
Broiler and layer production (Gallus gallus). The 
live biomass is estimated based on number of broilers 
produced (Table 3.1) and an average live weight at 
slaughter of 1.97 kg [Statistics Denmark, 2012] after an 
estimated average life span of 30 days. The estimated mean 
live biomass per broiler is assumed to be half of the weight 
at slaughter. In addition, there are an estimated 1 million 
parental animals in Denmark, with average live weight at 
slaughter of 2.3 kg [Statistics Denmark, 2012]. Rearing 
comprise an average of 1.06 million hens and 0.2 million 
cocks, with an average weight of 1.2 kg bodyweight. In the 
egg production chain, parent flocks comprise 1.06 million 
hens and 0.25 million cocks, with an average weight 
of 3.5 kg body weight. Overall in 2011, the estimated 
standing live biomass within the Danish broiler and layer 
production were 24.5 mill kg and 4.5 mill kg, respectively.
Turkey production. The live biomass is estimated based 
on number of turkeys produced (Table 3.1) and an average 
live weight at slaughter of 19 kg for male turkeys and 11 
kg for hens [Statistics Denmark, 2012] after an estimated 
average life span of 20 weeks and 17 weeks, respectively 
[Danish Agro]. The estimated mean live biomass per 
turkey is assumed to be half of the weight at slaughter, 
and the overall estimated standing live biomass within the 
Danish turkey production in 2011 were 2.8 mill kg.
Pig production. The live biomass is of the cattle 
population is estimated from census data [Statistics 
Denmark, 2012] and the average live weight of the different 
age groups. The average live weight was estimated for: 
sows and gilt in first gestation (210 kg); boars and sows for 
slaughter (228 kg); piglets before weaning (4 kg); weaned 
pigs up to 50 kg (28 kg) and finishers and gilts from 50 
kg to gestation (80 kg). Overall in 2011, the estimated 
standing live biomass within the Danish pig production 
was 677 mill kg.
Cattle production. The live biomass of the cattle 
population is estimated from census data [Statistics 
Denmark, 2012] and the average live weight of the different 
age groups. The Danish cattle population is mainly dairy, 
particularly Holstein Fresian, but also other breeds such 
as Jersey, and a small population of beef cattle. Most of 
the cattle slaughtered are dairy cows and bull calvs (young 
beef) of dairy origin. The average live weight was estimated 
for: cows and heifers, >2 years (600 kg); heifers, bull calves 
and steers, 1-2 years (400 kg); bulls and steer calves, ½-1 
years (300 kg); heifer calves, ½-1 years (230 kg); bull and 
steer calves, 0-½ years (135 kg) and heifer calves, 0-½ years 
of age (100 kg). These average body weights are estimated 
as the average weight in the respective age class of the large 
dairy breeds, and might represent a slight overestimation. 
Overall in 2011, the estimated standing live biomass within 
the Danish cattle production was 685 mill kg.
Fur Animals. The live biomass of mink is estimated 
from production data [Statistics Denmark, 2010] and the 
average weight at pelting was 2.45 kg [Danish Fur]. The 
progeny live for approximately 7 months. Taking into 
account the longer lifespan of the parental animals, an 
average lifespan of 8 months is used for the estimation. 
Overall in 2011, the estimated standing live biomass within 
the Danish mink production was 24.5 mill kg.
Pet animals. Only dogs and cats are taken into account, as 
the other population sizes are negligible in Denmark, and 
relatively rare in veterinary practice. The 2011 population 
is based on census data [Statistics Denmark, 2000] 
estimating 650.000 cats and 550.000 dogs. The number of 
dogs in Denmark has been relativ stable during the last ten 
yesrs [Danish Dog register, 2012] including approximately  
550.000 dogs . The average live weight for cats and dogs 
were estimated to 4 kg and 20 kg, respectively (based on 
pedigree registration data). Overall in 2011, the estimated 
standing live biomass of Danish cats and dogs was 13.6 
mill kg.
Aquaculture. Generally, the average live biomass of 
fresh water fish in aquaculture is around 40% of the total 
production, corresponding to approximately 14 ton  in 
2011 [NH Henriksen, Danish Aquaculture]. The live 
weight of saltwater fish, increase from zero in January up 
to around 10 ton in October-November. Assuming an 
average weight increase of 1 ton per month, the average 
annual standing live biomass of saltwater fish was 4.6 
tonnes (across 12 months). 
Figure 4.2, presents the live biomass (mill kg) and 
therapeutic antimicrobial consumption in the main animal 
species in Denmark in 2011.
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10.2.2 Antimicrobial consumption in humans
Data on consumption of antibacterial agents in humans 
were obtained from Statens Serum Institut (formerly 
the Danish Medicines Agency). The DMA has the 
legal responsibility for monitoring the consumption of 
all human medicinal products. This is performed by 
monthly reporting of consumption from all pharmacies 
in Denmark, including hospital pharmacies, to the DMA. 
Data from the primary health care sector have been 
collected since 1994, whereas data on consumption in 
hospitals are available from 1997.
Certain categories of hospitals were excluded when the 
consumption was measured by occupied bed-days and 
admissions. This year, data from private hospitals and 
clinics, psychiatric hospitals, specialised non-acute care 
clinics, rehabilitation centres and hospices were excluded 
from DANMAP (representing approximately 3% of the 
antimicrobial consumption at hospitals and of the number 
of bed-days).
In Denmark, all antimicrobial agents for human use are 
prescription-only medicines and are sold by pharmacies 
in defined packages. Each package is uniquely identified 
by a code which can be related to package size, content 
as number of unit doses (e.g. number of tablets), content 
as number of Defined Daily Doses (DDD), code of the 
antimicrobial agent in the Anatomical Therapeutic 
Chemical (ATC) classification system, and producer. In 
addition, the following information is collected for each 
transaction: social security number (CPR number) of the 
patient, code identifying the prescribing physician, date 
and place (pharmacy, hospital pharmacy, institution) of the 
transaction, and information regarding reimbursement of 
cost, if applicable. The data are transferred monthly to the 
DMA in an electronic format. 
Information on the indication for the prescription is 
not yet available, but due to legislative changes, more 
informative indication data will be available from 2012 
onwards. 
The present report includes data on the consumption of 
antibacterial agents for systemic use, or group J01, of the 
2011 update of the ATC classification, in primary health 
care and in hospitals. As recommended by the World 
Health Organization (WHO), consumption of antibacterial 
agents in primary health care is expressed as DIDs, i.e. 
the number of DDDs per 1,000 inhabitants and per day 
(DDD/1,000 inhabitant-days). Consumption in primary 
health care is also reported as a number of packages per 
1,000 inhabitants. Consumption of antibacterial agents 
in hospitals is expressed as DIDs for comparison to 
primary health care and DBD; the number of DDDs per 
100 occupied bed-days and per day (DDD/100 occupied 
bed-days). Since antimicrobial consumption expressed as 
DDD/100 occupied bed-days does not necessarily reflect 
changes in hospital activity and production, consumption 
in hospitals is also presented as DAD (the number of 
DDD/100 admitted patients). 
The number of occupied bed-days is calculated as the date 
of discharge minus the date of admission (minimum one 
day), and the number of admissions is calculated as one 
admission whenever a patient is admitted to one specific 
ward (one patient can be registered as admitted multiple 
times if transferred between wards during one hospital 
stay). Data on the number of occupied bed-days (or 
patient-days) and number of admissions in each hospital 
were obtained from the National Patient Registry at the 
National Board of Health [www.sst.dk].
10.3. Collection of bacterial isolates
10.3.1 Animals
In the DANMAP program, samples are collected 
from randomly selected healthy production animals 
at slaughter. The following bacteria were isolated from 
pigs: Escherichia coli, Enterococcus faecium, Enterococcus 
faecalis, Campylobacter coli, Campylobacter jejuni and 
Salmonella spp.; from cattle: E. coli, C. coli and C. jejuni, 
and from broilers: E. coli, C. coli, C. jejuni, E. faecalis and 
E. faecium. In addition, Salmonella isolates were collected 
from subclinical infections as well as from cases of clinical 
salmonellosis, and isolates of E. coli O149, E. coli F5 (K99) 
and Staphylococcus hyicus were collected from diagnostic 
submissions. 
Campylobacter, indicator E. coli and enterococci. 
Samples from healthy pigs, cattle and broilers were 
collected at slaughter for the DANMAP program, by 
meat inspection staff or company personnel, and sent for 
examination at the National Food Institute. For broilers, 
cloacal swab samples were collected weekly from April 
through September, representing 94% of all broiler farms 
in Denmark. A typical Danish broiler farm often houses 
several broiler flocks (e.g. 2–12 flocks), but even though 
more than one flock was sampled, only one isolate per 
farm of each bacterial species was finally included in the 
report. 
For pigs and cattle, the slaughter plants included in the 
DANMAP programme accounted for 98% and 94%, 
respectively, of the total number of animals slaughtered 
in Denmark during 2011. The number of pig and cattle 
samples taken at each slaughter plant was proportional 
to the number of animals slaughtered at the plant per 
year. Samples were collected once a month from January 
through November as ceacum samples from pigs and 
rectum samples from cattle. Only one isolate per farm 
of each bacterial species was included in the DANMAP 
report. Accordingly, the bacterial isolates from the 
production animals may be regarded as representing a 
stratified random sample of the respective populations, and 
the observed prevalence of resistant isolates provides an 
estimate of the true occurrence in the population. 
An overview of the number of samples analysed, the 
number of isolates obtained and the number of MIC-
determinations for pigs, cattle and broilers is presented 
in Table 10.1. For Campylobacter, the isolation rates of C. 
jejuni from pigs and of C. coli from cattle and broilers were 
low and MIC-determinations therefore not performed.  
Isolates from diagnostic submissions were collected 
specifically for the DANMAP programme at the 
Laboratory of Swine Diseases, the Danish Agriculture & 
Food Council, Kjellerup (E. coli O149 from diarrhoeic pigs 
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Table 10.1. Number of DANMAP samples, number of isolates and MIC-tests from healthy production animals at 
slaughter, Denmark     
E. coli E. faecium E. faecalis C. jejuni  C. coli  
Pigs(a) No. of samples analysed (1 per farm) 311 757 757 311 311
No. of isolates obtained 269 130 161 6 162
No. of isolates MIC-tested/reported 157 116 117 0 102
Cattle No. of samples analysed (1 per farm) 131 0 0 187 187
No. of isolates obtained 121 0 0 113 10
No. of isolates MIC-tested/reported 93 0 0 95 0
Broilers No. of samples analysed (no. of flocks) 160 201 201 231 231
No. of farms represented  150 150 150 150 150
No. of isolates MIC-tested/reported 134 107 110 43 0
Note: Data in this table should not be used for reportation of prevalences of the bacterial species
a) From 2011, the DANMAP samples from pigs were also part of the surveillance programme for Salmonella
and S. hyicus from skin infections) and at the National 
Veterinary Institute (E. coli F5 (K99) from diarrhoeic 
cattle). Due to a low number of isolates of E. coli F5 (K99) 
and S. hyicus, MIC-data for isolates collected over the last 
two and three years, respectively, were presented in this 
report with only one isolate per farm included.
   
Salmonella. The National Food Institute is the national 
reference laboratory for Salmonella in animals, feeding 
stuffs and food and therefore receives all isolates for 
typing. Among all serotyped isolates, only one isolate per 
serotype per farm was selected for the DANMAP report, 
except for isolates from broilers, where one isolate per 
flock was included. Isolates of S. Typhimurium include 
the monophasic variants with the antigenic formulas S. 
4,5,12:i:- and S. 4,12:i:-.  
The Salmonella isolates from pigs (202 isolates in 2011) 
primarily originated from the national surveillance 
programs: The results of a serological Salmonella 
surveillance at the slaughterhouses and in all breeding 
herds, appointed risk herds to be further examined by 
analysing pen-faecal samples (n = 107). In addition, 
a yearly surveillance of 100 farms, where pen-faecal 
samples were taken at medicine- and welfare control 
visits, was launched in 2011 (n = 12) together with the 
onset of additional analysis for Salmonella among the 
random sampling of healthy animals at slaughter (i.e. the 
ceacum samples described for isolation of Campylobacter, 
enterococci and E. coli isolates) (n = 50). Finally, 
Salmonella in samples from pig herds investigated due 
to clinical disease (not necessarily salmonellosis) were 
included (n = 33). 
No Salmonella data for broilers or cattle is presented in the 
DANMAP 2011 due to a low number of isolates observed 
per serotype (<15). For broilers, all flocks (including flocks 
intended for export) were sampled twice before slaughter 
as part of the Salmonella surveillance program. For cattle, 
the herds examined were based on clinical indications.  
Further details on the sampling procedures and the 
findings of the Danish Salmonella surveillance programs 
are presented in Textbox 4, and in the Annual Report on 
Zoonoses in Denmark, 2011 [www.dtu.food.dk]. 
DANMAP 2011
10.3.2 Meat 
Campylobacter, indicator E. coli and enterococci. The 
meat isolates originated from meat samples collected at 
wholesale and retail outlets by the Regional Veterinary 
and Food Control Authorities (RFCA) in all regions of 
Denmark. The samples were collected during the course 
of routine inspection carried out by the authorities or on 
specific request from the Danish Veterinary and Food 
Administration (DVFA) for the DANMAP programme. 
The collected material consisted of both Danish and 
imported meat. Only one isolate per bacterial species per 
meat sample was selected for DANMAP. Further details on 
sampling and findings are presented in Textbox 4. 
Salmonella. The Salmonella isolates from Danish pork and 
beef originated from the national Salmonella surveillance 
programme, comprising swab samples from pork and 
beef carcasses taken at the slaughterhouses after cooling. 
Salmonella isolates from imported poultry meat and other 
imported fresh meats originated from a case-by-case risk 
assessment control programme (DFVA). Further details 
on sampling and findings are presented in Textbox 4. One 
isolates of S. Typhimurium and S. Enteritidis per phage 
type from a positive batch of meat were included in the 
DANMAP report. Isolates of S. Typhimurium include the 
monophasic variants, antigenic formula S. 4,5,12:i:- and S. 
4,12:i:-.  
10.3.3 Humans
Salmonella enterica serovars Typhimurium and 
Enteritidis and Campylobacter jejuni. Antimicrobial 
susceptibility was performed on human faecal isolates 
submitted to Statens Serum Institut (SSI). Campylobacter 
isolates were submitted from Departments of Clinical 
Microbiology (DCM) covering three geographical 
regions: Northern Jutland, Funen and Roskilde/Køge. 
Information on travel history was obtained for these 
patients. Salmonella isolates were submitted from all DCM 
in Denmark. Exact figures of the proportion tested and the 
sampling strategy for the different species can be found in 
section 6.1 and 6.2. 
Staphylococcus aureus. All blood isolates were referred 
to the Staphylococcus reference laboratory at SSI on a 
voluntary basis. In November 2006, methicillin resistant S. 
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aureus (MRSA) became a notifiable disease in Denmark 
and since then it has been mandatory to send all MRSA 
isolates to the reference laboratory. 
Invasive Streptococcus pneumoniae, Streptococcus 
pyogenes (group A streptococci), group B, C and G 
streptococci. Invasive pneumococcal disease is a notifiable 
disease in Denmark, and therefore all blood and spinal 
fluid isolates nationwide are sent to SSI for determination 
or confirmation as well as susceptibility testing and typing. 
Group A, B, C and G streptococcal isolates are referred to 
SSI on a voluntary basis. 
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
invasive Enterococcus faecium and invasive Enterococcus 
faecalis. Data were provided on all isolates recorded 
from either blood samples (E. coli, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, E. faecium and E. faecalis) or 
urine samples (E. coli, Klebsiella pneumoniae) submitted 
for susceptibility testing to the participating DCM at the 
following hospitals: Rigshospitalet, Hvidovre, Herlev, 
Hillerød, Region Sealand, Odense, Esbjerg, Vejle, Herning/
Viborg, Aarhus, and Aalborg. 
No samples were collected from healthy humans.
10.4 Isolation and identification of 
bacteria
10.4.1 Animals 
Salmonella. Examination of samples processed at the 
National Food Institute was done by non-selective pre-
enrichment of 25 g material in a 1:10 dilution with 
buffered peptone water (BPW) incubated 16-20 hours 
at 37°C. A plate with Modified Semi-solid Rappaport-
Vassiliadis (MSRV) medium was inoculated with 0.1 ml of 
BPW deposited as 3 drops. After incubation o/n at 41.5°C, 
material from MSRV swarming zones were inoculated onto 
Brilliant Green Agar. Incubation o/n at 37°C was followed 
by serotyping of suspect colonies by slide agglutination. 
Isolates submitted for typing to the National Food Institute 
from other laboratories, were isolated according to the 
standard methods at the submitting laboratory, and upon 
reception, inoculated onto Brilliant Green Agar at the 
National Food Institute followed by serotyping. All isolates 
received for typing are stored at -80°C.
Campylobacter. The material was inoculated directly 
onto mCCD agar (Oxoid, Denmark) and incubated in 
micro-aerophilic atmosphere for 2-3 days at 41.5°C. For 
cattle, selective enrichment in Preston broth at a ratio of 
1:10 incubated in microaerophilic atmosphere for 24 h at 
41.5°C was performed followed by inoculation of 10 µl 
of the enrichment broth to mCCD agar. Campylobacter 
suspect colonies were verified by microscopy and 
identification was performed by a Real-Time PCR  assay 
[Mayr et al. 2010, J Food Prot. 73(2):241-50] and all 
isolates of C. jejuni and C. coli were stored at -80°C.  All 
analyses were performed at the National Food Institute. 
Indicator E. coli. Material from healthy animals were 
inoculated directly onto Drigalski agar (SSI Diagnostica, 
Denmark) and incubated o/n at 37°C. Yellow colonies 
were inoculated onto BBL CHROM agar Orientation 
Medium (Becton Dickinson, Germany) and red colonies 
were identified as E. coli after o/n incubation at 37°C. All 
analyses were performed at the National Food Institute and 
all isolates were stored at -80°C.
Indicator enterococci.  One drop of material suspended in 
2 ml sodium chloride (0.9%) was spread on Slanetz-Bartley 
agar and incubated two days at 42°C. Up to four colonies 
with a typical morphology of E. faecalis or E. faecium were 
sub-cultivated on blood agar. Colonies were identified 
by the following criteria: Colour, motility, arginine 
dihydrolase testing and the ability to ferment mannitol, 
sorbitol, arabinose and raffinose. All analyses were 
performed at the National Food Institute and all isolates of 
E. faecium and E. faecalis were stored at -80°C. 
Veterinary pathogens. Diagnostic submissions were 
examined according to the standard methods at the 
Laboratory of Swine Diseases, the Danish Agriculture & 
Food Council, Kjellerup (for E. coli O149 and S. hyicus) 
and at the National Veterinary Institute (for E. coli 
F5(K99)). All isolates were stored at -80°C at the National 
Food Institute.
10.4.2 Meat   
Salmonella was isolated by the regional laboratories within 
the DVFA according to the open reference methods issued 
by NMKL (NMKL No. 187, 2007 or NMKL No. 71, 1999) 
or the ISO 6579:2002, or alternative methods validated 
against the reference method according to ISO 16140:2001. 
Sero- and phage-typing was performed at the National 
Food Institute. 
Campylobacter was isolated according to the guidelines 
for microbiological examination of food (NMKL No. 119, 
2007). Identification was performed by microscopy or test 
kit DRO150M (Oxoid), and by oxidase activity, catalase 
activity and the ability to hydrolyse indoxyl acetate and 
hippurate. Isolation and identification was performed by 
the regional laboratories within the DVFA. All isolates of 
C. jejuni, C. coli and C. lari were sent to the National Food 
Institute for MIC-testing and stored at -80°C.
Indicator E. coli was isolated by the regional laboratories 
within the DVFA, by adding 5 g of the sample to 45 
ml of MacConkey- or laurylsulfphate-broth, which 
was incubated o/n at 44°C, and subsequently streaked 
onto violet red bile agar and incubated for 24h at 44°C. 
Presumptive E. coli was identified by CHROMagar 
Orientation Medium or by indole- and lactose testing in 
laurylsulphate-broth incubated o/n at 44°C. The E. coli 
isolates were sent to the National Food Institute for MIC-
testing and stored at -80°C.
                                                                           
       129DANMAP 2011  
10.MATERIALS AND METHODS
 
Indicator enterococci were isolated by the regional 
laboratories within the DVFA, by adding 5 g of the sample 
to 45 ml azide dextrose broth, which was incubated o/n at 
44°C and subsequently streaked on Slanetz-Bartley agar. 
After incubation at 44°C for 48 hours, colonies typical of E. 
faecium and E. faecalis were identified by a real-time PCR 
assay. All isolates of E. faecium and E. faecalis were sent to 
the National Food Institute for MIC-testing and stored at 
-80°C.
 
10.4.3 Humans
Salmonella isolates were serotyped according to the 
Kauffman-White Scheme. 
Campylobacter. Species identification was performed 
using a species specific PCR assay [Klena et al. 2004. J Clin 
Microbiol. 42: 5549–5557]. 
Staphylococcus aureus. Sequencing of the S. aureus 
specific spa gene was used both for species conformation 
and typing purposes. Any spa negative isolates were 
confirmed as S. aureus by MALDI-TOF.  The spa typing 
[Harmsen et al. 2003. J Clin Microbiol. 41: 5442–5448] and 
additional typing by multi locus sequence typing (MLST) 
was performed [Enright et al. 2000. J Clin Microbiol. 38: 
1008–1015] and annotated using eBURST v.3 software 
(www.mlst.net). Based on the spa and MLST typing, each 
isolate was assigned to a clonal complex (CC). For MRSA 
isolates, presence of the mecA or the mecC methicillin 
resistance genes was confirmed by PCR [Larsen et al. 2008. 
Clin Microbiol Infect. 14: 611–614; Stegger et al. 2012. Clin 
Microbiol Infect. 18: 395–400]. For all isolates, presence of 
lukF-PV gene (PVL) was demonstrated by PCR [Larsen et 
al. 2008. Clin Microbiol Infect. 14: 611–614; Stegger et al. 
2012. Clin Microbiol Infect. 18: 395–400].
10.5 Susceptibility testing
  
Animal and meat isolates
Antimicrobial susceptibility testing of Salmonella, 
Campylobacter, indicator E. coli, Enterococcus and the 
veterinary pathogens was performed as microbroth 
dilution MIC using Sensititre (Trek Diagnostic Systems 
Ltd., East Grinstead, UK). Inoculation and incubation 
procedures were in accordance with the CLSI guidelines 
[Clinical and Laboratory Standards Institute, USA] and the 
European standard ISO 20776-1:2006. 
The following quality control strains were used: 
Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 
25922, Pseudomonas aeruginosa ATCC 27853, Enterococcus 
faecalis ATCC 29212 and Campylobacter jejuni ATCC 
33560. 
Isolates from animals and meat were tested at the National 
Food Institute, and the Salmonella and Campylobacter 
isolates of human origin were tested at SSI. MIC-testing at 
the National Food Institute is accredited by DANAK (the 
Danish national body for accreditation).   
One isolate per bacterial species per farm, per meat sample 
or per patient was tested for antimicrobial susceptibility. 
For salmonella isolates from poultry, one isolate per 
serotype per flock was tested. For isolates in excess 
numbers (e.g. isolates from healthy animals), a random 
selection of 100 to 150 isolates was appointed to MIC. Due 
to low number of isolates, C. jejuni from pigs and C. coli 
from cattle and broilers were not susceptibility tested. 
Table 10.2 presents the interpretation of MIC-values 
used for all combinations of bacteria and antimicrobial 
agents. Since 2007, data were interpreted by EUCAST 
epidemiological cut-off values (ECOFFs) with a few 
exceptions (see footnotes in Table 10.2). In the figures, data 
from before 2007 have been interpreted using the 2007 
ECOFFs, otherwise interpretation is based on the ECOFFs 
from the year in question. The corresponding EUCAST 
clinical breakpoints are also presented in both Table 10.2 
and the MIC-distribution tables to visualize the impact of 
the use of ECOFFs contra clinical breakpoints. 
The MIC-distributions are presented in the web annex at 
www.danmap.org. Each of the tables provides information 
on the number of isolates tested, the applied interpretation 
of the MIC-values and the estimated level of resistance 
together with the corresponding confidence intervals.  
Multi-resistance was defined as resistance to 3 or more 
of the antimicrobial classes listed in Table 10.3.  Isolates 
were considered fully sensitive if susceptible to all the 
antimicrobial agents included in the test panel.
Staphylococcus aureus from humans
Susceptibility testing was performed by disc diffusion 
according to EUCAST methodology using discs from 
Oxoid (Ballerup, Denmark) on Mueller-Hinton Agar (SSI, 
Copenhagen, Denmark). The following antimicrobials 
were tested: Erythromycin, clindamycin, kanamycin, 
rifampicin, penicillin, cefoxitin, fusidic acid, norfloxacin, 
linezolid, tetracycline, trimethoprim-sulfametoxazole and 
mupirocin. In addition, MRSA isolates were screened for 
resistance towards glycopeptides by spot test on Brain-
Heart infusion (BHI) agar (Becton Dickinson, Germany) 
with teicoplanin (5 mg/L) and confirmed by Etest® 
(AB Biodisk, Solna, Sweden) on BHI with inoculum of 
McFarland 2.0. In case of MIC ≥ 8 mg/L for vancomycin 
and teicoplanin or an MIC ≥12 mg/L for teicoplanin, 
population analysis profile against vancomycin was 
performed [Wootton et al. 2001. J Antimicrob Chemother. 
47: 399–403].
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Table 10.2. Interpretation criteriae for MIC-testing by EUCAST epidemiological cut-off values (blue fields) and the 
corresponding EUCAST clinical breakpoints (white fields)
* EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints.  Orange fields mark changes in ECOFF values since 
DANMAP 2010
a) The EUCAST ECOFF (>1) was not applied for quinopristin/dalfopristin according to investigations presented in DANMAP 2006 (trade name 
synercid)
b) The EUCAST ECOFF (>4) was not applied for ciprofloxacin; the aim was to look for high level ciprofloxacin-resistance as described by Werner 
et al, 2010 (Int J Antimicob Agents;35:119-125)
c) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium, but for S. Enteritidis the ECOFF >8 was applied as recommended by 
Agersøe et al, 2011 [Textbox 6]
d) S. aureus ECOFFs were applied for S. hyicus, except for erythromycin where a specific S. hyicus ECOFF was available
Antimicrobial 
agent
Salmonella E. coli E. faecium E. faecalis C. jejuni  C. coli  S. hyicus(d)  
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
ECOFF
μg/ml
Clinical 
break-
point
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Apramycin >16 >16
Cefotaxime >0.5* >2* >0.25* >2*
Cefoxitin >4*
Ceftiofur >2* >1*
Chloram-
phenicol >16* >8* >16* >8* >32* >32* >16* >16* >16*
Ciprofloxacin >0.06 * >1* >0.06* >1* >16(b) >8(b) >1* >1* >1* >1* >1* >1*
Colistin >2*/ >8(c) >2* >2* >2*
Erythromycin >4* >4* >4* >4* >16* >1 >2*
Florfenicol >16* >16* >8*
Gentamicin >2* >4* >2* >4* >32*  >32* >1* >2* >0.5* >1*
Kanamycin >1,024 >1,024
Linezolid >4* >4* >4* >4*
Nalidixic acid >16* >16* >16* >32*
Neomycin >4* >8*
Penicillin >16* >16* >0.125* >0.125*
Quinupristin/
dalfopristin >4
(a) >4*
Salinomycin >4 >4
Spectinomycin >64 >64* >128*
Streptomycin >16* >16* >128* >512* >2* >4* >16*
Sulfonamide >256 >64* >128*
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8* >4* >4* >2* >2* >1* >2*
Tiamulin >2*
Tigecycline >0.25* >0.5* >0.25* >0.5*
Trimethoprim >2* >4* >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
 (c)
>2*
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Table 10.3. Definitions of antimicrobial classes for calculation of multi-resistance (MR) in zoonotic and indicator 
bacteria in DANMAP 2011
Note: An isolate is considered fully sensitive if susceptable to all antimicrobial agensts included in the panel for the selected bacterial 
species     
a) An isolates is considered multi-resistant if  resistant to three or more of the ten antimicrobial classes  
b) An isolates is considered multi-resistant if  resistant to three or more of the six antimicrobial classes   
 
Antimicrobial
classes
Salmonella and 
E. coli(a) Campylobacter
(b) Enterococcus(a)
Tetracyclines Tetracycline Tetracycline Tetracycline
Phenicoles Chloramphenicol and/or florfenicol Chloramphenicol Chloramphenicol
Penicillins Ampicillin Ampicillin and/or penicillin 
Cephalosporins Ceftiofur and/or cefotaxime
Sulfonamides Sulfonamides  
Trimethoprim Trimethoprim  
Aminoglycosides I
 Gentamicin Gentamicin   
Gentamicin and/
or kanamycin and/or 
streptomycin 
Aminoglycosides II  Streptomycin Streptomycin 
Quinolones Ciprofloxacin and/or nalidixic acid  
Ciprofloxacin  and/or 
nalidixic acid  
Ciprofloxacin  and/or 
nalidixic acid  
Polymycins Colistin 
Macrolides Erythromycin Erythromycin
Glycopeptids Vancomycin and/or teicoplanin 
Ionophores Salinomycin
Oxazolidinones Linezolid
Glycylcyclines Tigecycline 
DANMAP 2011
Invasive Streptococcus pneumoniae from humans 
Screening for penicillin-resistant S. pneumoniae was 
performed using a 1 μg oxacillin tablet (Neo-Sensitabs®, 
A/S Rosco, Taastrup, Denmark) on Müller-Hinton agar 
(Mueller-Hinton plate, 5% blood, 20 mg beta-NAD, 
SSI Diagnostika), and for erythromycin-resistant S. 
pneumoniae using a 15 μg erythromycin tablet (Neo-
Sensitabs®, A/S Rosco, Taastrup, Denmark) on Müller-
Hinton agar (SSI Diagnostika). The breakpoints used are 
defined by the EUCAST. Penicillin and erythromycin 
MICs were determined using STP6F plate, Sensititre (Trek 
Diagnostic Systems Ltd., East Grinstead, United Kingdom) 
as recommended by the manufacturer. The breakpoints 
used are defined by EUCAST. Resistant isolates were 
defined as both fully and intermediary resistant isolates.  
Invasive Streptococcus pyogenes (group A), group B, C 
and G streptococci from humans 
Screening for penicillin-resistant streptococci was 
performed using a 1 μg oxacillin disk (Oxoid, Greve, 
Denmark) on Müller-Hinton Agar (SSI Diagnostika, 
Hillerød, Denmark), and for erythromycin-resistant 
streptococci using a 15 μg erythromycin tablet (Neo-
Sensitabs®, A/S Rosco, Taastrup, Denmark) on Müller-
Hinton Agar (SSI Diagnostika). Erythromycin resistant 
streptococci were tested with a 15 μg erythromycin disk 
(Oxoid) and a 2 μg clindamycin disk (Oxoid) on Mueller-
Hinton Agar. Erythromycin MICs were determined using 
the Etest® (AB Biodisk, Solna, Sweden) on Mueller-Hinton 
agar incubated at 36°C, 5% CO2. The breakpoints used are 
defined by the EUCAST. Resistant isolates were defined as 
both fully and intermediary resistant isolates. 
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive 
E. faecium and E. faecalis from humans 
The DCMs performed either disk (Oxoid, Basingstoke, 
UK) or tablet (Neo-Sensitabs®, A/S Rosco) diffusion 
susceptibility testing on a number of media using 
breakpoints defined by either CLSI or EUCAST (DCM 
at Hvidovre Hospital, Herlev Hospital, Slagelse Hospital/
Region Sealand (per May 2011), Odense University 
Hospital (per November 2011), Herning and Viborg 
Hospitals/Midt-Vest (Viborg per September 2011, and 
Herning), Aarhus Hospital, and Aalborg Hospital).
Data on antimicrobial resistance from private hospitals and 
clinics and psychiatric hospitals were excluded.
All submitting laboratories participate in national and 
international quality assurance collaborations such as the 
United Kingdom National External Quality Assessment 
Schemes (NEQAS).
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10.6 Data handling   
10.6.1 Animal  
The results from the primary examination of samples 
from slaughterhouses and primary production for the 
bacteria of interest - positive as well as negative findings - 
and of the susceptibility testing were stored in an Oracle 
Database 9i Enterprise Edition® at the National Food 
Institute. The susceptibility data were stored as continuous 
values (MIC) as well as categorised as susceptible or 
resistant, respectively, as defined by the relevant ECOFF. 
Each isolate was identified by the bacterial species, by 
subtype as applicable and by the date of sampling and 
species of animal. Information on the farm of origin was 
also recorded. All handling and evaluation of results was 
carried out using SAS®Software, SAS Enterprise Guide 4.3.
10.6.2 Meat
Results from the analysis of food samples were reported via 
the database administrated by the Danish Veterinary and 
Food Administration, except for the data on Salmonella, 
which were reported to and extracted from the laboratory 
database at the National Food Institute. For each bacterial 
isolate, information was available on food type, bacterial 
species, date and place of sampling, date of examination, 
country of slaughter, the RFCA that collected and 
processed the sample, and an identification number, which 
makes it possible to obtain further information about the 
isolate from the Authorities. Furthermore, information 
about the country of origin was recorded whenever 
possible. 
10.6.3 Human
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. 
This register includes only one isolate per patient within a 
window of six months and includes data on susceptibility 
testing of gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the 
characteristics of the isolates and the clinical/
epidemiological information were obtained from the 
Danish MRSA register at SSI (mandatory reportable). 
In this database, patients were registered, regardless of 
whether it was colonization or infection, the first time they 
were diagnosed with MRSA or when a new subtype was 
demonstrated. Based on the reported information, MRSA 
cases were classified as colonization/active screening (i.e. 
surveillance samples to detect nasal, throat, gut or skin 
colonisation), imported infection (i.e. acquired outside 
Denmark), infection acquired in a Danish hospital, defined 
as diagnosed >48 hours after hospitalisation with no 
sign of infection at admittance (HA-MRSA) or infection 
diagnosed outside hospitals (community onset). 
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months 
as either health-care associated with community onset 
(HACO) or community-acquired (CA). Health-care 
associated risk factors included prior hospitalisations 
or stay in long-term care facilities within 12 months 
prior to MRSA isolation and being a health-care worker. 
Community risk factors included known MRSA positive 
household members or other close contacts. 
Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Data on susceptibility testing of isolates were stored as 
MICs in a Microsoft® Access database placed at a SQL 
server at SSI. Analysis including selection of isolates from 
blood and spinal fluid samples and removal of duplicate 
isolates was performed in Microsoft® Access. 
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and invasive E. faecalis. Thirteen DCM provided 
data on resistance levels in E. coli, Klebsiella pneumoniae, 
invasive Pseudomonas aeruginosa, invasive E. faecium and 
invasive E. faecalis isolates. Data were extracted from the 
following laboratory information systems:
•	 ADBakt (Autonik AB, Skoldinge, Sweden) for the 
DCM at Hvidovre, Herlev and Aalborg Hospitals.
•	 MADS (DCM, Skejby Hospital, Aarhus, Denmark) 
for the DCM at Rigshospitalet and Slagelse/Region 
Sealand, Odense, Esbjerg, Vejle, Herning/Viborg, and 
Aarhus (Skejby) Hospitals.
•	 SafirLIS Microbiology (Profdoc Lab AB, Borlänge, 
Sweden) for the DCM at Hillerød Hospital.
Resistance data on the first isolate per patient per year 
were included. Generally, resistance data were excluded if 
susceptibility to a certain antimicrobial agent was tested on 
only a selected number of isolates. 
10.6.4 Calculation of confidence limits  
timation of exact 95% (two-sided) confidence intervals 
for proportions were based on binomial probability 
distributions as described in Armitage & Berry [Statistical 
Methods in Medical Research, 4th ed. 2001, Oxford: 
Blackwell Scientific Publications]. 
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 4.3 or StatCalc in EpiInfo™ v. 6. When 
appropriate, significance of temporal trends are tested 
using linear logistic regression using Proc LOGISTC 
procedure in SAS (Wald test). In the text, significant 
differences imply statistically significant differences where 
p<0.05 using Chi-square, or Fisher’s Exact Test when the 
number of samples is low (<25).
When comparing proportions between years, the EUCAST 
epidemiological cut-off values for 2011 were also used for 
interpretation of previous years MIC’s. 
 
Anne Mette Seyfarth 
and Line Skjøt-Rasmussen
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List of abbreviations
ACD  Defined Animal Course Dose
ADD  Defined Animal Daily Dose
ADDkg  Defined Animal Daily Dose per kg animal
AGP  Antimicrobial Growth Promoter
ATC  Anatomical Therapeutic Chemical Classification System
CHR  Central Husbandry Register
CI  Confidence Interval
CNS  Central Nervous System
CPR  Danish Civil Registry
DAD  Defined Daily Doses per 100 admissions
DBD  Defined Daily Doses per 100 occupied bed-days
DCM  Department of Clinical Microbiology
DID  Defined Daily Doses per 1,000 inhabitants per day
DDD  Defined Daily Dose
DMA  Danish Medicines Agency
DTU  Technical University of Denmark
DVFA  Danish Veterinary and Food Administration
EARS-Net  The European Antimicrobial Resistance Surveillance Network
ESBL  Extended Spectrum Beta-Lactamase 
GI  Gastrointestinal 
GP  General Practitioner
HLGR  High-level gentamicin resistance
MIC  Minimum Inhibitory Concentration
MRSA  Methicillin-resistant Staphylococcus aureus
N  Number of samples
n  Number of isolates tested for antimicrobial susceptibility
OIE  World Organisation for Animal Health 
PMWS  Postweaning multisystemic wasting syndrome
RFCA  Regional Veterinary and Food Control Authorities
SSI  Statens Serum Institut
VetStat   Danish Register of Veterinary Medicines
VRE  Vancomycin Resistant Enterococci
WHO  World Health Organization
WT  Wild type
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List of words
Anatomical Therapeutic Chemical (ATC) classification.  International classification system for drug 
consumption studies. The ATC code identifies the therapeutic ingredient(s) of each drug for human use 
according to the organ or system on which it acts and its chemical, pharmacological and therapeutic 
properties. Antibacterials for systemic use are known as ATC group J01. The ATC classification is 
maintained by the WHO Collaborating Centre for Drug Statistics and Methodology (Oslo, Norway) 
(http://www.whocc.no/atcddd/indexdatabase/). The ATC classification for veterinary medicinal 
products, ATCvet, is based on the same main principles as the ATC classification system for medicines 
for human use and is also maintained by the WHO Collaborating Centre for Drug Statistics and 
Methodology (http://www.whocc.no/atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural (antibiotics) substances that 
destroy bacteria or suppress bacterial growth or reproduction [Source: Dorland’s Illustrated Medical 
Dictionary]. Antimycobacterial agents are not included. In the section of human consumption, 
‘antibacterial agents’ are referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers antibacterial, antiviral, coccidiostatic and 
antimycotic agents. In the section on veterinary consumption, the broad term ‘antimicrobial agents’ 
is usually used because coccidiostats are included. Antiviral substances are not used in veterinary 
medicine, and antimycotics are only registered for topical veterinary use and used mainly in companion 
animals. Antimycobacterial agents are not included. The term ’antibacterial agents’ is only used in the 
veterinary section for precision, to distinguish from use of coccidiostats as feed additives (poultry only). 
In the section of human consumption, the term ‘antimicrobial agents’ refers to all antibacterial agents 
for systemic use (J01 in the ATC system).
Broiler. A type of chicken raised specifically for meat production. In Denmark, the average weight after 
slaughter is 1.66 kg.
Central Husbandry Register (CHR). This is a register of all Danish farms defined as geographical 
sites housing production animals. It contains numerous information concerning ownership, farm size, 
animal species, age groups, number of animals and production type. Each farm has a unique farm 
identity number (CHR-number).
Defined Daily Dose (DDD). This is the assumed average maintenance dose per day in adults. It 
should be emphasised that the Defined Daily Dose is a unit of measurement and does not necessarily 
reflect the recommended or prescribed daily dose. DDDs provide a fixed unit of measurement 
independent of price and formulation, enabling the assessment of trends in drug consumption and 
to perform comparisons between population groups. The DDDs are defined and revised yearly by 
the WHO Collaborating Centre for Drug Statistics and Methodology (http://www.whocc.no/atcddd/
indexdatabase/). DDD/1,000 inhabitant-days is called DID.
Defined Animal Daily Dose (ADD and ADDkg). This is a national veterinary equivalent to the DDD. 
This is an assumed average daily dose per animal, defined as the daily maintenance dose for a drug used 
for its main indication in a specified species. The dose is defined for a ‘standard animal’, i.e. an animal 
with an estimated average weight within a specified age group. In VetStat, ADDs are calculated for each 
age group. Otherwise, the general principles for standardisation of dosage for animals are similar to that 
used by the WHO Collaborating Centre for Drug Statistics and Methodology to calculate Defined Daily 
Dose (DDD) in humans [Jensen et al. 2004. Prev Vet Med. 64: 201-215]. The ADDkg is the ADD per 
kg animal. Consumption calculated in ADDkg allows summation of consumption across different age 
groups and animal species.
Defined Animal Course Dose (ACD and ACDkg). The duration of the treatment related to one 
application may vary substantially between antimicrobial drugs. To correct for this, total course dose 
has been introduced as unit of measurement for antimicrobial usage. As a standard, the length of the 
course is here defined as 6 days, if nothing else is stated. Course doses are assigned per kilogram 
(live weight) of the animal species (ACDkg) or age group of the relevant species (ADCxx) and are 
based on the corresponding ADDkg or ADDxx, respectively, for the relevant animal species and 
drug formulations. 
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ESBL. In the DANMAP report ‘ESBL’ describes the clinically important acquired beta-lactamases with 
activity against extended-spectrum cephalosporins; including the classical class A ESBLs (CTX-M, SHV, 
TEM), the plasmid-mediated AmpC and OXA-ESBLs [Giske et al. 2009. J Antimicrob Chemother. 63: 
1-4]. 
Finishers. Pigs from 30 kilogram live weight to time of slaughter at app. 100 kilogram live weight.
Fully sensitive. An isolate will be referred to as fully sensitive if susceptible to all antimicrobial agents 
included in the test panel for the specific bacteria.
 
Heifer. A young female cow before first calving. 
Intramammaria. Antimicrobial agents for local application in the mammary gland (udder) to treat 
mastitis.
Intramammary syringe. A one dose applicator for use in the udder.
Layer. A hen raised to produce eggs for consumption.
Minimum Inhibitory Concentration (MIC). This is the lowest concentration of antimicrobial agent in a 
given culture medium, e.g. broth or agar, below which growth of the bacteria is not inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus or  E. coli isolate is assumed multi-resistant 
if resistant to three or more antimicrobial classes. The number of antimicrobial classes and antimicrobial 
agent included therein depend on the test panel for each bacteria. See table 10.3 in section 10.5 for a 
detailed description.
Pet animals. Dogs, cats, birds, mice, guinea pigs and more exotic species kept at home for pleasure, rather 
than one kept for work or food. Horses not included.
Piglet. The newborn pig is called at piglet from birth till they are permanently separated from the sow at 
3-4 weeks of age. The weight of the piglet at weaning is approximately 7 kilogram. 
Poultry. The major production species are fowl - Gallus gallus (broilers, layers, including breeding and 
rearing) and turkey. Regarding antimicrobial consumption, ‘poultry’ also includes domesticated ducks, 
geese, game birds and pigeons. 
 
Significant. When written in the text, significant differences imply statistically significant differences 
where p<0.05. Pairwise comparisons are made using Chi-square or Fisher’s Exact Test when the number of 
samples is low (<25). When appropriate, linear logistic regression is used to analyse for significant trends 
over several years.   
Sow. Any breeding female pig that has been served and is on the farm.
Steer. Castrated male cattle, usually young animal.
Weaner. Any pig, 7–30 kilogram live weight. 
Wild type. The typical form of an organism, strain, gene, or characteristic as it occurs in nature.
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